

CITATION REPORT

List of articles citing

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

DOI: 10.1056/nejm199005313222203

New England Journal of Medicine, 1990, 322, 1561-6.

Source: <https://exaly.com/paper-pdf/21871203/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2266	Risk stratification of left ventricular hypertrophy in systemic hypertension using noninvasive ambulatory blood pressure monitoring. 1990 , 66, 583-90		56
2265	Measurement of cardiac output by M-mode and two-dimensional echocardiography: application to patients with hypertension. 1990 , 11 Suppl I, 67-78		59
2264	Glomerular Hyperfiltration Indicates Early Target Organ Damage in Essential Hypertension. 1990 , 264, 2775		68
2263	The Value of Noninvasive Measurements in Hypertension. 1990 , 264, 2798		2
2262	Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. <i>New England Journal of Medicine</i> , 1990 , 323, 1706-7	59.2	49
2261	Cardiovascular risk associated with hypertension; interactions with other risk indicators. 1990 , 49-58		
2260	Significance of increased left ventricular mass in isolated systolic hypertension of the elderly. 1991 , 17, 431-2		2
2259	Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. 1991 , 17, 1277-82		139
2258	Relation of alcohol intake to left ventricular mass: The Framingham Study. 1991 , 17, 717-21		111
2257	Regression of increased left ventricular mass by antihypertensives. 1991 , 42, 945-61		36
2256	Left ventricular hypertrophy in hypertension. 1991 , 122, 312-5		10
2255	Clinical benefits of structural and functional changes with calcium antagonists. 1991 , 122, 370-4		1
2254	Cardiovascular and metabolic characteristics of hypertension. 1991 , 91, 4S-10S		13
2253	Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. 1991 , 18, 1287-94		114
2252	Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. 1991 , 17, 1595-602		59
2251	Toward a more complete understanding of left ventricular afterload. 1991 , 17, 122-4		13
2250	Ultrasound characterization of myocardial hypertrophy. 1991 , 17, 1091-3		16

2249	A comparison of left ventricular mass and volume using different echocardiographic conventions. 1991 , 30, 103-8	4
2248	Initiating proper blood pressure control. 1991 , 26 Suppl 2, 7-12; discussion 31-3	
2247	Hypertension and non-insulin dependent diabetes. 1991 , 303, 730-2	14
2246	Mechanisms of Arrhythmias in Ventricular Hypertrophy. 1991 , 2, 249-261	47
2245	Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. 1991 , 114, 345-52	1649
2244	The limited echocardiogram: a modification of standard echocardiography for use in the routine evaluation of patients with systemic hypertension. 1991 , 67, 1027-30	48
2243	Gender differences in left ventricular anatomy, blood viscosity and volume regulatory hormones in normal adults. 1991 , 68, 1704-8	88
2242	Bivariate genetic analysis of left ventricular mass and weight in pubertal twins (the Medical College of Virginia twin study). 1991 , 68, 661-8	128
2241	Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. 1991 , 68, 925-9	69
2240	Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. 1991 , 67, 295-9	123
2239	Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). 1991 , 68, 85-9	429
2238	Comparison of ambulatory left ventricular ejection fraction and blood pressure in systemic hypertension in patients with and without increased left ventricular mass. 1991 , 67, 597-603	15
2237	Left ventricular hypertrophy: Its prevalence, etiology, and significance. 1991 , 14, 13-17	5
2236	The calcium binding protein tropomyosin in human platelets and cardiac tissue: elevation in hypertensive cardiac hypertrophy. 1991 , 21, 472-8	12
2235	How reliable is the electrocardiogram in detecting left ventricular hypertrophy in hypertension?. 1991 , 67, 646-8	6
2234	Hemostatic risk factors for coronary heart disease. 1991 , 83, 1098-100	30
2233	Left ventricular hypertrophy associated with chronic cocaine abuse. 1991 , 84, 1130-5	128
2232	Hypertension, hypertrophy, and the coronary circulation. 1991 , 83, 1101-3	6

2231	Renin-sodium profile and the risk of myocardial infarction in patients with hypertension. <i>New England Journal of Medicine</i> , 1991 , 325, 1106-7	59.2	1
2230	The Impact of Obesity on Left Ventricular Mass and Geometry. 1991 , 266, 231		363
2229	Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. 1991 , 84, 583-93		24
2228	Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. 1991 , 83, 845-53		179
2227	Regression of left ventricular hypertrophy--a meta-analysis. 1992 , 14, 173-80		26
2226	The heart in hypertension. <i>New England Journal of Medicine</i> , 1992 , 327, 998-1008	59.2	549
2225	Left Ventricular Mass in Diabetes-Hypertension. 1992 , 152, 1001		63
2224	Low plasma growth hormone binding protein in IDDM. 1992 , 41, 605-9		69
2223	Variability between current definitions of 'normal' ambulatory blood pressure. Implications in the assessment of white coat hypertension. 1992 , 20, 555-62		163
2222	Sodium-Lithium Countertransport Activity and Insulin Resistance in Normotensive IDDM Patients. 1992 , 41, 610-615		24
2221	Transient ischaemic attacks: which patients are at high (and low) risk of serious vascular events?. 1992 , 55, 640-52		87
2220	Sex differences in the determinants of left ventricular mass in childhood. The Medical College of Virginia Twin Study. 1992 , 85, 1661-5		53
2219	'Silent ischemia,' ventricular arrhythmias, and complications of hypertension. 1992 , 85, 1948-50		12
2218	The stroke preventive effect in elderly hypertensives cannot fully be explained by the reduction in office blood pressure--insights from the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). 1992 , 1, 168-72		21
2217	Fibrosis of the human heart and systemic organs in adrenal adenoma. 1992 , 1, 149-56		49
2216	Left ventricular hypertrophy. 1992 , 40, 71-80		11
2215	The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. 1992 , 117, 831-6		345
2214	Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. 1992 , 116, 6-12		463

2213 Hypertension in Children and Adolescents. **1992**, 20, 96-110

2212 Clinical utility of ambulatory blood pressure monitoring in target organ complications and equipment choices. **1992**, 32, 620-6

6

2211 Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. **1992**, 13 Suppl D, 66-9

37

2210 Diuretics, arrhythmias and silent myocardial ischaemia in hypertensive patients. **1992**, 13 Suppl G, 81-4

7

2209 Effect of diuretic therapy on hypertensive left ventricular hypertrophy. **1992**, 13 Suppl G, 53-60

22

2208 Pharmacotherapeutic effects of antihypertensive agents on myocardium and coronary arteries in hypertension. **1992**, 13 Suppl D, 100-6

12

2207 Lipid screening in aircrew: pros and cons. **1992**, 13 Suppl H, 50-3

55

2206 Inter-study variability in left ventricular mass measurement. Comparison between M-mode echography and MRI. **1992**, 13, 1011-9

113

2205 Echocardiographic left ventricular hypertrophy: clinical characteristics. The Framingham Heart Study. **1992**, 14, 85-97

15

2204 Effects of a long-term treatment with alacepril on left ventricular hypertrophy and function in patients with essential hypertension. **1992**, 32, 667-70

2

2203 Higher left ventricle mass in normotensives with exaggerated blood pressure responses to exercise associated with higher ambulatory blood pressure load and sympathetic activity. **1992**, 13 Suppl A, 30-6

27

2202 Antihypertensive therapy. Current issues and challenges. **1992**, 91, 163-6, 171-4, 179-86 passim

7

2201 Left ventricular hypertrophy. Its relationship to obesity and hypertension. **1992**, 91, 131-2, 135-8, 141-3

46

2200 Is there a relationship between exercise systolic blood pressure response and left ventricular mass? The Framingham Heart Study. **1992**, 116, 203-10

132

2199 Echocardiographic design of a multicenter investigation of free-living elderly subjects: the Cardiovascular Health Study. **1992**, 5, 63-72

195

2198 Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. **1992**, 1, 75-85

68

2197 Blood pressure load determines left ventricular mass in essential hypertension. **1992**, 34, 335-8

28

2196 Limitations of the electrocardiographic diagnosis of left ventricular hypertrophy: the influence of left anterior hemiblock and right bundle branch block. **1992**, 34, 41-8

15

2195	Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. 1992 , 19, 130-4	142
2194	Remodeling and reparation of the cardiovascular system. 1992 , 20, 3-16	271
2193	Ambulatory blood pressure monitoring and left ventricular mass and function after successful surgical repair of coarctation of the aorta. 1992 , 20, 197-204	72
2192	Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. 1992 , 20, 1180-6	295
2191	Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. 1992 , 20, 1251-60	1421
2190	What is the role of silent coronary artery disease and left ventricular hypertrophy in the genesis of ventricular arrhythmias in men with essential hypertension?. 1992 , 19, 803-8	28
2189	Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. 1992 , 19, 1550-8	1218
2188	Patterns of left ventricular response in essential hypertension. 1992 , 19, 1559-60	19
2187	Lessons From Framingham: Cardiac Disease in the General Population. 1992 , 19-38	
2186	The Natural History of Myocardial Disease in Dialysis Patients. 1992 , 39-51	
2185	Increased stiffness and persistent narrowing of the aorta after successful repair of coarctation of the aorta: relationship to left ventricular mass and blood pressure at rest and with exercise. 1992 , 123, 1594-600	98
2184	New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach. 1992 , 123, 1337-67	26
2183	Effect of the renin-angiotensin system in the vascular disease of type II diabetes mellitus. 1992 , 92, 13S-19S	16
2182	Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. 1992 , 93, 21S-26S	14
2181	High-frequency analysis of the signal-averaged ECG. Correlation with left ventricular mass in rabbits. 1992 , 25, 111-8	13
2180	Impact of the daily blood pressure load on the development of hypertensive heart disease. 1992 , 81, 299-306	4
2179	Antihypertensive profile of carvedilol. 1992 , 70 Suppl 1, S43-52	3
2178	Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs. 1992 , 70 Suppl 1, S87-92	1

2177	Calcium antagonists for the treatment of systemic hypertension. 1992 , 69, 13E-16E	3
2176	Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). 1992 , 70, 1180-4	118
2175	Angiotensin-converting enzyme inhibitors as cardioprotective agents. 1992 , 70, 10I-17I	4
2174	Echocardiographic determinants of clinical outcome in subjects with coronary artery disease (the Framingham Heart Study). 1992 , 70, 971-6	47
2173	Effects of sustained-release nifedipine on regression of left ventricular hypertrophy in systemic hypertension. 1992 , 69, 1559-64	11
2172	Racial differences in left ventricular structure in healthy young adults. 1992 , 69, 1196-9	58
2171	Frequency of ventricular ectopic activity in isolated systolic systemic hypertension. 1992 , 69, 557-9	10
2170	Effects of long-acting nifedipine on casual office blood pressure measurements, 24-hour ambulatory blood pressure profiles, exercise parameters and left ventricular mass and function in black patients with mild to moderate systemic hypertension. 1992 , 70, 474-8	15
2169	Left ventricular mass quantitation using single-phase cardiac magnetic resonance imaging. 1992 , 70, 259-62	20
2168	Morphologic, hemodynamic and coronary perfusion characteristics in severe left ventricular hypertrophy secondary to systemic hypertension and evidence for nonatherosclerotic myocardial ischemia. 1992 , 69, 219-24	31
2167	Regression of left ventricular mass in systemic hypertension. 1992 , 15, 5-16	18
2166	The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. 1992 , 34, 983-91	28
2165	The use of isolated myocytes to evaluate myocardial remodeling. 1992 , 2, 152-5	29
2164	Sudden cardiac death. 1992 , 17, 693-778	5
2163	The pathophysiology of sudden death in atherosclerotic heart disease. 1993 , 26, 111-23	1
2162	Function and energy metabolism of isolated hearts obtained from hyperthyroid spontaneously hypertensive rats (SHR). A ³¹ P-nuclear magnetic resonance study. 1993 , 119, 43-50	2
2161	The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats. 1993 , 20, 135-40	18
2160	Summary of 1993 WHO/ISH guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Guidelines Sub-Committee of WHO/ISH Mild Hypertension Liaison Committee. 1993 , 20, 801-8	1

2159	Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. 1993 , 71, 17A-20A	97
2158	Accuracy and reproducibility of left ventricular mass measurement by subcostal M-mode echocardiography in hypertensive patients and professional bicyclists. 1993 , 72, 620-4	11
2157	Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. 1993 , 71, 575-81	24
2156	Relation between body fat distribution and left ventricular mass in men without structural heart disease or systemic hypertension. 1993 , 71, 1477-9	9
2155	Left ventricular mass determined by transesophageal echocardiography and correlation with transthoracic echocardiography. 1993 , 72, 1085-6	2
2154	Echocardiographic assessment of left ventricular structure and diastolic filling in elderly subjects with borderline isolated systolic hypertension (the Framingham Heart Study). 1993 , 72, 662-5	41
2153	Controversies in the diagnosis and treatment of hypertension: a personal review of JNC V. 1993 , 72, 3H-9H	10
2152	Angiotensin-converting enzyme inhibitors: more different than alike? Focus on cardiac performance. 1993 , 72, 25H-36H	11
2151	Proportional hazards (Cox) regression. 1993 , 8, 702-11	65
2150	Cardioprotection with angiotensin-converting enzyme inhibitors: redefined for the 1990s. 1993 , 16, 95-103	13
2149	Structural basis for pathologic left ventricular hypertrophy. 1993 , 16, 1110-4	35
2148	Nonsustained ventricular tachycardia: identification and management of high-risk patients. 1993 , 126, 189-200	13
2147	Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. 1993 , 95, 197-202	140
2146	The cardiologist's approach to evaluation and management of the patient with essential hypertension. 1993 , 126, 648-66	4
2145	Pathogenesis and treatment of hypertension associated with diabetes mellitus. 1993 , 125, 1498-513	62
2144	Alterations in heart rate variability and its circadian rhythm in hypertensive patients with left ventricular hypertrophy free of coronary artery disease. 1993 , 126, 1364-72	93
2143	Postinfarct treatment with verapamil. Effect of verapamil in patients with hypertension. 1993 , 46 Suppl 2, 54-60	1
2142	Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy. 1993 , 46 Suppl 2, 88-94	3

2141	Individualised selection of antihypertensive therapy. 1993 , 46 Suppl 2, 142-8	6
2140	The pathogenesis of hypertension in obese subjects. 1993 , 46 Suppl 2, 197-208; discussion 208-9	17
2139	Management of the patient with left ventricular hypertrophy. 1993 , 14 Suppl D, 22-32	9
2138	Improved detection of echocardiographic left ventricular hypertrophy using a new electrocardiographic algorithm. 1993 , 21, 1680-6	64
2137	Scintigraphic and electrocardiographic evidence of silent coronary artery disease in asymptomatic hypertension: a case-control study. 1993 , 22, 1598-606	30
2136	Left ventricular hypertrophy and mortality after aortic valve replacement for aortic stenosis. A high risk subgroup identified by preoperative relative wall thickness. 1993 , 22, 1679-83	184
2135	Ambulatory blood pressure monitoring use in hypertension research and clinical practice. 1993 , 21, 510-24	180
2134	Cardioreparation and the concept of modulating cardiovascular structure and function. 1993 , 2, 6-21	29
2133	Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). 1993 , 87, 476-86	175
2132	Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in nondiabetic atherosclerotic patients. 1993 , 13, 900-6	36
2131	Interrelation of cardiac and vascular structure in young men with borderline hypertension. 1993 , 14, 1304-14	9
2130	The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. 1993 , 2, 86-100	76
2129	Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. 1993 , 14 Suppl D, 8-15	101
2128	Obstructive sleep apnea and blood pressure elevation: what is the relationship? Working Group on OSA and Hypertension. 1993 , 2, 166-82	60
2127	Left ventricular hypertrophy and hypertension. 1993 , 15, 1025-32	25
2126	Cardiac abnormalities in end stage renal failure and anaemia. 1993 , 68, 637-43	34
2125	Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension. 1993 , 21, 886-93	197
2124	Sudden cardiac death. Support for a role of triggering in causation. 1993 , 87, 1442-50	208

2123	Treatment of Mild Hypertension Study. 1993 , 270, 713	544
2122	Noninvasive 24 hour ambulatory blood pressure monitoring: current status. 1993 , 69, 255-67	10
2121	1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.. 1993 , 22, 392-403	160
2120	Vasodilator Therapy for Congestive Heart Failure. 1993 , 153, 445	13
2119	Heart disease in black and white. <i>New England Journal of Medicine</i> , 1993 , 329, 656-8	59.2 52
2118	Blood Pressure, Systolic and Diastolic, and Cardiovascular Risks. 1993 , 153, 598	735
2117	Hypertension: Steps Forward and Steps Backward. 1993 , 153, 149	22
2116	Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. 1993 , 88, 986-92	227
2115	Insulin resistance is an important determinant of left ventricular mass in the obese. 1993 , 88, 1431-6	156
2114	Ambulatory blood pressure monitoring and blood pressure self-measurement in the diagnosis and management of hypertension. 1993 , 118, 867-82	129
2113	Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Subcommittee of WHO/ISH Mild Hypertension Liaison committee. 1993 , 307, 1541-6	73
2112	Transthoracic echocardiography for evaluation of hypertensive heart disease. 1993 , 10, 295-302	1
2111	The place of alpha blockers in the antihypertensive armamentarium. 1993 , 33, 260-3	1
2110	Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. 1993 , 88, 1444-55	230
2109	Left ventricular hypertrophy: epidemiological prognosis and associated critical factors. 1993 , 14 Suppl D, 16-21	51
2108	Pressor hormone profile during stress in hypertension: does vasopressin interfere with left ventricular hypertrophy?. 1993 , 15, 539-55	5
2107	Healthy adiposity in women: the Framingham Offspring Study. 1993 , 12, 357-62	4
2106	Echocardiography in the evaluation of cardiac sources of emboli: the role of transthoracic echocardiography. 1993 , 10, 373-96	3

2105	The relationship of autonomic neuropathy to other diabetic complications. 1993 , 10 Suppl 2, 74S-76S	5
2104	Memorandum from a Who/Ish Meeting. 1993 , 15, 1363-1395	17
2103	Left ventricular hypertrophy and myocardial ischaemia in hypertension: the THAMES Study. 1993 , 14, 1622-8	16
2102	Pathophysiology and clinical aspects of hypertensive hypertrophy. 1993 , 14 Suppl D, 2-7	21
2101	Ischaemia and left ventricular hypertrophy. 1993 , 14 Suppl F, 2-6	160
2100	A multifactorial approach to coronary disease risk assessment. 1993 , 15, 1077-86	6
2099	Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin. 1993 , 9, 490-504	12
2098	Hypertension. 1993 , 159, 604-608	2
2097	An osteopathic cardiologist's review of hypertension: Beyond The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. 1994 , 94, 833-833	1
2096	Hypertension and the heart. 1994 , 50, 299-321	14
2095	Predictors of left ventricular mass in old age: an echocardiographic, clinical and biochemical investigation of a random population sample. 1994 , 15, 769-80	13
2094	Left Ventricular Geometrie Adaptation to Chronic Pressure Overload: Differences between Systemic Hypertension and Valvular Aortic Stenosis. 1994 , 8, 346-351	2
2093	Differential effects of antihypertensive drugs on hypertension: associated risk factors. 1994 , 85 Suppl 1, 78-83	
2092	Hypertension and left ventricular hypertrophy: is drug therapy beneficial?. 1994 , 14, 60-88	5
2091	Nuclear Magnetic Resonance Studies of Bioenergetics in Normal and Abnormal Myocardium. 1994 , 413-437	1
2090	Bibliography. 1994 , 160, S16	
2089	Exercise induces cardiac dysfunction in both moderate, compensated and severe hypertrophy. 1994 , 89, 2219-31	26
2088	Left Ventricular Mass and Risk of Stroke in an Elderly Cohort. 1994 , 272, 33	186

2087	Angiotensin-Converting Enzyme Inhibitors in Hypertension. 1994 , 154, 513	51
2086	Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. 1994 , 23, 600-6	320
2085	Left Ventricular Mass and Stroke. 1994 , 272, 71	4
2084	Intramural myocardial shortening in hypertensive left ventricular hypertrophy with normal pump function. 1994 , 89, 122-31	179
2083	Forearm blood flow reserve and cardiac and renal indexes of pressure load in normotensive and hypertensive individuals. 1994 , 24, 24-9	12
2082	Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uraemia?. 1994 , 71, 119-22	28
2081	Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. 1994 , 90, 1786-93	501
2080	Regulation of mitogen-activated protein kinase cascade in adult rat heart preparations in vitro. 1994 , 75, 932-41	77
2079	Left ventricular remodeling and function in adult aortic stenosis. 1994 , 45, 1033-8	14
2078	Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. 1994 , 89, 2204-11	197
2077	Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. 1994 , 90, 928-36	149
2076	Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. 1994 , 90, 2786-96	291
2075	Role of ACE inhibitors in hypertension with left ventricular hypertrophy. 1994 , 72, S24-32	6
2074	Left ventricular mass and cardiovascular reactivity in young men. 1994 , 23, 1168-71	25
2073	Growth hormone and the heart. 1994 , 15, 555-73	422
2072	Exercise blood pressure predicts cardiovascular mortality in middle-aged men. 1994 , 24, 56-62	163
2071	Cardiac and arterial hypertrophy and atherosclerosis in hypertension. 1994 , 23, 802-9	36
2070	Posttranscriptional modification of myosin heavy-chain gene expression in the hypertrophied rat myocardium. 1994 , 91, 3468-72	47

2069	Racial differences in the age-related increase in left ventricular mass in youths. 1994 , 24, 747-51	24
2068	Correlates of left ventricular mass in a population sample aged 36 to 37 years. Focus on lifestyle and salt intake. 1994 , 89, 1041-50	93
2067	Abnormalities of autonomic nervous control in human hypertension. 1994 , 8 Suppl 1, 11-20	35
2066	Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. 1994 , 8 Suppl 3, 549-56	32
2065	Effects of bisoprolol on left ventricular hypertrophy in essential hypertension. 1994 , 8, 837-43	5
2064	Echocardiography in multicenter clinical trials: experience from the Treatment of Mild Hypertension Study. 1994 , 15, 395-410	19
2063	In vitro methods to study hypertrophy of cardiac cells. 1994 , 32, 19-23	2
2062	Cardiovascular reactivity in cardiovascular disease: "once more unto the breach". 1994 , 1, 4-31	271
2061	Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes. 1994 , 73, 242-6	6
2060	Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular masses. 1994 , 73, 247-52	48
2059	Echocardiographic evidence of left ventricular hypertrophy in a general aged population. 1994 , 74, 385-90	39
2058	Disparate structural effects on left and right ventricles by angiotensin-converting enzyme inhibitors and calcium antagonists in essential hypertension. 1994 , 73, 483-7	24
2057	Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. 1994 , 74, 585-9	22
2056	A new method for indexing left ventricular mass for differences in body size. 1994 , 74, 487-91	121
2055	Comparison of ventricular mass and function in early versus late repair of coarctation of the aorta. 1994 , 73, 698-701	19
2054	Essential hypertension: pathophysiology. 1994 , 6, 322-33; quiz 334-6	
2053	Essential hypertension: evaluation and treatment. 1994 , 6, 421-35; quiz 436-8	
2052	Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. 1994 , 46, 1118-23	54

2051	The clinical significance of nonsustained ventricular tachycardia: current perspectives. 1994 , 17, 637-64	18
2050	Renin and angiotensin-converting enzyme genotypes in patients with essential hypertension and left ventricular hypertrophy. 1994 , 21, 207-10	19
2049	Mild hypertension: a summary of the 1993 World Health Organization/International Society of Hypertension (WHO/ISH) guidelines for the management of mild hypertension. Memorandum from a WHO/ISH meeting. 1994 , 235, 21-9	4
2048	Antihypertensive drugs: issues beyond blood pressure control. 1994 , 36, 397-415	8
2047	Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. 1994 , 24, 1492-8	138
2046	Echocardiographic measures of left ventricular structure and their relation with rest and ambulatory blood pressure in blacks and whites in the United Kingdom. 1994 , 24, 1499-505	68
2045	Three-dimensional echocardiography: in vitro and in vivo validation of left ventricular mass and comparison with conventional echocardiographic methods. 1994 , 24, 504-13	104
2044	Heart size: one-, two- and now three-dimensional echocardiography. 1994 , 24, 514-6	11
2043	Electrocardiographic diagnosis of left ventricular hypertrophy by the time-voltage integral of the QRS complex. 1994 , 23, 133-40	39
2042	Pathobiology of sudden death: coronary causes. 1994 , 3, 105-15	8
2041	Effect of obesity on echocardiographic parameters in children. 1994 , 46, 7-13	26
2040	Use of the signal-averaged QRS duration for diagnosing left ventricular hypertrophy in hypertensive patients. 1994 , 44, 261-70	11
2039	Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. <i>New England Journal of Medicine</i> , 1994 , 330, 1634-8	59.2 623
2038	Normalization of cardiac structure and function after regression of cardiac hypertrophy. 1994 , 128, 333-43	23
2037	Correlates of ventricular ectopic activity in isolated systolic hypertension. SHEP Cooperative Research Group. 1994 , 127, 112-21	9
2036	Total biventricular volume and total left ventricular volume by ultrafast computed tomography: prediction of left ventricular mass. 1994 , 127, 667-73	6
2035	Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy. 1994 , 96, 9S-18S	5
2034	DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. 1994 , 90, 2622-8	189

2033	Efficacy and safety of hydrochlorothiazide versus a combination of benazepril and hydrochlorothiazide. 1994 , 55, 747-758	
2032	Ambulatory blood pressure and left ventricular mass in alcohol-associated hypertension. 1994 , 55, 828-832	
2031	Sleep-disordered breathing and obesity. 1994 , 8, 601-28	22
2030	Echocardiographic assessment of left ventricular mass--what more can we learn?. 1994 , 69, 291-2	
2029	Angiotensin Converting Enzyme Inhibition with Quinapril and Left Ventricular Mass in the Hypertensive Patient. 1994 , 8, 38-48	2
2028	Insulin resistance and hypertension in the elderly. Optimal drug therapy. 1994 , 4, 403-9	4
2027	Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. 1994 , 90, 2056-69	388
2026	Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. 1994 , 24, 793-801	1369
2025	Effects of long-term treatment with sustained-release nifedipine on left ventricular hypertrophy and function in patients with essential hypertension. 1994 , 34, 266-9	4
2024	Transthoracic echo/Doppler in the identification of patients with chronic non-valvular atrial fibrillation at risk for thromboembolic events. 1994 , 15, 1545-51	24
2023	Microalbuminuria in non-diabetic individuals: a prognostic index of cardiovascular disease. 1994 , 9, 59-74	2
2022	Left ventricular mass and subsequent blood pressure changes among middle-aged men in rural and urban Japanese populations. 1994 , 89, 1717-24	35
2021	Hypertensive heart disease. 1994 , 95, 59-76	7
2020	Automated blood pressure monitoring. 1994 , 95, 89-108	4
2019	Left ventricular hypertrophy in hypertension--general and local trends in diagnosis and therapy. 1994 , 39, 35-7	1
2018	Cardiac hypertrophy in obstructive sleep apnea syndrome. 1995 , 107, 1538-44	123
2017	Remodelling of intramyocardial arterioles and extracellular matrix in patients with arterial hypertension and impaired coronary reserve. 1995 , 16 Suppl I, 82-6	31
2016	Angiotensin I converting enzyme gene polymorphism and coronary heart disease. 1995 , 16 Suppl K, 13-22	32

2015	Hypertension and ischaemic heart disease in renal transplant recipients. 1995 , 10 Suppl 1, 95-100	55
2014	Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. 1995 , 35, 1052-9	7
2013	Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. 1995 , 16, 1120-5	14
2012	Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. 1995 , 20, 364-440	27
2011	Left ventricular mass and diastolic filling patterns in quadriplegia and implications for effects of normal aging on the heart. 1995 , 75, 201-3	26
2010	Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. 1995 , 76, 699-701	243
2009	Effect of total adipose weight and systemic hypertension on left ventricular mass in children. 1995 , 76, 785-7	27
2008	Impact of echocardiographic left ventricular mass on mechanistic implications of exercise testing parameters. 1995 , 76, 952-6	15
2007	Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. 1995 , 76, 24D-30D	13
2006	Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. 1995 , 76, 48D-53D	31
2005	Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. 1995 , 76, 54D-59D	20
2004	Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. 1995 , 76, 60D-63D	20
2003	Which definition for echocardiographic left ventricular hypertrophy?. 1995 , 75, 498-502	64
2002	New concepts regarding events that lead to myocardial infarction. 1995 , 9 Suppl 3, 479-87	7
2001	Left ventricular hypertrophy and diastolic dysfunction: their relation to coronary heart disease. 1995 , 9 Suppl 3, 533-7	22
2000	Diastolic dysfunction is not related to changes in glycaemic control over 6 months in type 2 (non-insulin-dependent) diabetes mellitus. A cross-sectional study. 1995 , 32, 110-5	25
1999	Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. 1995 , 47, 186-92	881
1998	Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in patients with hypertensive heart disease. 1995 , 18, 377-83	16

1997	Effects of ACE inhibition on cardiovascular risk factors, insulin resistance, and microalbuminuria. 1995 , 18, 1-3-1-11		
1996	Coronary Heart Disease. 1995 , 6, 37-53		
1995	Framingham study insights into hypertensive risk of cardiovascular disease. 1995 , 18, 181-96		114
1994	Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment. 1995 , 16, 1981-7		8
1993	Metabolic and Cardiovascular Characteristics of Hypertension. 1995 , 13, 539-547		2
1992	The role of the autonomic nervous system in hypertension. 1995 , 18, 99-110		48
1991	Structural changes in the cardiovascular system of untreated essential hypertensives. 1995 , 4, 42-7		12
1990	Normotension and hypertension defined by 24-hour ambulatory blood pressure monitoring. 1995 , 4, 266-82		71
1989	Blood pressure variability and its implications for antihypertensive therapy. 1995 , 4, 5-11		52
1988	Silent myocardial ischaemia in untreated essential hypertensives. 1995 , 4, 97-104		5
1987	The Relative Effects of Left Ventricular Hypertrophy, Coronary Artery Disease, and Ventricular Dysfunction on Survival Among Black Adults. 1995 , 273, 1592		193
1986	Cellular mechanisms of cardiac hypertrophy. 1995 , 73, 496-9		34
1985	Birth weight, weight at one year, and left ventricular mass in adult life. 1995 , 73, 363-7		73
1984	Quantitative Echocardiography Part III: A Review of Methods for the Assessment of Left Ventricular Systolic Performance by Two-Dimensional and Doppler Echocardiography. 1995 , 11, 285-299		
1983	Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. <i>New England Journal of Medicine</i> , 1995 , 333, 1462-7	59.2	234
1982	Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. 1995 , 270, 23173-8		240
1981	Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry. 1995 , 73, 548-54		105
1980	Determination of left ventricular mass in systemic hypertension: comparison of standard and signal averaged electrocardiography. 1995 , 74, 277-81		4

1979	Left ventricular mass index negatively correlates with heart rate variability in essential hypertension. 1995 , 8, 183-8	30
1978	White coat hypertension and white coat effect. Similarities and differences. 1995 , 8, 790-8	126
1977	Ischemic episodes in 24-h ambulatory electrocardiograms of elderly persons: the Cardiovascular Health Study. 1995 , 51, 165-75	12
1976	Ambulatory blood pressure measurement and the occurrence of hypertensive organ involvement. 1995 , 47, 145-51	4
1975	Hemodialysis versus continuous ambulatory peritoneal dialysis: effects on the heart. 1995 , 19, 241-4	30
1974	Echocardiographic left ventricular systolic function and volumes in young adults: distribution and factors influencing variability. 1995 , 129, 571-7	26
1973	The effect of amlodipine on the mass and functions of the left ventricle in patients with primary hypertension and left ventricular hypertrophy. 1995 , 56, 607-616	2
1972	Left ventricular mass estimation by echocardiography: is it clinically useful?. 1995 , 12, 185-93	3
1971	Left ventricular diastolic function in hypertension: a 4 year follow-up study. 1995 , 50, 181-8	16
1970	Association of carotid atherosclerosis and left ventricular hypertrophy. 1995 , 25, 83-90	206
1969	Influence of left ventricular hypertrophy on left ventricular function during dynamic exercise in the presence or absence of coronary artery disease. 1995 , 25, 91-8	25
1968	Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. 1995 , 25, 417-23	310
1967	Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. 1995 , 25, 424-30	163
1966	Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. 1995 , 25, 871-8	336
1965	Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) study. 1995 , 25, 895-900	22
1964	Prognosis of left ventricular geometric patterns in the Framingham Heart Study. 1995 , 25, 879-84	417
1963	Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. 1995 , 25, 1056-62	760
1962	Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. 1995 , 25, 1154-61	429

1961	Left ventricular geometry, pathophysiology and prognosis. 1995 , 25, 885-7	68
1960	Cardiac function in smokers and nonsmokers: the CARDIA study. The Coronary Artery Risk Development in Young Adults Study. 1995 , 26, 211-6	53
1959	Gender-specific reference M-mode values in adults: population-derived values with consideration of the impact of height. 1995 , 26, 1039-46	82
1958	Comparison of M-mode and two-dimensional echocardiographic algorithms used to estimate left ventricular mass: the Coronary Artery Risk Development in Young Adults Study. 1995 , 8, 780-92	11
1957	The defense reaction: a common denominator of coronary risk and blood pressure in neurogenic hypertension?. 1995 , 17, 375-86	32
1956	Cell-free thymic extract from hypertensive rats induces hypertension in normotensive rats. 1995 , 17, 137-49	1
1955	Left ventricular hypertrophy. Prevalence in older patients and management. 1995 , 6, 301-11	3
1954	Goals of antihypertensive therapy. 1995 , 49, 161-75	26
1953	Choosing the right ACE inhibitor. A guide to selection. 1995 , 49, 516-35	51
1952	Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. 1995 , 49, 618-49	27
1951	Risk and management of hypertension-related left ventricular hypertrophy. 1995 , 50, 959-70	3
1950	Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. 1996 , 9, 119-28	134
1949	Increased cardiovascular morbidity and mortality in diabetes mellitus: identification of the high risk patient. 1996 , 30 Suppl, 85-8	20
1948	Angiotensin II mediates mechanical stress-induced cardiac hypertrophy. 1996 , 30 Suppl, 107-11	12
1947	Carotid artery and left ventricular structural relationship in asymptomatic men at risk for cardiovascular disease. 1996 , 127, 103-12	53
1946	Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to definition of hypertrophy and presence of obesity. 1996 , 27, 124-31	77
1945	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. 1996 , 27, 978-90	80
1944	Severe aortic stenosis without left ventricular hypertrophy: prevalence, predictors, and short-term follow up after aortic valve replacement. 1996 , 76, 250-5	36

1943	Adverse effects of thyroid hormone preparations and antithyroid drugs. 1996 , 15, 53-63	65
1942	Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. 1996 , 132, 1004-9	20
1941	Vascular hypertrophy is an early finding in essential hypertension and is related to arterial pressure waveform contour. 1996 , 132, 621-7	17
1940	Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. 1996 , 131, 313-9	62
1939	Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. 1996 , 132, 222-228	6
1938	Blood pressure control. 1996 , 101, 50S-55S	9
1937	Blood pressure levels and variability, smoking, and left ventricular structure in normotension and in borderline and mild hypertension. 1996 , 9, 1110-8	10
1936	Sensitivity to ischemia of chronically infarcted rat hearts; effects of long-term captopril treatment. 1996 , 298, 121-8	7
1935	Blood Pressure as a Cardiovascular Risk Factor. 1996 , 275, 1571	635
1934	Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke. 1996 , 78, 425-9	41
1933	Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. 1996 , 27, 347-54	548
1932	Effect of echocardiography on clinical impact and patient outcome in hypertension. 1996 , 9, 585-90	2
1931	Cardiovascular risk associated with hypertension; interactions with other risk indicators. 1996 , 59-69	1
1930	Investigation of the relationship between regression of hypertensive cardiac hypertrophy and improvement of cardiac sympathetic nervous dysfunction using iodine-123 metaiodobenzylguanidine myocardial imaging. 1996 , 23, 756-61	16
1929	How important is 24-hour control of blood pressure?. 1996 , 15, 243-8	8
1928	Current drug treatment and treatment patterns with antihypertensive drugs. 1996 , 52, 1-16	21
1927	Effects of Angiotensin-Converting Enzyme Inhibitors on the Heart and Vessels in Clinical and Experimental Hypertension. 1996 , 12, 226-243	6
1926	Cardiovascular structural alterations in hypertension: effect of treatment. 1996 , 18, 513-22	3

1925	Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. 1996 , 271, 33592-7	171
1924	Clinical significance of pressor responses to laboratory stressor testing in hypertension. 1996 , 19, 133-7	12
1923	Cardiovascular Disease in Peritoneal Dialysis. 1996 , 16, 19-22	12
1922	The Effects of Amlodipine on Left Ventricular Mass and Diastolic Function in Concentric and Eccentric Left Ventricular Hypertrophy. 1996 , 1, 95-100	6
1921	Age and gender differences in left ventricular function among patients with stable angina and a matched control group. A report from the Angina Prognosis Study in Stockholm. 1996 , 87, 287-93	7
1920	Clinical Insights Derived from Cardiovascular Epidemiology. 1996 , 5, 172-186	
1919	Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. 1996 , 44, 524-9	38
1918	Effects of angiotensin-converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension. 1996 , 36, 1141-8	6
1917	Reversal of left-ventricular hypertrophy in uremic patients by treatment with daily hemodialysis (DHD). 1996 , 119, 152-6	40
1916	Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat?. 1996 , 14, 315-20	1
1915	Prevalence of left ventricular hypertrophy in a hypertensive population. 1996 , 17, 143-9	27
1914	Analyses of cost effectiveness in the management of essential hypertension: what they can and what they do not teach us. 1996 , 19, 810-6	7
1913	A case of hypertension. 1996 , 11, 226-8	0
1912	Blood pressure responses to stress: Relation to left ventricular structure and function. 1996 , 18, 61-6	12
1911	123I-MIBG myocardial imaging in hypertensive patients: abnormality progresses with left ventricular hypertrophy. 1996 , 10, 315-21	5
1910	Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. 1996 , 78, 197-202	106
1909	Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. 1996 , 77, 17b-19b	19
1908	Carotid artery measures are strongly associated with left ventricular mass in older adults (a report from the Cardiovascular Health Study). 1996 , 77, 628-33	43

1907	Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. 1996 , 77, 1315-9	82
1906	Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function. 1996 , 78, 56-60	26
1905	Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). 1996 , 78, 61-5	121
1904	Torsade de pointes due to consumption of Sauropus androgynus as a weight-reducing vegetable. 1996 , 78, 1186-7	11
1903	ECG identification of left ventricular hypertrophy. Relationship of test performance to body habitus. 1996 , 29 Suppl, 256-61	31
1902	Hemodynamic benefits of the Toronto Stentless Valve. 1996 , 112, 1431-45; discussion 1445-6	92
1901	Stressful events as a trigger of sudden death: a study of 43 medico-legal autopsy cases. 1996 , 79, 1-10	53
1900	Influence of obesity on cardiac mass and blood pressure in the elderly. 1996 , 22 Suppl 1, 149-55	
1899	Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. 1996 , 91, 248-55	65
1898	Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy and failure. 1996 , 91 Suppl 2, 65-71	10
1897	Molecular aspects of mechanical stress-induced cardiac hypertrophy. 1996 , 163-164, 197-201	22
1896	Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. 1996 , 10 Suppl 2, 639-47	9
1895	Antiarrhythmic drug therapy for ventricular arrhythmias: current perspectives. 1996 , 7, 653-70	14
1894	Multivariate Analysis of Left Ventricular Mass Determinants in Adults: Different Patterns in Men and Women. 1996 , 13, 35-44	
1893	Classification Accuracy of Electrocardiographic Criteria for Left Ventricular Hypertrophy in Normal Weight and Overweight Older Adults. 1996 , 1, 121-132	7
1892	Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. 1996 , 49, 1379-85	349
1891	Left ventricular abnormalities in children, adolescents and young adults with renal disease. 1996 , 50, 998-1006	127
1890	Down-regulation of angiotensin II receptors in hypertrophied human myocardium. 1996 , 23, 514-8	9

1889	Cardiac growth during high and low dose perindopril treatment in spontaneously hypertensive rats. 1996 , 23, 605-7		8
1888	Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. <i>New England Journal of Medicine</i> , 1996 , 334, 1023-8	59.2	201
1887	Hypertension, hypertrophy, heart failure. 1996 , 76, 92-7		9
1886	Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy. 1996 , 1, 17-22		
1885	The renin-angiotensin system and cardiac hypertrophy. 1996 , 76, 33-5		12
1884	Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. 1996 , 271, 3221-8		267
1883	Influence of measurement inaccuracies on determination of left ventricular mass by M mode echocardiography. 1996 , 75, 312-3		7
1882	Coronary haemodynamics in left ventricular hypertrophy. 1996 , 75, 369-76		9
1881	The Concept of Cardioreparation: Part 1. Pathophysiology of Remodelling. 1996 , 3, 281-285		1
1880	Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment. 1996 , 5, 5-15		16
1879	Ambulatory blood pressure and echocardiographic left ventricular dimensions in elderly hypertensive subjects. 1996 , 47, 981-9		6
1878	Reversal of Left Ventricular Hypertrophy in Essential Hypertension. 1996 , 275, 1507		343
1877	The renin-angiotensin-aldosterone system and cardiac ischaemia. 1996 , 76, 60-7		7
1876	Regression of Left Ventricular Hypertrophy. 1996 , 275, 1517		10
1875	Calcium antagonist drugs in hypertensive patients with angina pectoris. 1996 , 17 Suppl G, 20-4		4
1874	Cardiac anatomy, function and metabolism in elite cyclists assessed by magnetic resonance imaging and spectroscopy. 1996 , 17, 1271-8		36
1873	Cardiovascular characteristics in normotensive subjects with or without family history of hypertension. 1996 , 18, 901-20		8
1872	Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. <i>New England Journal of Medicine</i> , 1996 , 335, 1070; author reply 1071	59.2	2

1871	The effect of preoperative intra-aortic balloon pump support in patients with coronary artery disease, poor left-ventricular function (LVEF 1997, 45, 60-4	42
1870	Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. 1997 , 82, 106-12	176
1869	Intra-arterial blood pressure during exercise and left ventricular indices in normotension and borderline and mild hypertension. 1997 , 6, 5-12	6
1868	Structural Changes in the Heart and Carotid Arteries in Hypertensive Patients Associated with Cardiovascular Risk Factors. 1997 , 4, 283-289	
1867	Salt. 1997 , 157, 2449	65
1866	The relationship of blood pressure to cardiac hypertrophy: experimental studies in rats. 1997 , 19, 827-41	7
1865	Arterial structural modifications in hypertension: Effects of treatment. 1997 , 18, 2-4	8
1864	Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. 1997 , 77, 24-31	91
1863	The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status. 1997 , 6, 365-7	18
1862	Should the contribution of ACE gene polymorphism to left ventricular hypertrophy be reconsidered?. 1997 , 77, 489-90	7
1861	Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. 1997 , 29, 519-24	74
1860	Prognostic value of arrhythmogenic markers in systemic hypertension. 1997 , 18, 1484-91	26
1859	Smoking status and nicotine administration differentially modify hemodynamic stress reactivity in men and women. 1997 , 59, 294-306	54
1858	Measurement of left ventricular mass: methodology and expertise. 1997 , 15, 801-9	63
1857	Effect of benidipine on microvascular remodeling and coronary flow reserve in two-kidney, one clip Goldblatt hypertension. 1997 , 15, 1285-94	19
1856	Heart rate and the cardiovascular risk. 1997 , 15, 3-17	357
1855	Myocardial and forearm blood flow reserve in mild-moderate essential hypertensive patients. 1997 , 15, 667-73	16
1854	Prognostic value of ventricular arrhythmias in systemic hypertension. 1997 , 15, 1779-83	27

1853	Cardiac disease in chronic uremia: pathophysiology. 1997 , 4, 212-24	75
1852	Left ventricular morphology in chronic renal failure by echocardiography. 1997 , 19, 799-806	13
1851	[Comparison of the sensitivity and specificity of the electrocardiography criteria for left ventricular hypertrophy according to the methods of Romhilt-Estes, Sokolow-Lyon, Cornell and Rodríguez Padial]. 1997 , 50, 31-5	12
1850	The heart and conduit vessels in hypertension. 1997 , 81, 1247-71	6
1849	Determination of left ventricular mass and circumferential wall thickness by three-dimensional reconstruction: in vitro validation of a new method that uses a multiplane transesophageal transducer. 1997 , 10, 107-19	27
1848	Freehand three-dimensional echocardiography for determination of left ventricular volume and mass in patients with abnormal ventricles: comparison with magnetic resonance imaging. 1997 , 10, 853-61	95
1847	Hypertension and coronary artery disease. 1997 , 81, 1147-63	2
1846	Disfunci3n diast3lica, hipertrofia ventricular izquierda y microalbuminuria en la hipertensi3n arterial esencial ligera-moderada. 1997 , 50, 233-238	4
1845	[Nifedipine in the treatment of moderate and severe arterial hypertension. Long-term effect on arterial pressure and on the left ventricle]. 1997 , 50, 567-72	0
1844	Impact of a Low-Dose Reserpine/Thiazide Combination on Left Ventricular Hypertrophy Assessed with Magnetic Resonance Tomography and Echocardiography. 1997 , 14, 109-116	
1843	Hypertension. 1997 , 2, 8-21	
1842	Screening For Left Ventricular Dysfunction and Chronic Heart Failure. 1997 , 1, 169-184	16
1841	Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension. 1997 , 134, 557-64	9
1840	Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study. 1997 , 133, 36-43	126
1839	Nonlipoprotein risk factors for coronary heart disease: evaluation and management. 1997 , 102, 7-14	34
1838	Impact of alpha- versus beta-blockers on hypertensive target organ damage: results of a double-blind, randomized, controlled clinical trial. 1997 , 10, 985-91	11
1837	How should we treat hypertensive women with cardiac and renal impairment?. 1997 , 10, 242S-246S	4
1836	Current trends in the treatment of hypertension: a mixed picture. 1997 , 10, 300S-305S	7

1835	Effect of a dominant negative ras on myocardial hypertrophy by using adenoviral-mediated gene transfer. 1997 , 122, 404-10; discussion 410-1	8
1834	Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. 1997 , 121, 157-61	42
1833	Cardiac myocytes and fibroblasts contain functional estrogen receptors. 1997 , 416, 107-12	279
1832	Prediction of mortality risk by different methods of indexation for left ventricular mass. 1997 , 29, 641-7	147
1831	How best to identify prognostically important left ventricular hypertrophy: a cut to the chase. 1997 , 29, 648-50	22
1830	Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. 1997 , 29, 1109-16	141
1829	Freehand three-dimensional echocardiography for measurement of left ventricular mass: in vivo anatomic validation using explanted human hearts. 1997 , 30, 802-10	72
1828	Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. 1997 , 30, 1802-8	28
1827	Relation of hemodynamic volume load to arterial and cardiac size. 1997 , 29, 1303-10	42
1826	Relationship between left ventricular hypertrophy, myocardial contractility, and load conditions in hemodialysis patients: an echocardiographic study. 1997 , 30, 780-5	29
1825	Ambulatory blood pressure monitoring in renal dialysis and transplant patients. 1997 , 29, 593-600	64
1824	Sodium sensitivity and cardiovascular events in patients with essential hypertension. 1997 , 350, 1734-7	354
1823	Hypertension and pathologic cardiovascular remodeling: a potential therapeutic role for T-type calcium antagonists. 1997 , 19 Suppl A, 27-38	5
1822	Myocardial ischemia and ventricular arrhythmias in relation to left ventricular mass and resistance artery structure. 1997 , 88, 141-6	2
1821	Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. 1997 , 94, 14730-5	490
1820	Angiotensin-converting enzyme gene insertion/deletion polymorphism and left ventricular hypertrophy in hemodialysis patients. 1997 , 38, 821-30	6
1819	Discussion. 1997 , 8, 269-269	
1818	Research in coronary heart disease in blacks: issues and challenges. 1997 , 8, 250-69	1

1817	Effects of ACE inhibitors versus calcium antagonists on left ventricular morphology and function in patients with essential hypertension. 1997 , 20, 7-10	5
1816	The epidemiology of heart failure. 1997 , 18, 208-25	665
1815	Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. 1997 , 20, 85-90	124
1814	New insights into the treatment of hypertension. 1997 , 24, 978-81	
1813	Congestive heart failure and arrhythmias: therapeutic modalities. 1997 , 8, 89-97	10
1812	Role of intracellular sodium overload in the genesis of cardiac arrhythmias. 1997 , 8, 700-21	57
1811	Interobserver Variability of Left Ventricular Measurements in a Population of Predominantly Obese Hypertensives Using Simultaneously Acquired and Displayed M-Mode and 2-D Cine Echocardiography. 1997 , 14, 9-14	7
1810	Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene. 1997 , 51, 1205-11	28
1809	Coronary circulation and left ventricular function in hypertension. 1997 , 11, 639-659	
1808	Hypertension, cardiac hypertrophy and the effects of anaesthesia. 1997 , 11, 675-703	
1807	Extent and pattern of regression of left ventricular hypertrophy in patients with small size CarboMedics aortic valves. 1997 , 113, 901-9	25
1806	Left ventricular size determined by electron beam computed tomography predicts significant coronary artery disease and events. 1997 , 79, 1236-8	18
1805	Cardiac effects of calcium antagonists in systemic hypertension. 1997 , 79, 39-46; discussion 47-8	26
1804	Comparison of left ventricular mass and geometric remodeling in treated and untreated men and women >50 years of age with systemic hypertension. 1997 , 80, 648-51	6
1803	MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. 1997 , 16, 1888-900	121
1802	Hostility, testosterone, and vascular reactivity to stress: effects of sex. 1997 , 4, 242-63	21
1801	Body composition and source of weight loss after bariatric surgery. 1997 , 7, 184-8	23
1800	Left ventricular mass assessed by three-dimensional echocardiography using rotational acquisition. 1997 , 20, 957-62	12

1799	Ultrastructural changes during myocardial hypertrophy and its regression: long-term effects of nifedipine in adult spontaneously hypertensive rats. 1997 , 12, 143-51	13
1798	Reversing effects of DDPH on cardiac hypertrophy and increased collagen content induced by partial narrowing of abdominal aorta. 1997 , 17, 147-50	
1797	Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. 1997 , 431, 265-73	53
1796	Hemostatic variables and ischemic cardiovascular disease: do we need a concerted effort for more profitable future clinical investigations?. 1997 , 10, 743-9	1
1795	Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. 1997 , 14, 538-46	35
1794	Adverse reactions to antihypertensive therapy. 1998 , 12, 189-96	8
1793	Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. 1998 , 12, 469-74	31
1792	Beneficial effects of renal transplantation on cardiovascular disorders in dialysis patients. 1998 , 28, 811-5	7
1791	Left atrial abnormality by electrocardiogram predicts left ventricular hypertrophy by echocardiography in the presence of right bundle-branch block. 1998 , 21, 109-14	3
1790	Symmetric and asymmetric left ventricular hypertrophy in patients with end-stage renal failure on long-term hemodialysis. 1998 , 21, 672-8	15
1789	Ventricular arrhythmias in adult aortic stenosis: prevalence, mechanisms, and clinical relevance. 1998 , 113, 482-91	54
1788	Hypertension, blood pressure variability, and target organ damage. 1998 , 12 Suppl 1, 57s-63s	1
1787	Absence of detectable regression of human hypertensive left ventricular hypertrophy following drug treatment for 1 year. 1998 , 25, 208-15	1
1786	Cardiac autonomic modulation and incidence of late potentials in essential hypertension: role of age, sex, ventricular mass and remodeling. 1998 , 12, 13-20	2
1785	Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VENTricular hypertrophy Regression. 1998 , 12, 479-83	9
1784	Significance of blood pressure levels achieved with felodipine anti-hypertensive treatment on cardiovascular structure and function changes. 1998 , 12, 427-32	2
1783	Gender specific differences in left ventricular adaptation to obesity and hypertension. 1998 , 12, 685-91	73
1782	Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ changes?. 1998 , 12, 743-8	50

1781	Clinical and hemodynamic comparison of the Medtronic Freestyle and Toronto SPV stentless valves. 1998 , 13, 398-407	5
1780	Impact of ethnicity on left ventricular mass and relative wall thickness in essential hypertension. 1998 , 81, 412-7	30
1779	A simple nomogram for determination of echocardiographic left ventricular geometry. 1998 , 82, 485-9	6
1778	Comparison in systemic hypertension of left ventricular mass and geometry with systolic and diastolic function in patients or = 65 years of age. 1998 , 82, 604-8	39
1777	Systemic hypertension and coronary artery disease: the link. 1998 , 82, 2H-7H	23
1776	The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial. 1998 , 82, 23R-28R	27
1775	Aortic valve replacement with stentless and stented porcine valves: a case-match study. 1998 , 116, 236-41	112
1774	Signalling pathways for cardiac hypertrophy. 1998 , 10, 693-8	80
1773	Experimental validation of an automated edge-detection method for a simultaneous determination of the endocardial and epicardial borders in short-axis cardiac MR images: application in normal volunteers. 1998 , 8, 1006-14	34
1772	Comparison of fast spiral, echo planar, and fast low-angle shot MRI for cardiac volumetry at .5T. 1998 , 8, 1033-9	16
1771	Functional and metabolic evaluation of the hypertrophied heart using MRI and 31P-MRS. 1998 , 6, 168-70	2
1770	[The renin-angiotensin system in cardiovascular diseases]. 1998 , 93, 416-25	4
1769	Heat shock protein expression in hearts hypertrophied by genetic and nongenetic hypertension. 1998 , 13, 30-9	4
1768	Postexercise vasodilatation reduces diastolic blood pressure responses to stress. 1998 , 20, 77-83	25
1767	Effects of perindopril on vascular wall and left ventricular hypertrophy in rats with experimental hypertension. 1998 , 18, 78-82	1
1766	Quantitative examination of the cardiac myocytes in hypertensive rats under chronic inhibition of nitric oxide synthesis. 1998 , 5, 363-9	12
1765	Functional and metabolic evaluation of the hypertrophied heart using MRI and 31P-MRS. 1998 , 6, 168-170	2
1764	Sodium, angiotensin II, blood pressure, and cardiac hypertrophy. 1998 , 67, S213-5	21

1763	Left ventricular geometry and function are related to electrocardiographic characteristics and diagnoses. 1998 , 18, 463-70	18
1762	Improved quantification of myocardial mass by three-dimensional echocardiography using a deposit contrast agent. 1998 , 24, 647-53	11
1761	Are insulin metabolism and night-time blood pressure related to left ventricular hypertrophy?. 1998 , 63, 261-5	4
1760	[Aging and regression of cardiac hypertrophy in the hypertensive patient]. 1998 , 19, 870-7	
1759	Ethnic (black-white) contrasts in heart rate variability during cardiovascular reactivity testing in male adolescents with high and low blood pressure: the Bogalusa Heart Study. 1998 , 11, 196-202	40
1758	Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus. 1998 , 11, 184-9	13
1757	Left ventricular geometric patterns and QT dispersion in borderline and mild hypertension: their evolution and regression. 1998 , 11, 286-92	21
1756	Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. 1998 , 11, 263-71	22
1755	Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. 1998 , 11, 387-96	58
1754	Association Between Left Atrial Enlargement and Target Organ Damage in Essential Hypertension. 1998 , 11, 732-733	2
1753	Is Sexual Dysfunction in Hypertensive Women Uncommon or Understudied?. 1998 , 11, 733-735	4
1752	Determinants of left ventricular mass in early hypertension. 1998 , 11, 1248-51	7
1751	Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. 1998 , 11, 1171-7	34
1750	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. 1998 , 11, 1394-404	48
1749	Hypertension: where have we gone wrong and how can we fix it?. 1998 , 11, 150S-157S	5
1748	Prediction of adult hypertension by K4 and K5 diastolic blood pressure in children: the Bogalusa Heart Study. 1998 , 132, 687-92	53
1747	Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. 1998 , 31, 383-90	172
1746	Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients. 1998 , 31, 1064-73	123

1745	Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. 1998 , 31, 1635-40	178
1744	The associations of body size and body composition with left ventricular mass: impacts for indexation in adults. 1998 , 32, 451-7	120
1743	Association of chronotropic incompetence with echocardiographic ischemia and prognosis. 1998 , 32, 1280-6	66
1742	Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. 1998 , 32, 1454-9	627
1741	Left ventricular hypertrophy and sudden death. 1998 , 32, 1460-2	5
1740	Increased intraventricular velocities: an unrecognized cause of systolic murmur in adults. 1998 , 32, 1589-95	13
1739	Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. 1998 , 135, S21-30	75
1738	New concepts in hypertension: focus on the elderly. 1998 , 135, S2-7	22
1737	[Current indications for implantable automatic defibrillators]. 1998 , 51, 259-73	2
1736	Hypertension in women: current understanding of gender differences. 1998 , 73, 157-65	41
1735	Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease. 1998 , 32, 356-9	16
1734	Nicardipine normalizes elevated levels of antioxidant activity in response to xanthine oxidase-induced oxidative stress in hypertensive rat heart. 1998 , 29, 143-50	13
1733	Isolated systolic hypertension: an important cardiovascular risk factor. 1998 , 7, 197-207	41
1732	Effects of Amlodipine and Lisinopril on Left Ventricular Mass and Diastolic Function in Previously Untreated Patients with Mild to Moderate Diastolic Hypertension. 1998 , 7, 109-117	14
1731	Clinical Advantages of Lipophilic Dihydropyridines. 1998 , 7, 23-26	5
1730	Action potential prolongation and potassium currents in left-ventricular myocytes isolated from hypertrophied rabbit hearts. 1998 , 30, 43-53	49
1729	Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. 1998 , 135, 58-66	69
1728	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. 1998 , 140, 199-270	422

1727	Selection bias in clinical research when subjects are excluded because of failure to estimate left ventricular mass by echocardiography. 1998 , 11, 1050-5	9
1726	Hypertension as a Candidate for Disease Management Initiatives. 1998 , 3, 215-227	1
1725	Haemodynamics and left ventricular mass regression: a comparison of the stentless, stented and mechanical aortic valve replacement. 1998 , 13, 572-5	37
1724	Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. 1998 , 7, 160-9	10
1723	Carvedilol in the treatment of hypertension--a review of the clinical data base. 1998 , 47, 67-80	5
1722	Clinical Advantages of Lipophilic Dihydropyridines. 1998 , 7, 23-26	3
1721	Hypertrophic cardiomyopathy--beyond the sarcomere. <i>New England Journal of Medicine</i> , 1998 , 338, 1303-4.2	14
1720	Utility of electrocardiogram for predicting increased left ventricular mass in asymptomatic men at risk for cardiovascular disease. 1998 , 11, 861-5	5
1719	Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study. 1998 , 32, 424-9	30
1718	Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. 1998 , 98, 794-9	441
1717	Isolated diastolic heart failure--what is it?. 1998 , 74, 451-4	9
1716	Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. 1998 , 97, 1907-11	323
1715	Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. 1998 , 97, 569-75	164
1714	Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. 1998 , 32, 989-97	253
1713	Concerning minimal cardiac effects in asymptomatic athyreotic patients treated with thyrotropin-suppressive doses of L-thyroxine. 1998 , 83, 2607-8	1
1712	Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. 1998 , 83, 4284-8	51
1711	Hyperinsulinaemia, regional adipose tissue distribution and left ventricular mass in normotensive, elderly, obese subjects. 1998 , 19, 326-31	37
1710	Bone and collagen turnover in patients with active and preclinical Cushing's syndrome and in subjects with adrenal incidentaloma. 1998 , 83, 2605-6	

1709	Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?. <i>New England Journal of Medicine</i> , 1998 , 338, 1305-6	59.2	29
1708	Comment on prostatic hyperplasia in patients with acromegaly. 1998 , 83, 2606-7		1
1707	Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function. 1998 , 24, 797-804		15
1706	Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. 1998 , 3, 5-13		26
1705	Regression of Left Ventricular Wall Thickness during Ace-Inhibitor Treatment of Essential Hypertension is Associated with an Increase in Insulin Mediated Skeletal Muscle Blood Flow. 1998 , 7, 118-126		8
1704	Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. 1998 , 98, 2037-42		164
1703	Normotensive Offspring of Hypertensive Parents: No Evidence of Left Ventricular Diastolic Dysfunction in a Cross-sectional Study. 1998 , 7, 5-9		
1702	Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice. 1998 , 273, 24037-43		108
1701	Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. 1998 , 97, 666-72		121
1700	Relations of left ventricular mass to fat-free and adipose body mass: the strong heart study. The Strong Heart Study Investigators. 1998 , 98, 2538-44		199
1699	The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. 1998 , 7, 176-83		132
1698	Acute pressure overload could induce hypertrophic responses in the heart of angiotensin II type 1a knockout mice. 1998 , 82, 779-85		73
1697	Prognostic significance of serial changes in left ventricular mass in essential hypertension. 1998 , 97, 48-54		514
1696	Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. 1998 , 32, 983-8		335
1695	Clinical and epidemiological significance of left ventricular mass assessed in children and adolescents. 1998 , 97, 1893-4		6
1694	Time-voltage QRS area of the 12-lead electrocardiogram: detection of left ventricular hypertrophy. 1998 , 31, 937-42		69
1693	Tracking of left ventricular mass in children: race and sex comparisons: the MCV Twin Study. Medical College of Virginia. 1998 , 97, 1901-6		56
1692	What is the value of home (self) blood pressure monitoring in patients with hypertensive heart disease?. 1998 , 11, 813-9		15

1691	Ethnic differences in the hypertensive heart and 24-hour blood pressure profile. 1998 , 31, 1190-4	52
1690	Hypertensive vascular disease as a cause of death in blacks versus whites: autopsy findings in 587 adults. 1998 , 31, 1070-6	15
1689	Prediction of Left Ventricular Mass in Youth with Family Histories of Essential Hypertension. 1998 , 315, 118-123	
1688	Variants of renin-angiotensin system genes and echocardiographic left ventricular mass. 1998 , 19, 1109-17	23
1687	Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. 1998 , 19, 1434-503	757
1686	Endothelin as a regulator of cardiovascular function in health and disease. 1998 , 16, 1081-98	281
1685	Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. 1998 , 16, 1389-95	15
1684	Ambulatory blood pressure in the hypertensive population: patterns and prevalence of hypertensive subforms. 1998 , 16, 1735-43	29
1683	A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. 1998 , 89, 263-70	11
1682	Long-term prognosis after acute myocardial infarction in patients with a history of arterial hypertension. TRACE study group. 1998 , 19, 588-94	47
1681	Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. 1998 , 16, 1031-41	223
1680	Cardiac hypertrophy and hypertension. 1998 , 7, 211-6	10
1679	Various ways of calculating echocardiographic left ventricular mass and their relative prognostic values. 1998 , 16, 1201-6	7
1678	Cardiothoracic ratio and relative heart volume as predictors of coronary heart disease mortality. The Whitehall study 25 year follow-up. 1998 , 19, 859-69	27
1677	Heterogeneity of left ventricular hypertrophy--does it have clinical implications?. 1998 , 13, 17-9	46
1676	Relationship between left ventricular mass and serum cholesterol level in the untreated hypertensive. 1998 , 16, 1043-7	15
1675	Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. 1998 , 16, 1345-55	46
1674	Structural association between the carotid artery and the left ventricle in a general population in Northern Italy: the Vobarno study. 1998 , 16, 1805-12	24

1673	Prevalence of episodes of ST-segment depression among mild-to-moderate hypertensive patients in northern Italy: the Cardioscreening Study. 1998 , 16, 681-8	24
1672	Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. 1998 , 16, 689-96	19
1671	Assessment of prevalence of left ventricular hypertrophy in hypertension. 1998 , 16, 715-23	36
1670	The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. 1998 , 16, 1685-91	157
1669	Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. 1998 , 16, 1515-22	18
1668	Should exercise blood pressure be measured in clinical practice?. 1998 , 16, 15-7	7
1667	Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24 h blood pressure. 1998 , 16, 1253-9	17
1666	Left ventricular systolic function in primary aldosteronism and hypertension. 1998 , 16, 2075-7	21
1665	Clinical impact of various geometric models for calculation of echocardiographic left ventricular mass. 1998 , 16, 1207-14	18
1664	Effect of treatment of isolated systolic hypertension on left ventricular mass. 1998 , 279, 778-80	34
1663	Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy. 1998 , 62, 47-52	9
1662	Changes of ischemic heart disease in Utsunomiya, Japan, over 10 years: a survey of primary care physicians. 1998 , 62, 675-9	3
1661	Long-term effects of delapril hydrochloride on procollagen type III amino-terminal peptide, left ventricular mass and left ventricular function in hypertensive patients. 1998 , 62, 900-2	2
1660	Preinfarction blood pressure and smoking are determinants for a fatal outcome of myocardial infarction: a prospective analysis from the Finnmark Study. 1998 , 158, 1326-32	32
1659	Relation between coronary blood flow and left ventricular mass in hypertension: noninvasive quantification of coronary blood flow by thallium-201 myocardial scintigraphy. 1998 , 21, 227-34	17
1658	Relationship between electrocardiographic voltage and geometric patterns of left ventricular hypertrophy in patients with essential hypertension. 1998 , 21, 259-66	13
1657	Assessment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropine stress echocardiography: effect of the left ventricular hypertrophy. 1998 , 89, 52-8	15
1656	Prostatic Hyperplasia in Patients with AcromegalyâAuthorsâResponse. 1998 , 83, 2606-a-2607	3

1655	Minimal Cardiac Effects in Asymptomatic Athyreotic Patients Chronically Treated with Thyrotropin-suppressive Doses of L-ThyroxineâAuthorsâResponse. 1998 , 83, 2607-2608	6
1654	Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine. 1998 , 31, 32-8	27
1653	Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. 1999 , 131, 376-86	104
1652	Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Troms�Study. 1999 , 20, 755-63	28
1651	Aortic stenosis. Gender influence on left ventricular geometry and function in patients under 70 years of age. 1999 , 72, 475-82	3
1650	Disorders of left ventricular structure and function in chronic uremia: how often, why and what to do with it?. 1999 , 1, 327-36	16
1649	Downregulation of voltage-gated K(+) channels in rat heart with right ventricular hypertrophy. 1999 , 277, H1725-31	25
1648	Early response kinase and PI 3-kinase activation in adult cardiomyocytes and their role in hypertrophy. 1999 , 276, H1655-63	23
1647	Factors contributing to pressure overload-induced immediate early gene expression in adult rat hearts in vivo. 1999 , 277, H380-7	3
1646	Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors. 1999 , 277, R1321-30	10
1645	Regulation of growth in the adult cardiomyocytes. 1999 , 13 Suppl, S17-22	41
1644	Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. 1999 , 92, 39-44	2
1643	Serum creatinine level underestimates hypertensive renal involvement in elderly patients with essential hypertension. 1999 , 22, 297-301	5
1642	Angiotensin-converting enzyme gene polymorphism and geometric patterns of hypertensive left ventricular hypertrophy. 1999 , 40, 589-98	6
1641	Why Is Left Ventricular Hypertrophy So Predictive of Morbidity and Mortality?. 1999 , 317, 168-175	65
1640	Abnormalities of Kidney Function as a Cause and a Consequence of Cardiovascular Disease. 1999 , 317, 176-182	3
1639	Prevalence of left ventricular hypertrophy in a general population; The Troms�Study. 1999 , 20, 429-38	73
1638	Editorials. 1999 , 20, 397-405	

1637	Myocardial insulin resistance in cardiac hypertrophy. 1999 , 42, 12-4	1
1636	Scaling cardiac structural data by body dimensions: a review of theory, practice, and problems. 1999 , 20, 495-502	76
1635	Left ventricular hypertrophy in hypertension. <i>New England Journal of Medicine</i> , 1999 , 340, 1279-80	59.2 15
1634	RGS4 inhibits G-protein signaling in cardiomyocytes. 1999 , 99, 441-7	62
1633	Clinical trials of single-drug therapy for the cardiac effects of hypertension. 1999 , 12, 12S-18S	6
1632	The renin-angiotensin system in essential hypertension: associations with cardiovascular risk. 1999 , 8, 70-8	15
1631	Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. 1999 , 84, 722-8	122
1630	Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. 1999 , 84, 1127-36	257
1629	Hemodynamic function at rest, during acute stress, and in the field: predictors of cardiac structure and function 2 years later in youth. 1999 , 34, 1026-31	92
1628	Prospectively randomized evaluation of stentless versus conventional biological aortic valves: impact on early regression of left ventricular hypertrophy. 1999 , 100, 116-10	81
1627	Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. 1999 , 100, 2213-8	35
1626	Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. 1999 , 100, 2449-54	129
1625	Cosegregation analysis in genetic crosses suggests a protective role for atrial natriuretic factor against ventricular hypertrophy. 1999 , 84, 1453-8	42
1624	Relation between body fat-corrected ECG voltage and ambulatory blood pressure in patients with essential hypertension. 1999 , 33, 1159-63	13
1623	Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. 1999 , 100, 1802-7	154
1622	Increased pulse pressure and risk of heart failure in the elderly. 1999 , 281, 634-9	389
1621	Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. 1999 , 99, 1991-6	86
1620	The physiological determinants and risk correlations of elevated heart rate. 1999 , 12, 3S-8S	51

1619	Cardiac Disease in the Adult: MR Evaluation. 1999 , 40, 203-249	3
1618	Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. 1999 , 34, 1041-6	51
1617	Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. 1999 , 274, 21840-6	92
1616	Selective Increase of the Contractile Response to Endothelin-1 in Subcutaneous Arteries from Patients with Essential Hypertension. 1999 , 8, 9-15	8
1615	Impact of aortic stiffness on survival in end-stage renal disease. 1999 , 99, 2434-9	1756
1614	Ambulatory blood pressure monitoring. 1999 , 21, 703-15	20
1613	Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. 1999 , 274, 24858-64	75
1612	Irbesartan reduces QT dispersion in hypertensive individuals. 1999 , 33, 713-8	48
1611	Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?. 1999 , 47, 125-30	9
1610	Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. 1999 , 50, 321-8	157
1609	Endothelium-dependent vasodilation and structural and functional changes in the cardiovascular system are dependent on age in healthy subjects. 1999 , 19, 400-9	21
1608	A novel method for indexing echocardiographic left ventricular mass in infants, children and adolescents: evaluation of obesity-induced left ventricular hypertrophy. 1999 , 41, 126-31	11
1607	Epidemiology of Cardiac Disease in Dialysis Patients. 1999 , 12, 69-76	47
1606	Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. 1999 , 13, 635-45	14
1605	Amplification of angiotensin II signaling in cardiac myocytes by adenovirus-mediated overexpression of the AT1 receptor. 1999 , 874, 20-6	8
1604	Time-Frequency Analysis of Heart Rate Variability in Hypertension: Clinical and Echocardiographic Associations. 1999 , 4, 27-34	
1603	Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. 1999 , 13 Suppl 1, S43-7; discussion S49-50	26
1602	Prediction of cardiovascular damage in hypertensive patients: clinic or ambulatory blood pressures?. 1999 , 13, 81-3	1

1601	Left ventricular hypertrophy predicts outcome of hypertension regardless of the type of ventricular arrhythmia present. 1999 , 13, 617-23	6
1600	Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?. 1999 , 13, 505-9	35
1599	Relation of ambulatory blood pressure load with left ventricular geometry in untreated patients with mild-to-moderate hypertension. 1999 , 13, 677-82	20
1598	Clinical implications of white coat hypertension: an ambulatory blood pressure monitoring study. 1999 , 13, 817-22	17
1597	[Determination of left ventricular mass by transthoracic three-dimensional echocardiography in patients with dilated cardiomyopathy]. 1999 , 88, 922-31	3
1596	Cardiac Remodeling: From Concepts to Therapeutics. 1999 , 4, 7-20	1
1595	Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure. 1999 , 13, 455-63	7
1594	Exercise and the skeleton, 17 november 1998, london, UK. 1999 , 9, 367-78	
1593	[Hormone therapy in heart failure: growth hormone and insulin-like growth factor I]. 1999 , 88, 1-9	5
1592	Hypertensive cardiovascular disease in African Americans. 1999 , 1, 521-8	26
1591	Relevance of heart rate as a risk factor in hypertension. 1999 , 1, 219-24	22
1590	Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension. 1999 , 1, 305-12	10
1589	Influence of aortic valve replacement, prosthesis type, and size on functional outcome and ventricular mass in patients with aortic stenosis. 1999 , 118, 57-65	43
1588	Ambulatory blood pressure monitoring and echocardiography--noninvasive techniques for evaluation of the hypertensive patient. 1999 , 41, 397-440	12
1587	Effect of hormone replacement therapy on left ventricular hypertrophy. 1999 , 83, 1132-4, A9	41
1586	³¹ P nuclear magnetic resonance spectroscopy: a noninvasive tool to monitor metabolic abnormalities in left ventricular hypertrophy in human. 1999 , 83, 19H-24H	10
1585	Role of the renin-angiotensin system in cardiac hypertrophy. 1999 , 83, 53H-57H	71
1584	Impact of hypertension and antihypertensive treatment on organ damage. 1999 , 84, 18K-24K	94

1583	Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study). 1999 , 84, 558-62	57
1582	Patterns of body fat deposition in youth and their relation to left ventricular markers of adverse cardiovascular prognosis. 1999 , 84, 583-8	42
1581	Relation of maximum blood pressure during exercise and regular physical activity in normotensive men with left ventricular mass and hypertrophy. MARATHOM Investigators. Medida de la Actividad fisica y su Relaci3n Ambiental con Todos los L3pidos en el HOMBRE. 1999 , 84, 890-3	23
1580	PREOPERATIVE EVALUATION OF HYPERTENSION: Anesthetic Implications in Patients With Coronary Disease. 1999 , 17, 549-565	1
1579	PERIOPERATIVE HYPERTENSION AND OUTCOME. 1999 , 17, 581-591	
1578	Evaluation of Patients with Hypertension. 1999 , 5, 263-271	
1577	Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. 1999 , 84, 458-66	168
1576	Left ventricular hypertrophy as a surrogate end-point in hypertension. 1999 , 21, 583-93	23
1575	1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. 1999 , 21, 1009-60	410
1574	Left ventricular mass regression with amlodipine in elderly hypertensives. 1999 , 21, 113-9	3
1573	Borderline hypertension. 1999 , 21, 741-7	10
1572	Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group. 1999 , 15, 1-8	18
1571	Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function. 1999 , 69, 409-12	22
1570	Nocturnal blood pressure reduction and development of left ventricular hypertrophy in patients with treated essential hypertension. 1999 , 10, 21-26	1
1569	Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. 1999 , 12, 194-203	27
1568	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. 1999 , 12, 418-422	22
1567	Ethnic differences in the identification of left ventricular hypertrophy in the hypertensive patient. 1999 , 12, 437-42	58
1566	Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. 1999 , 12, 1000-8	25

1565	Diastolic function and tachycardia in hypertensive children. 1999 , 12, 1009-14	28
1564	Is high blood pressure a late manifestation of the hypertension syndrome?. 1999 , 12, 215S-223S	19
1563	Determinants of left ventricular mass in untreated mildly hypertensive subjects: hospitalet study in mild hypertension. 1999 , 12, 1084-90	20
1562	Canadian hypertension society guidelines for ambulatory blood pressure monitoring. 1999 , 12, 1149-57	45
1561	Brain natriuretic peptide as a marker of cardiac involvement in hypertension. 1999 , 69, 169-77	27
1560	Electrocardiographic left ventricular hypertrophy by five criteria among civil servants in Benin City, Nigeria: prevalence and correlates. 1999 , 70, 1-14	13
1559	Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. 1999 , 34, 125-34	650
1558	Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. 1999 , 353, 611-6	1650
1557	Prevention of coronary heart disease. Part I. Primary prevention. 1999 , 45, 497-571	8
1556	Endothelin-1 induces expression of fetal genes through the interleukin-6 family of cytokines in cardiac myocytes. 1999 , 456, 103-7	26
1555	Left ventricular mass reduction after aortic valve replacement: homografts, stentless and stented valves. 1999 , 67, 966-71	73
1554	Epidemiology of risk factors for hypertension: implications for prevention and therapy. 1999 , 57, 695-712	30
1553	Duration of Trandolapril Antihypertensive Effect after 24 and 48 Hours from Last Dose THOR Study. 1999 , 17, 43-50	4
1552	Family support and cardiovascular responses in married couples during conflict and other interactions. 1999 , 6, 40-63	40
1551	Familial predisposition of left ventricular hypertrophy. 1999 , 33, 1685-91	39
1550	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). 1999 , 33, 2092-197	482
1549	Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling. 1999 , 34, 1427-34	27
1548	Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. 1999 , 34, 1625-32	284

1547	Growth hormone therapy for heart failure: swimming against the stream. 1999 , 5, 269-75	15
1546	Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. 1999 , 138, 810-7	21
1545	Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: The Bogalusa Heart Study. 1999 , 138, 122-7	60
1544	Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling. 1999 , 31, 2017-30	47
1543	Influence of exercise on QT dispersion in hypertensive patients with left ventricular hypertrophy without coronary artery disease. 1999 , 63, 881-4	4
1542	Discrepancies between echocardiographic measurements of left ventricular mass in a healthy adult population. 1999 , 97, 377-383	8
1541	Discrepancies between echocardiographic measurements of left ventricular mass in a healthy adult population. 1999 , 97, 377	2
1540	Modeling relationships among socioeconomic status, hostility, cardiovascular reactivity, and left ventricular mass in African American and White children.. 1999 , 18, 140-150	104
1539	Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. 1999 , 91 Suppl 1, 8-13	8
1538	Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. 1999 , 91 Suppl 1, 3-7	9
1537	Circadian blood pressure changes and cardiac abnormalities in IgA nephropathy. 1999 , 19, 546-51	11
1536	Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. 1999 , 92, 110-4	27
1535	Myocardial diastolic impairment caused by left ventricular hypertrophy involves basal septum more than other walls: analysis by pulsed Doppler tissue imaging. 1999 , 17, 685-93	41
1534	Blood pressure measurement in haemodialysis patients. 1999 , 25, 9-11	
1533	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 17, 151-183	467
1532	Left ventricular mass correlates with fat-free mass but not fat mass in adults. 1999 , 17, 569-74	25
1531	Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines?. 1999 , 17, 817-24	18
1530	Blood pressure control in a hypertension hospital clinic. 1999 , 17, 835-41	21

1529	A pressure-time index' for assessing the severity of essential hypertension. 1999 , 17, 1387-93	6
1528	Relationship between left ventricular mass index and 24-h urinary free cortisol and cortisone in essential arterial hypertension. 1999 , 17, 1583-8	8
1527	Influence of a rapid change of left ventricular dimensions on the echocardiographic measurement of left ventricular mass by the Penn convention. 1999 , 17, 1323-8	5
1526	Grading, staging and scoring of left-ventricular hypertrophy, left-ventricular dilatation, asymptomatic left-ventricular dysfunction and chronic heart failure. 1999 , 20, 1224-33	1
1525	1999 World Health Organization & International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 8, 9-43	42
1524	Genetic aspects of heart failure. 1999 , 1, 121-6	10
1523	Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. 1999 , 17, 1161-8	32
1522	The impact of different echocardiographic diagnostic criteria on the prevalence of left ventricular hypertrophy in essential hypertension: the VITAE study. Ventriculo Izquierdo Tension Arterial Espa�. 1999 , 17, 1471-80	48
1521	Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension. Reliability of M-mode Echocardiographic Studies. 1999 , 17, 1955-63	60
1520	Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. 1999 , 17, 993-1000	81
1519	Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. 1999 , 131, 564-72	250
1518	High intensity training and the heart. 1999 , 60, 187-91	1
1517	Differential suppression of pressure-overload cardiac and aortic hypertrophy in rats by angiotensin-converting enzyme inhibitors. 1999 , 80, 333-42	4
1516	Epidemiological and clinical studies on insulin resistance and diabetes. 2000 , 105, 135-50	6
1515	Transesophageal 3-Dimensional Echocardiography: In Vivo Determination of Left Ventricular Mass in Comparison with Magnetic Resonance Imaging. 2000 , 13, 205-215	33
1514	Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. 2000 , 18, 1725-32	398
1513	Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. 2000 , 74, 111-117	15
1512	Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension. 2000 , 64, 499-504	32

1511	Antihypertensive effect of low-dose hydrochlorothiazide alone or in combination with quinapril in black patients with mild to moderate hypertension. 2000 , 40, 713-21	8
1510	Cardiac hypertrophy depends upon sleep blood pressure: a study in rats. 2000 , 18, 445-51	23
1509	Exercise and hypertension. 2000 , 11, 99-102	44
1508	Increased left ventricular mass is not associated with impaired left ventricular diastolic filling in normal individuals. 2000 , 18, 757-62	6
1507	The Association of Left Ventricular Mass with Cardiovascular Risk Factors in African American Women. 2000 , 320, 13-17	2
1506	Markers of electrical instability in hypertensive patients with and without ventricular arrhythmias. Are they useful in identifying patients with different risk profiles?. 2000 , 18, 763-8	5
1505	Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. 2000 , 18, 1465-75	126
1504	Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. 2000 , 18, 1129-38	60
1503	Smoking, Oral Contraceptives, and Cardiovascular Reactivity to Stress. 2000 , 95, 78-83	
1502	Current status of stentless aortic xenografts. 2000 , 15, 74-81	10
1501	Direct and surrogate measures of the white-coat effect: methodological aspects and clinical relevance. 2000 , 18, 379-82	11
1500	Influence of movement arousal on circadian rhythm of blood pressure in obstructive sleep apnea syndrome. 2000 , 18, 539-44	25
1499	The potential prognostic value of ultrasonic characterization (videodensitometry) of myocardial tissue in essential arterial hypertension. 2000 , 11, 513-21	6
1498	Carotid remodeling in essential hypertension: role of blood pressure, indexed parameters, and association with cardiac mass and aortic stiffness. 2000 , 22, 717-29	7
1497	The role of cardiovascular magnetic resonance in heart failure. 2000 , 2, 241-52	40
1496	Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. 2000 , 58, 260-8	40
1495	Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. 2000 , 58, 889-97	69
1494	Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. 2000 , 57, 561-9	53

1493	Determination of left ventricular mass by real-time three-dimensional echocardiography: in vitro validation. 2000 , 17, 665-74	8
1492	Three-dimensional echocardiography: research toy or clinical tool?. 2000 , 9, 98-107	1
1491	Increased left ventricular mass index and nocturnal systolic blood pressure in patients with Type 2 diabetes mellitus and microalbuminuria. 2000 , 17, 321-5	36
1490	Effects of successful parathyroidectomy on altered arterial reactivity in patients with hypercalcaemia: results of a 3-year follow-up study. 2000 , 53, 229-33	20
1489	Coronary artery disease and arterial hypertension: clinical, angiographic and follow-up data. 2000 , 247, 219-30	8
1488	Relationships between cardiovascular remodelling and the pulse pressure in never treated hypertension. 2000 , 14, 23-30	43
1487	Fifty years of Framingham Study contributions to understanding hypertension. 2000 , 14, 83-90	188
1486	The association of RBC sodium-lithium countertransport (V _{max}) with left ventricular mass in African American women. 2000 , 14, 213-9	3
1485	The accuracy of non-invasive methods for the detection of obstructive coronary artery disease in the presence of left ventricular hypertrophy. 2000 , 14, 295-8	5
1484	Absence of sympathetic overactivity in Afro-Caribbean hypertensive subjects studied by heart rate variability. 2000 , 14, 337-42	20
1483	Hypertension and the heart. 2000 , 14, 597-604	63
1482	Should all patients with hypertension have echocardiography?. 2000 , 14, 417-21	13
1481	Heart failure development in rats with ascending aortic constriction and angiotensin-converting enzyme inhibition. 2000 , 130, 1671-7	15
1480	Assessment of elastic properties of the descending thoracic aorta by transesophageal echocardiography with acoustic quantification in patients with a stroke. 2000 , 17, 713-20	6
1479	Determination of left ventricular volume, ejection fraction, and myocardial mass by real-time three-dimensional echocardiography. 2000 , 17, 781-6	26
1478	Ethnic (Black-White) Contrasts in 24-Hour Heart Rate Variability in Male Adolescents with High and Low Blood Pressure: The Bogalusa Heart Study. 2000 , 5, 207-213	2
1477	A novel role for STAT3 in cardiac remodeling. 2000 , 10, 298-303	59
1476	Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. 2000 , 135, 353-9	27

1475	Usefulness of left atrial abnormality for predicting left ventricular hypertrophy in the presence of left bundle branch block. 2000 , 85, 354-9	15
1474	Case 3: A patient with systemic hypertension and left ventricular hypertrophy. 2000 , 85, 522	0
1473	Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. 2000 , 397, 113-20	14
1472	Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. 2000 , 85, 1199-206	51
1471	Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. 2000 , 86, 1117-22	68
1470	Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. 2000 , 10, 169-80	37
1469	Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. 2000 , 212, 177-182	36
1468	Guanabenz combination therapy inhibits sympathetic nerve activity and regresses left ventricular hypertrophy. 2000 , 14, 61-6	6
1467	The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. 2000 , 19, 6341-50	585
1466	Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. 2000 , 215, 65-72	16
1465	A simple single slice method for measurement of left and right ventricular enlargement by electron beam tomography. 2000 , 16, 383-90	11
1464	Three-dimensional echocardiographic measurement of left ventricular mass: comparison with magnetic resonance imaging and two-dimensional echocardiographic determinations in man. 2000 , 16, 347-57	38
1463	Molecular basis of cardiac hypertrophy. 2000 , 89, 1-6	38
1462	Is ventricular repolarization heterogeneity a cause of serious ventricular tachyarrhythmias in aortic valve stenosis?. 2000 , 23, 449-52	3
1461	Changes of the T-wave amplitude and angle: an early marker of altered ventricular repolarization in hypertension. 2000 , 23, 600-6	20
1460	Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy. 2000 , 2, 260-70	
1459	Hypertension and the heart. 2000 , 2, 565-9	13
1458	Differences in left ventricular response between rheumatic and myxomatous mitral valve disease following mitral valve replacement. 2000 , 48, 751-6	2

1457	Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. 2000 , 14, 898-902	182
1456	The effect of moderate weight loss on echocardiographic parameters in obese female patients. 2000 , 87, 241-51	7
1455	The influence of the peripheral reflection wave on left ventricular hypertrophy in patients with essential hypertension. 2000 , 23, 451-8	35
1454	Usefulness of beta blocker therapy in patients with Takayasu arteritis and moderate or severe aortic regurgitation. 2000 , 41, 325-37	8
1453	Effects of coronary blood flow on left ventricular function in essential hypertensive patients. 2000 , 23, 239-45	23
1452	Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement. 2000 , 14, 669-79	324
1451	Assessment of Diastolic Function using Mitral Annulus Velocity by Doppler Tissue Velocity in the Patients with Hypertension. 2000 , 30, 1117	
1450	Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. 2000 , 108 Suppl 3, 545-53	342
1449	Genetic mapping of quantitative trait loci influencing left ventricular mass in rats. 2000 , 279, H2062-7	17
1448	The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. 2000 , 23, 317-22	14
1447	Gradiente residual em operaç� de valva a�tica. 2000 , 15, 136	
1446	Possible involvement of endothelin-1 in cardioprotective effects of benidipine. 2000 , 23, 491-6	12
1445	QT intervals and heart rate variability in hypertensive patients. 2000 , 41, 173-82	12
1444	Molecular mechanism of mechanical stress-induced cardiac hypertrophy. 2000 , 41, 117-29	21
1443	Time-course changes in left ventricular geometry and function during the development of hypertension in Dahl salt-sensitive rats. 2000 , 23, 613-23	30
1442	Blood pressure level and relation to other cardiovascular risk factors in male hypertensive patients without clinical evidence of ischemic heart disease. 2000 , 9, 91-7	2
1441	G-Protein beta(3) subunit gene variant and left ventricular hypertrophy in essential hypertension. 2000 , 35, 214-8	66
1440	Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. 2000 , 275, 13571-9	177

1439	Anticipatory blood pressure responses to exercise are associated with left ventricular mass in Finnish men: Kuopio Ischemic Heart Disease Risk Factor Study. 2000 , 102, 1394-9	40
1438	Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO). 2000 , 51, 131-9	19
1437	Effect of endurance exercise training on left ventricular size and remodeling in older adults with hypertension. 2000 , 55, M245-51	53
1436	Enhanced adrenomedullin production by mechanical stretching in cultured rat cardiomyocytes. 2000 , 35, 1210-4	61
1435	Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension. 2000 , 102, 1996-2004	35
1434	Attenuation of the "white-coat effect" by antihypertensive treatment and regression of target organ damage. 2000 , 35, 614-20	50
1433	Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage. 2000 , 16, 66-79	36
1432	Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. 2000 , 101, 2431-7	130
1431	Early echocardiographic changes and survival following renal transplantation. 2000 , 15, 93-8	45
1430	Pulse pressure and mortality in older people. 2000 , 160, 2765-72	171
1429	[Epidemiology of arterial hypertension and implications for its prevention. 10-year results of the MONICA Study Augsburg]. 2000 , 125, 1397-402	11
1428	[Cardiac arrhythmias in arterial hypertension]. 2000 , 125, 1437-43	
1427	Three-dimensional echocardiography: assessment of inter- and intra-operator variability and accuracy in the measurement of left ventricular cavity volume and myocardial mass. 2000 , 45, 1255-73	11
1426	Application of stress echocardiography to the evaluation of non-coronary heart disease. 2000 , 1, 171-9	13
1425	[Cardiomyopathy in obesity--a disease entity?]. 2000 , 125, 944-9	4
1424	Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. 2000 , 85, 4701-5	234
1423	More non-Q-wave myocardial infarctions but similar infarct sizes in patients with hypertension. 2000 , 9, 98-103	6
1422	The Role of Echocardiography in Hypertensive Heart Disease in the Elderly. 2000 , 9, 330-341	

1421	Pathophysiology of Hypertension in the Elderly. 2000 , 9, 16-26	1
1420	Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. 2000 , 97, 1196-201	262
1419	Calcineurin and beyond: cardiac hypertrophic signaling. 2000 , 87, 731-8	192
1418	Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. 2000 , 101, 2863-9	262
1417	Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. 2000 , 35, 580-6	396
1416	Impact of diabetes on cardiac structure and function: the strong heart study. 2000 , 101, 2271-6	690
1415	Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. 2000 , 35, 6-12	200
1414	Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives. 2000 , 102, 1802-6	31
1413	Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?. 2000 , 21, 1653-65	84
1412	Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat. 2000 , 36, 747-54	80
1411	Left ventricular mass and global function in essential hypertension after antihypertensive therapy. 2000 , 28, 9-19	14
1410	Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. 2000 , 35, 13-8	107
1409	Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. 2000 , 101, 2595-600	97
1408	Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. 2000 , 36, 766-73	84
1407	Transforming growth factor beta in hypertensives with cardiorenal damage. 2000 , 36, 517-22	111
1406	Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. 2000 , 160, 1905-11	46
1405	Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. 2000 , 83, 278-82	67
1404	Left ventricular hypertrophy: pathogenesis, detection, and prognosis. 2000 , 102, 470-9	786

1403	Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. 2000 , 35, 48-54	80
1402	Prognostic value of ambulatory blood pressure : current evidence and clinical implications. 2000 , 35, 844-51	463
1401	Performance of classic electrocardiographic criteria for left ventricular hypertrophy in an African population. 2000 , 36, 54-61	22
1400	Gender-differences in myocardial adaptation to afterload in normotensive and hypertensive rats. 2000 , 36, 774-9	52
1399	Differential regulation of phospholipase C-beta isozymes in cardiomyocyte hypertrophy. 2000 , 275, 1-6	37
1398	Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags. 2000 , 66, 1-14	93
1397	Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. 2000 , 32, 947-60	100
1396	Interpretation of echocardiographic measurements: a call for standardization. 2000 , 139, 412-22	52
1395	Left ventricular function, cardiac dysrhythmias, atrial activation, and volumes in nondipper hypertensive individuals with left ventricular hypertrophy. 2000 , 139, 529-36	30
1394	Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. 2000 , 108, 627-33	28
1393	Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction. 2000 , 74, 177-83	26
1392	Cardiovascular disease and chronic renal disease: a new paradigm. 2000 , 35, S117-31	396
1391	Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. 2000 , 35, 250-6	217
1390	Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left ventricular hypertrophy. 2000 , 49, 1356-60	23
1389	Therapeutic options in minimizing left ventricular hypertrophy. 2000 , 139, S9-14	31
1388	Race, baseline characteristics, and clinical outcomes after coronary intervention: The New Approaches in Coronary Interventions (NACI) registry. 2000 , 140, 162-9	29
1387	Enhanced prognostic stratification of patients with left ventricular hypertrophy with the use of single-photon emission computed tomography. 2000 , 140, 456-62	18
1386	Ambulatory blood pressure monitoring and organ damage. 2000 , 36, 894-900	253

1385	Vital epidemiologic clues in heart failure. 2000 , 53, 229-35	84
1384	Autonomic imbalance, hypertension, and cardiovascular risk. 2000 , 13, 112S-122S	148
1383	Left ventricular mass and atrial volume determined by cine magnetic resonance imaging in essential hypertension. 2000 , 13, 1103-9	10
1382	Spot urinary albumin-creatinine ratio predicts left ventricular hypertrophy in young hypertensive African-American men. 2000 , 13, 1168-72	12
1381	Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. 2000 , 13, 1149-54	35
1380	Mild left ventricular hypertrophy in essential hypertension: is it really arrhythmogenic?. 2000 , 13, 340-5	2
1379	Risk stratification in hypertension: new insights from the Framingham Study. 2000 , 13, 3S-10S	332
1378	Do patients with de novo hypertension differ from patients with previously known hypertension when malignant phase hypertension occurs?. 2000 , 13, 934-9	8
1377	Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. 2000 , 36, 646-61	1093
1376	Chronic renal insufficiency: current understandings and their implications. 2000 , 36, S4-12	20
1375	Research directions: new clinical frontiers. 2000 , 36, S52-61	2
1374	Survival advantage of stentless aortic bioprostheses. 2000 , 70, 785-90; discussion 790-1	86
1373	Regression of hypertrophy after Carpentier-Edwards pericardial aortic valve replacement. 2000 , 69, 531-5	24
1372	Effects of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: A randomized, double-blind study. 2000 , 61, 331-338	7
1371	Left ventricular hypertrophy and angiotensin-converting enzyme gene polymorphism in renal allograft recipients. 2000 , 32, 542-4	3
1370	Determinants of left ventricular structure after kidney transplantation. 2000 , 32, 2801-6	5
1369	Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. 2000 , 356, 359-65	747
1368	Relationship between left ventricular mass and hemodynamic responses to physical and mental stress. 2000 , 48, 79-88	12

1367	Epidemiology and risk factors for heart failure in the elderly. 2000 , 16, 407-18	25
1366	Body composition and prevalence of left ventricular hypertrophy. 2000 , 102, 405-10	85
1365	Lack of Association of Angiotensin-converting Enzyme and Angiotensinogen Genes Polymorphisms with Left Ventricular Structure in Young Normotensive Men. 2000 , 9, 47-51	13
1364	Experimental aortic stenosis and corresponding left ventricular hypertrophy in sheep. 2000 , 13, 327-31	4
1363	Organ damage in treated middle-aged hypertensives compared to normotensives: results from a cross-sectional study in general practice. 2000 , 9, 28-33	9
1362	Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: the Cornell voltage. 2000 , 23, 139-44	5
1361	From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. 2000 , 1, 179-223	56
1360	Reducci3 del riesgo en la hipertensi3 arterial asociada a factores de riesgo cardiovascular. Proyecto HYDRA. 2000 , 17, 87-92	
1359	[Hypertension in the elderly and health global results with different pharmacological therapies]. 2000 , 26, 533-41	3
1358	Gu3as de pr3ctica cl3nica de la Sociedad Espa3ola de Cardiolog3 en ecocardiograf3. 2000 , 53, 663-683	22
1357	Comparison of ventricular volume and mass measurements from B- and C-scan images with the use of real-time 3-dimensional echocardiography: studies in an in vitro model. 2000 , 13, 910-7	20
1356	[Nocturnal drop of arterial blood pressure: determinant factors and relationship with organic damage secondary to hypertension]. 2000 , 26, 607-13	0
1355	Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. 2000 , 35, 1237-44	207
1354	Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. 2000 , 36, 438-43	190
1353	Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. 2000 , 36, 1131-41	457
1352	Baroreflex sensitivity and variants of the renin angiotensin system genes. 2000 , 35, 194-200	54
1351	"Repaired" aortic coarctation in adults: not a "simple" congenital heart defect. 2000 , 35, 1003-6	21
1350	The DD-ACE genotype and cardiovascular disease. 2000 , 1, 153-67	35

1349	Cytoplasmic signaling pathways that regulate cardiac hypertrophy. 2001 , 63, 391-426	561
1348	Effect of low-dose estrogen on hemodynamic response to stress. 2001 , 75, 394-9	7
1347	Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. 2001 , 37, 175-82	76
1346	Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. 2001 , 37, 878-84	43
1345	Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. 2001 , 37, 1042-8	423
1344	The importance of age and obesity on the relation between diabetes and left ventricular mass. 2001 , 37, 1957-62	35
1343	Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. 2001 , 38, 876-82	79
1342	Age-associated changes in regional aortic pulse wave velocity. 2001 , 38, 1123-9	180
1341	Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. 2001 , 38, 1711-7	134
1340	Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. 2001 , 38, 1829-35	279
1339	Cardio-aortic and Aortic Surgery. 2001 ,	
1338	Exercise as hypertension therapy. 2001 , 19, 507-16	67
1337	Emergence of obesity and cardiovascular risk for coronary artery disease: the Bogalusa Heart Study. 2001 , 4, 116-121	46
1336	Diastolic dysfunction in arterial hypertension. 2001 , 3, 22-7	23
1335	RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice. 2001 , 33, 209-18	60
1334	Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. 2001 , 33, 487-501	60
1333	Heat shock protein-56 is induced by cardiotrophin-1 and mediates its hypertrophic effect. 2001 , 33, 1209-21	17
1332	Prognostic implications of left ventricular hypertrophy. 2001 , 141, 334-41	535

1331	Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis. 2001 , 141, 671-6	20
1330	Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. 2001 , 141, 784-91	60
1329	End points for cardiovascular drug trials in pediatric patients. 2001 , 142, 229-32	5
1328	Antihypertensive effect of ACE inhibitory oligopeptides from chicken egg yolks. 2001 , 128, 27-33	42
1327	Plasma leptin concentration, insulin sensitivity, and 24-hour ambulatory blood pressure and left ventricular geometry. 2001 , 14, 114-20	28
1326	Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. 2001 , 14, 106-13	112
1325	Left ventricular hypertrophy and angiotensin II antagonists. 2001 , 14, 174-82	60
1324	Family history of hypertension and left ventricular mass in youth: possible mediating parameters. 2001 , 14, 351-6	17
1323	QT intervals and QT dispersion as measures of left ventricular hypertrophy in an unselected hypertensive population. 2001 , 14, 455-62	32
1322	Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. 2001 , 14, 524-9	37
1321	Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. 2001 , 14, 775-82	36
1320	Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study. 2001 , 14, 768-74	15
1319	Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy. 2001 , 14, 914-20	42
1318	Classic Images in hypertension. Hypertensive heart disease in a patient admitted to hospital with dyspnea, chest pain, and severe hypertension. 2001 , 14, 969-70	0
1317	Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network. 2001 , 14, 1226-30	60
1316	G protein beta3 subunit gene 825T allele is associated with increased left ventricular mass in young subjects with mild hypertension. 2001 , 14, 1191-5	26
1315	The genetics of coronary heart disease. 2001 , 12, 2-10	2
1314	Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. 2001 , 508, 57-60	66

1313	Effect of controlled-release nifedipine on left ventricular hypertrophy in Japanese patients with hypertension: An open-label, uncontrolled study. 2001 , 62, 773-782	2
1312	Alteraciones electrocardiográficas en la hipertensión arterial. 2001 , 18, 207-211	
1311	Anatomic validation of a novel method for left ventricular volume and mass measurements with use of real-time 3-dimensional echocardiography. 2001 , 14, 1-10	25
1310	[Early prevention of experimental left ventricular hypertrophy in experimental hypertension and angiotensin II levels]. 2001 , 54, 1287-94	1
1309	Masa ventricular en ancianos con cardiopatía isquémica. 2001 , 13, 47-53	
1308	Real-time 3-dimensional echocardiographic evaluation of left ventricular volume: correlation with magnetic resonance imaging--a validation study. 2001 , 14, 1001-9	43
1307	Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. 2001 , 14, 601-11	87
1306	Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. 2001 , 10, 101-10	20
1305	Effects of antihypertensive agents on the left ventricle: clinical implications. 2001 , 1, 263-79	18
1304	Myocardial insulin-mediated glucose uptake and left ventricular geometry. 2001 , 10, 27-32	4
1303	Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). 2001 , 104, 1385-92	371
1302	Therapeutic potential of Na-H exchange inhibitors for the treatment of heart failure. 2001 , 10, 835-43	17
1301	Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. 2001 , 104, 2039-44	215
1300	Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy. 2001 , 6, 5-21	136
1299	[Patient adapted valve selection: biological vs. mechanical heart valve replacement in aortic valve diseases]. 2001 , 90, 48-57	2
1298	[Risk of perioperative mortality and complications following biological aortic valve replacement in elderly patients: stented vs unstented bioprotheses]. 2001 , 90, 58-64	1
1297	Heat shock proteins and cardiovascular pathophysiology. 2001 , 81, 1461-97	308
1296	Guidelines for the management of hypertension for general practitioners. 2001 , 24, 613-34	109

1295	Relationship between fluctuation pattern of blood pressure during hemodialysis treatment and cardiovascular morphology: an autopsy study of 53 cases. 2001 , 88, 113-9	5
1294	Role of Calcineurin-Dependent Signaling Pathway on the Left Ventricular Hypertrophy Induced by Pressure Overload. 2001 , 31, 1159	
1293	Echocardiographic assessment of the different left ventricular geometric patterns in hypertensive patients. 2001 , 76, 15-28	6
1292	Blood Pressure and Left Ventricular Hypertrophy in Patients on Different Peritoneal Dialysis Regimens. 2001 , 21, 1-9	24
1291	An association study of five genetic loci and left ventricular hypertrophy amongst Gulf Arabs. 2001 , 24, 635-9	15
1290	Relative wall thickness is an independent predictor of left ventricular systolic and diastolic dysfunctions in essential hypertension. 2001 , 24, 493-9	41
1289	The relationship of left ventricular mass to endothelium-dependent vasodilation of the brachial artery in patients with hypertension. 2001 , 96, 7-15	10
1288	Left ventricular changes in isolated office hypertension: a blood pressure-matched comparison with normotension and sustained hypertension. 2001 , 161, 2677-81	23
1287	Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. 2001 , 19, 303-9	89
1286	Flow-mediated dilatation of the brachial artery and left ventricular geometry in hypertensive patients. 2001 , 19, 641-7	30
1285	Regression of left ventricular hypertrophy in human hypertension with irbesartan. 2001 , 19, 1167-76	127
1284	Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen. 2001 , 19, 1835-9	15
1283	Independent predictors of isolated clinic ("white-coat") hypertension. 2001 , 19, 1015-20	74
1282	Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study. 2001 , 19, 127-34	41
1281	Effect of angiotensin-converting enzyme inhibition on myocardial vascularization in the adolescent and adult spontaneously hypertensive rat. 2001 , 19, 785-94	11
1280	Left ventricular mass assessed by electrocardiography and albumin excretion rate as a continuum in untreated essential hypertension. 2001 , 19, 1473-8	9
1279	Arterial hypertension and cardiac arrhythmias. 2001 , 19, 167-77	41
1278	Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. 2001 , 19, 269-78	54

1277	Relation of hemodynamics and risk factors to ventricular-vascular interactions in the elderly: the Cardiovascular Health Study. 2001 , 19, 1893-903	29
1276	Is there an optimal parathyroid hormone level in end-stage renal failure: the lower the better?. 2001 , 10, 421-7	8
1275	Nocturnal non-dipping: what does it augur?. 2001 , 10, 611-6	88
1274	Use of ambulatory blood pressure monitoring data to predict left ventricular mass in hypertension. 2001 , 6, 73-80	1
1273	Indexation of left ventricular mass in adults with a novel approximation for fat-free mass. 2001 , 19, 135-42	26
1272	Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. 2001 , 19, 1883-91	86
1271	Left ventricular mass is not related to insulin sensitivity in never-treated primary hypertension. 2001 , 19, 311-7	12
1270	Pulse pressure is the best predictor of future left ventricular mass and change in left ventricular mass: 10 years of follow-up. 2001 , 19, 2047-54	24
1269	Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. 2001 , 19, 119-25	67
1268	The importance of early treatment of the anaemia of chronic kidney disease. 2001 , 16 Suppl 5, 45-9	73
1267	Effect of cilnidipine on left ventricular diastolic function in hypertensive patients as assessed by pulsed Doppler echocardiography and pulsed tissue Doppler imaging. 2001 , 65, 305-9	19
1266	Molecular mechanism of cardiac hypertrophy and development. 2001 , 65, 353-8	35
1265	Physiological relationships between central vascular haemodynamics and left ventricular structure. 2001 , 101, 79-85	8
1264	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. 2001 , 101, 621-628	51
1263	Physiological relationships between central vascular haemodynamics and left ventricular structure. 2001 , 101, 79	3
1262	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. 2001 , 101, 621	16
1261	Gender and the relationship between resting heart rate and left ventricular geometry. 2001 , 19, 367-73	12
1260	Appropriate or inappropriate left ventricular mass in the presence or absence of prognostically adverse left ventricular hypertrophy. 2001 , 19, 1113-9	51

1259	No impact of blood pressure variability on microalbuminuria and left ventricular geometry: analysis of daytime variation, diurnal variation and 'white coat' effect. 2001 , 6, 125-31	28
1258	Prognostic impact of plasma brain natriuretic peptide for cardiac events in elderly patients with congestive heart failure. 2001 , 47, 46-51	27
1257	Cardiovascular disease risk factors and atherosclerosis in children and adolescents. 2001 , 3, 479-85	51
1256	Meta-analyses of antihypertensive therapy: Are some of them misleading?. 2001 , 3, 381-6	5
1255	Do most antihypertensive agents have a sympatholytic action?. 2001 , 3, 305-13	12
1254	[Gq/G11-mediated cellular signal pathway and its significance for cardiac diseases]. 2001 , 90, 601-6	
1253	Extracellular matrix gene expression correlates to left ventricular mass index after surgical induction of left ventricular hypertrophy. 2001 , 96, 381-7	16
1252	Leg edema, ST-T abnormalities, and high BNP values are important signs of heart failure in the elderly. 2001 , 33, 37-52	3
1251	Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. 2001 , 21, 196-207	6
1250	Assessment of the left ventricular diastolic reserve in essential hypertension: the acute saline load test. 2001 , 31, 690-7	4
1249	Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance. 2000 , 81, 1-16	41
1248	Changes in left ventricular mass index in children and adolescents after renal transplantation. 2001 , 5, 279-84	61
1247	Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. 2001 , 52, 687-92	5
1246	The effects of ACE inhibitor therapy on left ventricular myocardial mass and diastolic filling in previously untreated hypertensive patients: a cine MRI study. 2001 , 14, 16-22	27
1245	Predictors of stroke mortality in elderly people from the general population. The CARDiovascular Study in the ELderly. 2001 , 17, 1097-104	75
1244	Effect of Amlodipine on Echocardiographic Variables in Cats with Systemic Hypertension. 2001 , 15, 52-56	52
1243	Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. 2001 , 132, 159-64	65
1242	Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. 2001 , 7, 1236-40	312

1241	An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease. 2001 , 15 Suppl 1, S13-8	11
1240	The spatial QRS-T angle as a marker of ventricular repolarisation in hypertension. 2001 , 15, 63-70	54
1239	Prevalence of left ventricular hypertrophy in Finnish primary health care hypertensive patients. 2001 , 15, 255-8	11
1238	The ECG and left ventricular hypertrophy in primary care hypertensives. 2001 , 15, 215-7	3
1237	Influence of different echocardiographic criteria for detection of left ventricular hypertrophy on cardiovascular risk stratification in recently diagnosed essential hypertensives. 2001 , 15, 619-25	4
1236	ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity?. 2001 , 15, 659-67	30
1235	Inappropriate left ventricular mass and angiotensin converting enzyme gene polymorphism. 2001 , 15, 811-3	8
1234	Prognostic value of midwall shortening fraction and its relation with left ventricular mass in systemic hypertension. 2001 , 87, 479-82, A7	21
1233	Usefulness of transthoracic echocardiography as a tool for risk stratification of patients undergoing major noncardiac surgery. 2001 , 87, 505-9	139
1232	Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. 2001 , 87, 663-6, A11	79
1231	Ventricular and myocardial function following treatment of hypertension. 2001 , 87, 732-6	12
1230	M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). 2001 , 87, 1051-7	314
1229	Effect of regression of left ventricular hypertrophy from systemic hypertension on systolic function assessed by midwall shortening (HOT echocardiographic study). 2001 , 88, 521-5	18
1228	Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). 2001 , 88, 646-50	31
1227	Outcome of patients with electrocardiographic evidence of left ventricular hypertrophy following thrombolytic therapy for acute myocardial infarction. 2001 , 88, 1024-6	5
1226	Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). 2001 , 88, 1163-8	98
1225	Beta-adrenergic axis and heart disease. 2001 , 17, S44-9	30
1224	[Left ventricular hypertrophy in hypertensive African blacks: echocardiographic study of 452 patients]. 2001 , 50, 197-201	1

1223	Independent risk for cardiovascular disease predicted by modified continuous score electrocardiographic criteria for 6-year incidence and regression of left ventricular hypertrophy among clinically disease free men: 16-year follow-up for the multiple risk factor intervention trial. 2001 , 34, 91-101	57
1222	Implications of increased left ventricular mass index on in-hospital outcomes in patients undergoing aortic valve surgery. 2001 , 122, 919-28	85
1221	Obesity in the pediatric patient: cardiovascular complications. 2001 , 12, 161-167	26
1220	Insulin resistance and cardiovascular risk in the pediatric patient. 2001 , 12, 169-175	26
1219	Evaluation of syncope in adult congenital heart disease. 2001 , 13, 83-90	
1218	Ras regulates NFAT3 activity in cardiac myocytes. 2001 , 276, 3524-30	70
1217	Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. 2001 , 2, 227-32	8
1216	Regression of cardiac hypertrophy in the SHR by combined renin-angiotensin system blockade and dietary sodium restriction. 2001 , 2, S148-S153	2
1215	A comparison of left ventricular abnormalities associated with glucose intolerance in African Caribbeans and Europeans in the UK. 2001 , 85, 643-8	12
1214	Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. 2001 , 103, 678-83	67
1213	Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. 2001 , 103, 836-41	103
1212	Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. 2001 , 104, I54-8	37
1211	Mortality after coronary artery occlusion in different models of cardiac hypertrophy in rats. 2001 , 37, 209-15	17
1210	Microalbuminuria, pulse pressure, left ventricular hypertrophy, and myocardial ultrasonic tissue characterization in essential hypertension. 2001 , 52, 175-83	11
1209	Baseline blood pressure and other variables influencing survival on haemodialysis of patients without overt cardiovascular disease. 2001 , 16, 793-7	17
1208	Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. 2001 , 37, 512-21	16
1207	Diversity of ion channel expression in health and disease. 2001 , 3, K31-K40	11
1206	The Treatment of Coronary Heart Disease: An Update. 2001 , 17, 18-26	27

1205	Myocardial imaging with 123I-metaiodobenzylguanidine in essential hypertension and renovascular hypertension. 2001 , 23, 293-304	3
1204	Exercise in patients with hypertension. 2001 , 10, 253-9, 273	7
1203	Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. 2001 , 104, 1248-54	181
1202	Prevalence of left ventricular hypertrophy and carotid thickening in a large selected hypertensive population: impact of different echocardiographic and ultrasonographic diagnostic criteria. 2001 , 10, 142-9	45
1201	Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin. 2001 , 104, 102-8	134
1200	Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. 2001 , 98, 3322-7	172
1199	gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. 2001 , 276, 23115-9	66
1198	Regulation of cardiomyocyte mechanotransduction by the cardiac cycle. 2001 , 103, 1459-64	50
1197	Electrical remodeling in pressure-overload cardiac hypertrophy: role of calcineurin. 2001 , 104, 1657-63	62
1196	The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. 2001 , 276, 30245-53	271
1195	Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. 2001 , 104, 1615-21	439
1194	Fibrinogen and preclinical echocardiographic target organ damage: the strong heart study. 2001 , 38, 1068-74	33
1193	Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. 2001 , 103, 226-30	111
1192	Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. 2001 , 37, 1236-41	2904
1191	Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. 2001 , 276, 24145-52	95
1190	Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. 2001 , 103, 2346-51	252
1189	Association of left ventricular hypertrophy and aortic dilation in patients with acute thoracic aortic dissection. 2001 , 52, 447-55	19
1188	Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. 2001 , 103, 1453-8	125

1187	Functional alterations of the Nppa promoter are linked to cardiac ventricular hypertrophy in WKY/WKHA rat crosses. 2001 , 88, 223-8	40
1186	Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. 2001 , 104, 97-101	109
1185	Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. 2001 , 104, 1670-5	184
1184	Relation of age to left ventricular function and systemic hemodynamics in uncomplicated mild hypertension. 2001 , 37, 1404-9	16
1183	Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. 2001 , 38, 846-51	37
1182	Essential hypertension: the heart and hypertension. 2001 , 86, 467-75	24
1181	Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. 2001 , 219, 637-43	38
1180	Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. 2001 , 103, 102-7	255
1179	Echocardiographic features of the right heart in sleep-disordered breathing: the Framingham Heart Study. 2001 , 164, 933-8	100
1178	Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. 2001 , 10, 74-82	97
1177	Direct, autocrine and paracrine effects of cyclic stretch on growth of myocytes and fibroblasts isolated from neonatal rat ventricles. 2001 , 109, 10-7	10
1176	The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy. 2002 , 11, 53-5	6
1175	Current practice and future promise for clinical noninvasive measurements of subclinical atherosclerotic disease in the elderly. 2002 , 11, 108-16; quiz 116-8	4
1174	The price you pay for hypertension management: incorporation of economic factors into clinical decision making. 2002 , 11, 4-5	2
1173	Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. 2002 , 105, 944-9	246
1172	Assessment of left ventricular mass by cardiovascular magnetic resonance. 2002 , 39, 750-5	220
1171	Epidemiologic appraisal of hypertension as a coronary risk factor in the elderly. 2002 , 11, 86-92	14
1170	In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. 2002 , 39, 332-6	41

1169	Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. 2002 , 99, 907-12	420
1168	Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. 2002 , 105, 1128-34	80
1167	PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). 2002 , 156, 905-19	161
1166	Obesity hypertension in children: a problem of epidemic proportions. 2002 , 40, 441-7	679
1165	Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial. 2002 , 105, 830-6	16
1164	Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. 2002 , 105, 1240-6	231
1163	Cardiovascular and coronary risk estimation in hypertension management. 2002 , 88, 306-12	16
1162	Regression of left ventricular hypertrophy: hoping for a longer life. 2002 , 3, 141-4	4
1161	Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. 2002 , 23, 1963-71	49
1160	Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure. 2002 , 3, 367-78	9
1159	Hypertension and arrhythmia: blood pressure control and beyond. 2002 , 4, 175-82	28
1158	[Biological markers in epidemiology: concepts, applications, perspectives (part I)]. 2002 , 64, 99-107	4
1157	Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects. 2002 , 16, 249-54	26
1156	Angiotensin II Type 1 receptor antagonists in chronic heart failure. 2002 , 11, 705-16	3
1155	Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. 2002 , 165, 1395-9	352
1154	Left ventricular concentric remodelling and extracardiac target organ damage in essential hypertension. 2002 , 16, 385-90	11
1153	Diagnostic value of the RR-variability indicators for mild hypertension. 2002 , 23, 671-82	4
1152	Relationship between left ventricular mass and blood pressure in treated hypertension. 2002 , 16, 61-6	24

1151	Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. 2002 , 13, 2213-22	151
1150	Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. 2002 , 159, 1019-28	110
1149	Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). 2002 , 40, 61-6	68
1148	Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. 2002 , 40, 23-7	186
1147	Intima-media thickness of the common carotid arteries is related to coronary atherosclerosis and left ventricular hypertrophy in older adults. 2002 , 53, 569-74	32
1146	Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. 2002 , 162, 1333-9	67
1145	Relation of the G protein beta3-subunit polymorphism with left ventricle structure and function. 2002 , 40, 162-7	17
1144	Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. 2002 , 40, 673-8	132
1143	Classification of blood pressure levels by ambulatory blood pressure in hypertension. 2002 , 40, 817-22	22
1142	Is carotid artery intima-media thickening a reliable marker of early atherosclerosis?. 2002 , 9, 77-81	9
1141	Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. 2002 , 277, 14266-73	127
1140	Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. 2002 , 105, 85-92	309
1139	Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. 2002 , 106, 909-12	142
1138	Growth of left ventricular mass in African American and European American youth. 2002 , 39, 943-51	69
1137	Left ventricular hypertrophy was infrequent in patients starting dialysis after undergoing a strict blood pressure control in the pre-dialytic period. 2002 , 41, 925-30	2
1136	Characterization of myocardium, isolated cardiomyocytes, and blood pressure in WKHA and WKY rats. 2002 , 282, H149-55	13
1135	Effects of subclinical thyroid dysfunction on the heart. 2002 , 137, 904-14	250
1134	Comorbidity and cardiovascular risk factors in patients with chronic kidney disease. 2002 , 22, 494-506	13

1133	Left ventricular hypertrophy screening using a hand-held ultrasound device. 2002 , 23, 1516-21	46
1132	Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. 2002 , 20, 657-63	48
1131	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. 2002 , 20, 1445-50	63
1130	Ethnic differences in carotid and left ventricular hypertrophy. 2002 , 20, 539-43	4
1129	Spontaneous baroreflex sensitivity: toward an ideal index of cardiovascular risk in hypertension?. 2002 , 20, 935-44	67
1128	alpha-Adducin Gly460Trp polymorphism, left ventricular mass and plasma renin activity. 2002 , 20, 1771-7	23
1127	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. 2002 , 20, 1855-64	90
1126	Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. 2002 , 74, 73-9	84
1125	. 2002 , 9, 77-81	15
1124	Left ventricular hypertrophy in hypertension as a predictor of coronary events: relation to geometry. 2002 , 11, 215-20	9
1123	Augmentation index as a measure of peripheral vascular disease state. 2002 , 17, 543-51	221
1122	Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. 2002 , 20, 103-10	16
1121	Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. 2002 , 20, 405-12	123
1120	Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. 2002 , 20, 1307-14	122
1119	Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. 2002 , 20, 323-31	128
1118	Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. 2002 , 20, 1527-33	10
1117	Magnetocardiographic indices of left ventricular hypertrophy. 2002 , 20, 2285-92	8
1116	Left ventricular hypertrophy, cardiac imaging and cardiac electric activity. 2002 , 20, 2153-6	3

1115	Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: the GLAECO and GLAOLD studies. 2002 , 4, 707-12	34
1114	Left ventricular remodelling impacts on coronary flow reserve in hypertensive patients: is there a vascular mechanism?. 2002 , 20, 1291-3	8
1113	Biobehavioral approaches to the treatment of essential hypertension.. 2002 , 70, 569-589	33
1112	Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. 2002 , 288, 1252-9	352
1111	Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. 2002 , 66, 993-9	26
1110	Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy. 2002 , 49, 1-13	20
1109	Dundee Step Test: A Novel Non-Invasive Method of Assessing Endothelial Function in Man. 2002 , 47, 3-6	
1108	Range and prevalence of cardiac abnormalities in patients hospitalized in a medical ICU. 2002 , 122, 1370-6	51
1107	Downregulation of ANG II receptor is associated with compensated pressure-overload hypertrophy in the young dog. 2002 , 282, H749-56	8
1106	The ADAMs: a new therapeutic avenue?. 2002 , 2, 73-4	1
1105	Insulin resistance syndrome and left ventricular mass in healthy young people. 2002 , 324, 72-5	46
1104	Effects of cocaine and alcohol alone and in combination on cardiovascular performance in dogs. 2002 , 324, 76-83	8
1103	Association between tyrosine hydroxylase polymorphisms and left ventricular structure in young normotensive men. 2002 , 59, 90-94	5
1102	Is exercise blood pressure a marker of vascular endothelial function?. 2002 , 95, 423-9	21
1101	Relationship of clinic, ambulatory, and laboratory stress blood pressure to left ventricular mass in overweight men and women with high blood pressure. 2002 , 64, 247-57	13
1100	High output heart failure in patients with newly diagnosed acromegaly. 2002 , 112, 610-6	39
1099	The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. 2002 , 39, 907-12	132
1098	Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. 2002 , 39, 1055-60	265

1097	Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. 2002 , 39, 1005-11	318
1096	Physical activity attenuates the effect of increased left ventricular mass on the risk of ischemic stroke: The Northern Manhattan Stroke Study. 2002 , 39, 1482-8	27
1095	Demographics and correlates of five-year change in echocardiographic left ventricular mass in young black and white adult men and women: the Coronary Artery Risk Development in Young Adults (CARDIA) study. 2002 , 40, 529-35	53
1094	Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. 2002 , 40, 703-9	52
1093	Cardiovascular remodeling is greater in isolated systolic hypertension than in diastolic hypertension in older adults: the Insufficienza Cardiaca negli Anziani Residenti (ICARE) a Dicomano Study. 2002 , 40, 1283-9	47
1092	Athlete's heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. 2002 , 40, 1856-63	306
1091	Left ventricular remodeling early after aortic valve replacement: differential effects on diastolic function in aortic valve stenosis and aortic regurgitation. 2002 , 40, 2182-8	76
1090	Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. 2002 , 46, 203-12	20
1089	Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. 2002 , 8, S452-64	36
1088	Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. 2002 , 132, 1126-32; discussion 1132	72
1087	Risk Factors for Cardiovascular and Ischaemic Heart Disease in a Mediterranean Country. 2002 , 22, 241-251	4
1086	Impact of a Low-Dose Combination of Isradipine SRO and Spirapril on Left Ventricular Mass and Left Ventricular Performance in Patients with Hypertension and Left Ventricular Hypertrophy. 2002 , 22, 667-675	1
1085	Risk-benefit assessment of angiotensin II receptor antagonists. 2002 , 1, 137-52	2
1084	[Cardiovascular and hormonal factors associated with the lack of nocturnal fall in blood pressure among individuals aged over 55]. 2002 , 202, 264-8	1
1083	Use of stentless xenografts in the aortic position: determinants of early and late outcome. 2002 , 74, 1450-7; discussion 1457-8	28
1082	Survival after stentless and stented xenograft aortic valve replacement: a concurrent, controlled trial. 2002 , 74, 1443-9	43
1081	Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. 2002 , 143, 319-26	107
1080	Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. 2002 , 143, 854-60	28

1079	Peripheral endothelium-dependent flow-mediated vasodilatation is associated with left ventricular mass in older persons with hypertension. 2002 , 144, 39-44	13
1078	Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. 2002 , 144, 508-15	60
1077	Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. 2002 , 144, 1057-64	57
1076	Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass. 2002 , 141, 186-90	74
1075	The aging of the cardiovascular system: when should children be treated like adults?. 2002 , 141, 159-61	4
1074	Cardiovascular sequelae of childhood hypertension. 2002 , 15, 615-635	15
1073	Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension. 2002 , 15, 340-5	27
1072	Left ventricular diastolic function in physiologic and pathologic hypertrophy. 2002 , 15, 513-7	35
1071	Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. 2002 , 15, 663-71	60
1070	Early onset of chondroitin sulfate and osteopontin expression in angiotensin II-dependent left ventricular hypertrophy. 2002 , 15, 644-52	43
1069	Antihypertensive effects of angiotensin converting enzyme inhibition by lisinopril in post-transplant patients. 2002 , 15, 911-6	9
1068	Left ventricular mass change during treatment and outcome in patients with essential hypertension. 2002 , 15, 1021-8	82
1067	Left ventricular mass and arterial compliance: relation to coronary heart disease and its risk factors in South Indian adults. 2002 , 83, 1-9	14
1066	Left ventricular mass, arterial compliance and high risk of coronary heart disease in South Asians. 2002 , 83, 9-11	
1065	Identification, tissue expression and chromosomal localization of human Obscurin-MLCK, a member of the titin and Dbl families of myosin light chain kinases. 2002 , 282, 237-46	75
1064	Dissecting the genetic architecture of the cardiovascular and renal stress response. 2002 , 61, 73-95	57
1063	The heart, kidney, and brain as target organs in hypertension. 2002 , 20, 225-47	41
1062	Chronic renal ischemia: implications for cardiovascular disease risk. 2002 , 13, 1187-98	15

1061	[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study]. 2002 , 55, 887-94	
1060	Estimation of myocardial cell damage on the basis of mean electrocardiographic voltage and anatomical left ventricular mass. 2002 , 25, 19-24	1
1059	Left ventricular hypertrophy evaluation in obese hypertensive patients: effect of left ventricular mass index criteria. 2002 , 78, 341-51	7
1058	Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes. 2002 , 283, H533-9	27
1057	Modulating Cardiac Hypertrophy by Manipulating Myocardial Lipid Metabolism?. 2002 , 105, 1152-1154	28
1056	Reduction of QT Dispersion by Losartan in Patients with Mild to Moderate Hypertension. 2002 , 2, 9-15	
1055	Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. 2002 , 25, 153-9	34
1054	An analysis of electrocardiographic criteria for determining left ventricular hypertrophy. 2002 , 78, 59-82	10
1053	Establishment and Magnetocardiographic Changes of Pressure Overload Left Ventricular Hypertrophy and Its Regression in Rats. 2002 , 32, 330	
1052	The hypertrophic heart rat: a new normotensive model of genetic cardiac and cardiomyocyte hypertrophy. 2002 , 9, 43-8	20
1051	The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus. 2002 , 3, 150-5	4
1050	Ischemia elicits a coordinated expression of pro-survival proteins in mouse myocardium. 2002 , 2, 997-1003	6
1049	Perindopril reverses myocyte remodeling in the hypertensive heart. 2002 , 25, 85-90	13
1048	Relationship between home blood pressure and longitudinal changes in target organ damage in treated hypertensive patients. 2002 , 25, 167-73	71
1047	Inhibitory molecules in signal transduction pathways of cardiac hypertrophy. 2002 , 25, 491-8	17
1046	Left Ventricular Hypertrophy in Hypertension. 2002 , 2, 142-156	2
1045	Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. 2002 , 25, 49-56	29
1044	Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A>G. 2002 , 2, 12	63

1043	Trends in lifestyle cardiovascular risk factors in women: analysis from the Canadian National Population Health Survey. 2002 , 39, 229-42	7
1042	Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study). 2002 , 90, 1133-4	6
1041	[Medical stress and blood pressure]. 2002 , 51, 81-5	
1040	[Routine electrocardiographic criteria for the diagnosis of left ventricular hypertrophy: performance in Black Africans]. 2002 , 51, 193-8	2
1039	[Holter EKG for the hypertensive heart disease]. 2002 , 51, 336-40	1
1038	Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. 2002 , 40, 728-36	58
1037	Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. 2002 , 40, 1202-10	92
1036	Cardiac and vascular structure and function are related to lipid peroxidation and metabolism. 2002 , 37, 231-6	36
1035	Hypertension, left ventricular hypertrophy, and sudden death. 2002 , 4, 449-57	41
1034	Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?. 2002 , 4, 474-8	22
1033	ESMRMB 2002 19th Annual Meeting Cannes, France, August 22-25, 2002. 2002 , 15, 1-293	
1032	Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. 2002 , 252, 430-9	56
1031	Pulse pressure in tests improves the prediction of left ventricular mass: 10 years of follow-up. 2002 , 22, 161-8	
1030	Effects of athletic training on heart rate variability triangular index. 2002 , 22, 279-84	23
1029	Central aortic pressure augmentation in stable renal transplant recipients. 2002 , 62, 166-71	52
1028	A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. 2002 , 62, 639-47	125
1027	Left ventricular mass and hemodynamic overload in normotensive hemodialysis patients. 2002 , 62, 1828-38	29
1026	Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. 2002 , 62, 1784-90	246

1025 Left ventricular hypertrophy in chronic renal failure patients. **2002**, 7, S64-S66

1024 Systolic and diastolic function in children with chronic renal failure. **2002**, 44, 18-23

13

1023 The role of home blood pressure measurement in managing hypertension: an evidence-based review. **2002**, 16, 469-72

18

1022 A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction. **2002**, 16, 591-5

30

1021 Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. **2002**, 16, 653-9

11

1020 Calcineurin and cardiac hypertrophy: where have we been? Where are we going?. **2002**, 541, 1-8

115

1019 Seven-transmembrane-spanning receptors and heart function. **2002**, 415, 206-12

763

1018 Shedding growth factors in cardiac hypertrophy. **2002**, 8, 20-1

16

1017 Tumor-specific mutations in p53: the acid test. **2002**, 8, 21-3

23

1016 Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. **2002**, 8, 35-40

655

1015 Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. **2002**, 8, 725-30

262

1014 Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. **2002**, 135, 961-8

86

1013 Left ventricular hypertrophy in chronic renal failure patients. **2002**, 7, S64-S66

0

1012 Arrhythmias, sudden death and syncope in hypertensive cardiovascular disease. **2002**, 6, 36-41

2

1011 Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. **2002**, 7, 317-25

71

1010 Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate. **2003**, 17, 335-41

33

1009 Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. **2003**, 7, 225-8

2

1008 Cardiovascular reactivity and left ventricular mass: an integrative review. **2003**, 26, 182-93

15

1007	Stressing the system. 2003 , 33, 635-41	3
1006	Technetium-99m sestamibi cavity/myocardium count ratio in the detection of left ventricular hypertrophy. 2003 , 26, 143-6	4
1005	Left ventricular mass index measured by quantitative gated myocardial SPECT with 99mTc-tetrofosmin: a comparison with echocardiography. 2003 , 17, 31-9	9
1004	The new epidemiology of heart failure. 2003 , 5, 181-6	11
1003	Regression of left ventricular hypertrophy is a key goal of hypertension management. 2003 , 5, 301-8	24
1002	Thyroid hormone and blood pressure regulation. 2003 , 5, 513-20	128
1001	Regression of left ventricular hypertrophy: are there preferred drugs?. 2003 , 5, 368-71	5
1000	[Left ventricular mass in endurance-athletes with athlete's heart and untrained subjects--comparison between different echocardiographic methods and MRI]. 2003 , 92, 309-18	8
999	Aldosterone action in the heart. 2003 , 446, 328-33	7
998	Role of phosphoinositide 3-kinase in cardiac function and heart failure. 2003 , 13, 206-12	34
997	Recognition of left ventricular hypertrophy in new recruits of professional sumo wrestling. 2003 , 6, 379-86	4
996	Electrical remodeling in cardiac hypertrophy. 2003 , 13, 316-22	52
995	Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. 2003 , 3, 11	15
994	Functional relevance of aldosterone for the determination of left ventricular mass. 2003 , 91, 297-301	16
993	Prevention and management of chronic heart failure in patients at risk. 2003 , 91, 10F-17F	17
992	Troponin-I elevation in patients with increased left ventricular mass. 2003 , 92, 88-90	47
991	The heart, kidney, and brain as target organs in hypertension. 2003 , 28, 156-93	8
990	Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. 2003 , 19, 263-8	234

989	Comparison of autograft and allograft aortic valve replacement in children. 2003 , 126, 240-6	35
988	Discussion. 2003 , 126, 245-246	
987	Computed tomography for functional evaluation of the heart. 2003 , 38, 303-8	3
986	Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. 2003 , 30, 278-83	4
985	Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus. 2003 , 2, 14	27
984	Non-dipper treated hypertensive patients do not have increased cardiac structural alterations. 2003 , 1, 1	30
983	The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. 2003 , 64, 1792-9	49
982	Aortic pulse wave velocity index and mortality in end-stage renal disease. 2003 , 63, 1852-60	373
981	Echocardiographic left ventricular mass in African-Americans: the Jackson cohort of the Atherosclerosis Risk in Communities Study. 2003 , 20, 111-20	46
980	Chronic renal insufficiency and renoprotective strategies. 2003 , 33, 237-41	
979	Facilitating best practice--cardiovascular risk management for patients with diabetes. 2003 , 5 Suppl 1, S29-34	
978	Dose-dependent effects of acute exercise on PKC levels in rat heart: is PKC the heart's prophylactic?. 2003 , 178, 97-106	18
977	Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study. 2003 , 58, 316-22	10
976	Growth hormone, acromegaly, and heart failure: an intricate triangulation. 2003 , 59, 660-71	71
975	Insulin resistance and cardiac mass: the end of the beginning?. 2003 , 11, 507-8	10
974	Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. 2003 , 11, 518-24	55
973	Change in cardiovascular risk profile by echocardiography in medium-risk elderly hypertensives. 2003 , 17, 101-6	8
972	The determinants of left ventricular hypertrophy defined by Sokolow-Lyon criteria in untreated hypertensive patients. 2003 , 17, 159-64	22

971	Night-time blood pressure load is associated with higher left ventricular mass index in renal transplant recipients. 2003 , 17, 239-44	29
970	Exercise blood pressure response is related to left ventricular mass. 2003 , 17, 333-8	25
969	Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy. 2003 , 17, 841-9	27
968	Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. 2003 , 107, 346-54	866
967	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. 2003 , 10, 420-428	14
966	Renal Ischemia as a Predictor of Cardiovascular Morbidity. 2003 , 14, P159-P164	
965	[Cardiopulmonary function and exercise capacity in patients with morbid obesity]. 2003 , 56, 594-600	30
964	Cardiac hypertrophy: the good, the bad, and the ugly. 2003 , 65, 45-79	1153
963	Prediction of mortality in patients with left ventricular hypertrophy by clinical, exercise stress, and echocardiographic data. 2003 , 41, 129-35	44
962	The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: do race and gender matter?. 2003 , 41, 949-54	59
961	Influence of systolic blood pressure and body mass index on left ventricular structure in healthy African-American and white young adults: the CARDIA study. 2003 , 41, 955-60	75
960	Ambulatory blood pressure, left ventricular mass, and conduit artery function late after successful repair of coarctation of the aorta. 2003 , 41, 2259-65	134
959	Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. 2003 , 42, 1199-205	302
958	The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. 2003 , 42, 1206-7	233
957	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). 2003 , 10, S1-S78	44
956	Regression of left ventricular hypertrophy after treatment of hypertension: comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes. 2003 , 9, 122-7	8
955	Instantaneous assessment of left ventricular midwall mechanics with tissue Doppler tracking technique. 2003 , 9, 392-7	5
954	Apparent protective effect of increased left ventricular wall thickness in an ICD population. 2003 , 9, 412-5	4

953	Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. 2003 , 108, 1567-74	348
952	Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. 2003 , 108, 2154-69	2515
951	The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. 2003 , 16, 1025-9	29
950	Effect of renal transplantation on left ventricular hypertrophy. 2003 , 35, 2714-5	
949	Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study. 2003 , 146, 527-34	47
948	Does the type of prosthesis influence early left ventricular mass regression after aortic valve replacement? Assessment with magnetic resonance imaging. 2003 , 146, E13	17
947	Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease. 2003 , 146, 662-7	35
946	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. 2003 , 115, 41-6	574
945	Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. 2003 , 35, 1385-94	192
944	Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. 2003 , 16, 434-8	161
943	High prevalence of target organ damage in young, African American inner-city men with hypertension. 2003 , 5, 24-30	17
942	17 beta-estradiol inhibits cardiac fibroblast growth through both subtypes of estrogen receptor. 2003 , 311, 454-9	23
941	Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. 2003 , 35, 637-44	61
940	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. 2003 , 35, 953-60	76
939	Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy. 2003 , 35, 1153-60	37
938	Mass regression in aortic stenosis after valve replacement with small size pericardial bioprosthesis. 2003 , 76, 1107-13	32
937	Does a prolonged QT peak identify left ventricular hypertrophy in hypertension?. 2003 , 89, 179-86	8
936	Plasma fatty acids response to central volume expansion in salt-sensitive hypertension. 2003 , 52, 508-13	2

935	Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. 2003 , 145, 467-74	31
934	Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio Study. 2003 , 13, 126-32	17
933	An appraisal of echocardiography as an epidemiological tool. The Strong Heart Study. 2003 , 13, 238-44	20
932	Correlates of myocardial oxygen demand measured by positron emission tomography in the hypertrophied left ventricle. 2003 , 16, 240-3	7
931	Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. 2003 , 16, 180-6	8
930	Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. 2003 , 16, 556-63	37
929	Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. 2003 , 16, 938-44	56
928	Molecular interplay between mechanical and humoral signalling in cardiac hypertrophy. 2003 , 9, 376-82	29
927	The possible roles of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. 2003 , 85, 439-42	35
926	AT1-receptor antagonism in hypertension: what has been learned with irbesartan?. 2003 , 1, 23-33	3
925	Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists. 2003 , 20, 805-15	13
924	Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. 2003 , 25, 525-35	16
923	Are gestational and essential hypertension similar? Left ventricular geometry and diastolic function. 2003 , 22, 225-37	15
922	Inferior vena cava diameter determines left ventricular geometry in continuous ambulatory peritoneal dialysis patients: an echocardiographic study. 2003 , 18, 2128-33	17
921	The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy. 2003 , 21, 573-85	13
920	ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. 2003 , 3, 351-60	8
919	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003 , 42, 1206-52	10207
918	Exercise blood pressure in congenital heart disease and in patients after coarctation repair. 2003 , 89, 125-6	16

917	Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy. 2003 , 41, 499-504	35
916	Symptomatic aortic stenosis: does systemic hypertension play an additional role?. 2003 , 41, 1268-72	111
915	Phenotyping hypertrophy: eschew obfuscation. 2003 , 92, 1171-5	220
914	Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. 2003 , 42, 500-6	73
913	Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. 2003 , 41, 75-82	33
912	Infections and the Cardiovascular System: New Perspectives. 2003 ,	5
911	Editorial comment--Left ventricular hypertrophy: an unseemly risk factor for stroke?. 2003 , 34, 2385-6	3
910	Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. 2003 , 108, 560-5	322
909	Left ventricular geometry and hypotension in end-stage renal disease: a mechanical perspective. 2003 , 14, 2421-7	31
908	Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. 2003 , 42, 1050-65	802
907	What is bright is not always gold. 2003 , 41, e9-10; author reply e9-10	0
906	The short-term effects of different regimens of hormone replacement therapy on left ventricular structure and performance in healthy postmenopausal women. A prospective, controlled echocardiographic study. 2003 , 55, 139-44	5
905	Roles of cardiac transcription factors in cardiac hypertrophy. 2003 , 92, 1079-88	276
904	Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. 2003 , 100, 12355-60	426
903	Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. 2003 , 14, 462-8	155
902	Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. 2003 , 107, 448-54	391
901	Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. 2003 , 163, 525-41	314
900	Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. 2003 , 62, 414-8	121

899	Effects of isolated obesity on systolic and diastolic left ventricular function. 2003 , 89, 1152-6	210
898	Left ventricular size, mass and function in relation to angiotensin-converting enzyme gene and angiotensin-II type 1 receptor gene polymorphisms in patients with coronary artery disease. 2003 , 41, 522-8	5
897	Parathyroid adenomas and cardiovascular risk. 2003 , 10, 309-22	54
896	Ral GDP dissociation stimulator and Ral GTPase are involved in myocardial hypertrophy. 2003 , 41, 956-62	15
895	Cardiac Drug Development Guide. 2003 ,	1
894	Association between periodontal disease and left ventricle mass in essential hypertension. 2003 , 41, 488-92	90
893	Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. 2003 , 108, 684-90	218
892	Left ventricular remodeling and renal function in never-treated essential hypertension. 2003 , 14, 881-7	37
891	Incremental value of ultrasonic tissue characterization (backscatter) in the evaluation of left ventricular myocardial structure and mechanics in essential arterial hypertension. 2003 , 107, 74-80	45
890	Elevated intracardiac angiotensin II leads to cardiac hypertrophy and mechanical dysfunction in normotensive mice. 2003 , 4, 186-90	32
889	Extended-release metoprolol succinate in chronic heart failure. 2003 , 37, 701-10	14
888	The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear factor-kappa B. 2003 , 278, 20770-7	51
887	Cardiac-specific overexpression of a high Ca ²⁺ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. 2003 , 17, 61-3	50
886	Coronary vasodilator capacity and hypertension-induced increase in left ventricular mass. 2003 , 41, 224-9	26
885	Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. 2003 , 93, 874-83	199
884	Electrophysiological effects accompanying regression of left ventricular hypertrophy. 2003 , 60, 510-7	20
883	Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease?. 2003 , 96, 449-52	5
882	Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. 2003 , 24, 1672-80	45

881	M-mode echocardiography overestimates left ventricular mass in patients with normal left ventricular shape: a comparative study using three-dimensional echocardiography. 2003 , 4, 312-9	30
880	Screening for treatable left ventricular abnormalities in diabetic patients. 2003 , 3, 107-12	4
879	Secondary harmonic imaging overestimates left ventricular mass compared to fundamental echocardiography. 2003 , 4, 178-81	11
878	Left ventricular hypertrophy is associated with asymptomatic cerebral damage in hypertensive patients. 2003 , 34, 1766-70	65
877	Left ventricular mass and geometry and the risk of ischemic stroke. 2003 , 34, 2380-4	101
876	Left ventricular structure and diastolic function with human ageing. Relation to habitual exercise and arterial stiffness. 2003 , 24, 2213-20	93
875	Risk in elderly patients after stentless versus stented aortic valve surgery. 2003 , 11, 37-41	7
874	No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. 2003 , 23, 466-70	15
873	Understanding the association between socioeconomic status and physical health: do negative emotions play a role?. 2003 , 129, 10-51	842
872	The genetic determination of left ventricular mass in healthy adults. 2003 , 24, 577-82	54
871	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. 2003 , 5, A43-A48	18
870	Pharmacogenomics of hypertension. 2003 , 12, 61-70	25
869	Silent myocardial ischaemia in treated hypertensives with and without left ventricular hypertrophy. 2003 , 8, 45-51	7
868	Left ventricular hypertrophy in treated hypertensive patients with good blood pressure control outside the clinic, but poor clinic blood pressure control. 2003 , 21, 1575-81	20
867	Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. 2003 , 42, 622-8	33
866	B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. 2003 , 21, 621-4	25
865	Pulse pressure responses to psychological tasks improve the prediction of left ventricular mass: 10 years of follow-up. 2003 , 21, 789-95	4
864	The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study. 2003 , 21, 1467-73	29

863	2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003 , 21, 1011-53	2526
862	Combined antihypertensive therapy improves moderate heart failure. 2003 , 21, 2195	
861	Left ventricular hypertrophy and endothelial functions in patients with essential hypertension. 2003 , 14, 541-4	8
860	Current thinking in stentless valve surgery. 2003 , 18, 117-23	8
859	Psychological behaviour, pulse pressure and left ventricular hypertrophy. 2003 , 21, 695-6	1
858	Cardiovascular reactivity and development of preclinical and clinical disease states. 2003 , 65, 46-62	474
857	Relation of coronary artery calcium to left ventricular mass and geometry in patients with essential hypertension. 2003 , 8, 9-15	17
856	Impact of essential hypertension and diabetes mellitus on left ventricular systolic and diastolic performance. 2003 , 4, 306-12	30
855	LV mass index significantly impacts on patient and renal outcomes in patients with coronary artery bypass grafting and poor left-ventricular function. 2003 , 25, 287-95	5
854	Combination of lisinopril and nifedipine GITS increases blood pressure control compared with single drugs in essential hypertensive patients. 2003 , 41, 579-85	10
853	Diagnostic value of exercise electrocardiography and dipyridamole stress echocardiography in hypertensive and normotensive chest pain patients with right bundle branch block. 2003 , 21, 2189-94	14
852	Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan. 2003 , 2, 5-15	8
851	Left ventricular mass measured by myocardial perfusion gated SPECT. Relation to three-dimensional echocardiography. 2003 , 28, 392-7	6
850	Bibliography. Current world literature. Imaging and echocardiography. 2003 , 18, 406-22	
849	Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. 2003 , 139, 901-6	376
848	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. 2003 , 10, 420-8	32
847	Genetics of hypertension. 2003 , 5, 413-29	35
846	Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. 2003 , 325, 214-27	38

845	Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. 2003 , 124, 594-601	125
844	Association between left ventricular diastolic dysfunction and renal hemodynamic change in patients with treated essential hypertension. 2003 , 26, 971-8	14
843	Evaluation of ECG criteria for left ventricular hypertrophy before and after aortic valve replacement using magnetic resonance imaging. 2003 , 5, 465-74	2
842	Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. 2003 , 44, 693-704	12
841	Detection of incipient left ventricular hypertrophy in mild to moderate arterial hypertension with normal electrocardiogram and echocardiogram: a new use for signal-averaged electrocardiography. 2003 , 81, 79-84, 73-8	1
840	Renin, angiotensin, sodium and organ damage. 2003 , 26, 349-54	26
839	Preface. 2003 , ix-xi	
838	Patterns of change in size and body composition. 2003 , 75-110	
837	Determinants of growth. 2003 , 111-171	1
836	Secular changes in growth and maturity. 2003 , 172-187	2
835	Significance of human growth. 2003 , 188-204	
834	References. 2003 , 205-304	
833	Differential influence of family history of hypertension and premature myocardial infarction on systolic blood pressure and left ventricular mass trajectories in youth. 2003 , 111, 1387-93	21
832	Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. 2003 , 284, H1043-7	41
831	Measurement and assessment. 2003 , 1-74	1
830	Statins and the Modulation of Cardiac Hypertrophy and Fibrosis: Implications in the Therapy of Heart Failure. 2004 , 143-162	1
829	High levels of myocardial antioxidant defense in aging nondiabetic normotensive Zucker obese rats. 2004 , 286, R793-800	32
828	Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. 2004 , 97, 369-76	61

827	An Appraisal of the Electrocardiographic Criteria for Diagnosis of Left Ventricular Hypertrophy in Koreans: Comparison to Echocardiographic Measurement of Left Ventricular Mass. 2004 , 34, 775	3
826	Update in nephrology. 2004 , 140, 106-11	
825	Recent insights in the development of organ damage caused by hypertension. 2004 , 59, 369-81	11
824	Pediatric Hypertension. 2004 ,	1
823	All antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. 2004 , 20, 279-93	17
822	Targeted expression of calmodulin increases ventricular cardiomyocyte proliferation and deoxyribonucleic acid synthesis during mouse development. 2004 , 145, 1356-66	19
821	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. 2004 , 292, 2343-9	472
820	Diet and the prevention of coronary heart disease. 2004 , 21-55	0
819	Genetic variation and physical performance. 2004 , 93, 270-302	1
818	Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. 2004 , 13, 158-63	11
817	Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria. 2004 , 13, 144-51	14
816	EX filter wire usage in stenting right coronary artery lesion with diffuse aneurysmal dilatation. 2004 , 90, 475	
815	Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. 2004 , 44, 459-64	55
814	Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. 2004 , 44, 61-6	47
813	Cardiac effects of anabolic steroids. 2004 , 90, 473-5	65
812	Hypertrophy of the heart: a new therapeutic target?. 2004 , 109, 1580-9	627
811	Late systemic hypertension and aortic arch geometry after successful repair of coarctation of the aorta. 2004 , 25, 1853-9	126
810	Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function. 2004 , 55, 669-78	5

809	Body mass index and blood pressure influences on left ventricular mass and geometry in African Americans: The Atherosclerotic Risk In Communities (ARIC) Study. 2004 , 44, 55-60	55
808	17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. 2004 , 109, 269-76	88
807	Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. 2004 , 24, 6231-40	96
806	Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. 2004 , 150, 65-71	181
805	Fighting renal diseases in poor countries: building a global fund with the help of the pharmaceutical industry. 2004 , 15, 704-7	8
804	Physiological growth synergizes with pathological genes in experimental cardiomyopathy. 2004 , 95, 1200-6	64
803	Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. 2004 , 63, 373-80	108
802	Relation between socioeconomic status, race-ethnicity, and left ventricular mass: the Northern Manhattan study. 2004 , 43, 775-9	44
801	Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. 2004 , 24, 8467-76	497
800	Surrogate markers for cardiovascular disease: structural markers. 2004 , 109, IV22-30	146
799	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. 2004 , 110, 1456-62	379
798	Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. 2004 , 110, 3488-92	162
797	Heterogeneity of cardiorenal characteristics in normotensive subjects. 2004 , 43, 219-23	15
796	Combined echocardiographic left ventricular hypertrophy and electrocardiographic ST depression improve prediction of mortality in American Indians: the Strong Heart Study. 2004 , 43, 769-74	54
795	Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. 2004 , 43, 1182-8	155
794	Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. 2004 , 53, 434-40	88
793	Role of the epidermal growth factor receptor in signaling strain-dependent activation of the brain natriuretic peptide gene. 2004 , 279, 9287-97	24
792	Prognostic significance of left ventricular mass change during treatment of hypertension. 2004 , 292, 2350-6	592

791	Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. 2004 , 63, 467-75	343
790	Left ventricular mass: manual and automatic segmentation of true FISP and FLASH cine MR images in dogs and pigs. 2004 , 230, 389-95	70
789	Pharmacogenomics of left ventricular hypertrophy reversal: beyond the 'one size fits all' approach to antihypertensive therapy. 2004 , 22, 2273-5	3
788	Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects. 2004 , 103, 169-80	27
787	Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. 2004 , 22, 883-6	12
786	Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. 2004 , 109, 2581-6	86
785	Synchronization and integration of multiple hypertrophic pathways in the heart. 2004 , 63, 367-72	12
784	Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. 2004 , 5, 2311-20	7
783	Resolution of intracoronary thrombus with direct thrombin inhibition in a cocaine abuser. 2004 , 90, 501	4
782	Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. 2004 , 101, 18135-40	268
781	The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. 2004 , 279, 4782-93	287
780	Stentless aortic valve replacement: current status and future trends. 2004 , 2, 127-40	7
779	Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide. 2004 , 20, 639-44	2
778	Early target organ damage and its reversibility: the heart. 2004 , 26, 673-87	12
777	Network integration of the adrenergic system in cardiac hypertrophy. 2004 , 63, 391-402	64
776	Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. 2004 , 109, 1789-94	85
775	Early regression of left ventricular hypertrophy after aortic valve replacement by the Ross procedure detected by cine MRI. 2004 , 6, 1-8	11
774	Accuracy of one- and two-dimensional algorithms with optimal image plane position for the estimation of left ventricular mass: a comparative study using magnetic resonance imaging. 2004 , 6, 845-54	12

773	Echocardiographic Assessment of Left Ventricular Structure in Hypertension and the Impact on Clinical Outcomes. 2004 , 20, 304-314	1
772	Elevated dietary sodium intake exacerbates myocardial hypertrophy associated with cardiac-specific overproduction of angiotensin II. 2004 , 5, 169-75	2
771	Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?. 2004 , 90, 496-501	150
770	Electrophysiological properties of the L-type Ca(2+) current in cardiomyocytes from bluefin tuna and Pacific mackerel. 2004 , 286, R659-68	23
769	QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. 2004 , 43, 1029-34	115
768	Echocardiographic changes and risk factors for left ventricular hypertrophy in children and adolescents after renal transplantation. 2004 , 8, 249-54	51
767	Arterial stiffness, endothelial function and novel pharmacological approaches. 2004 , 31, 795-9	71
766	Cardiovascular consequences of parathyroid disorders in adults. 2021 , 82, 151-157	5
765	Variation in left ventricular cardiac magnetic resonance normal reference ranges: systematic review and meta-analysis. 2021 , 22, 494-504	2
764	Racial differences of early vascular aging in children and adolescents. 2021 , 36, 1087-1108	6
763	The role of mechanotransduction in heart failure pathobiology-a concise review. 2021 , 26, 981-995	0
762	Disruption of actin dynamics regulated by Rho effector mDia1 attenuates pressure overload-induced cardiac hypertrophic responses and exacerbates dysfunction. 2021 , 117, 1103-1117	2
761	Impact of pericoronary adipose tissue inflammation on left ventricular hypertrophy and regional physiological indices in stable coronary artery disease patients with preserved systolic function. 2021 , 36, 24-37	3
760	Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: Results of the IBERICAN study. 2021 , 156, 157-165	3
759	APD or CAPD: one glove does not fit all. 2021 , 53, 1149-1160	4
758	Prognostic value of Goldberger's electrocardiographic criteria for left ventricular dysfunction. 2021 , 64, 18-22	
757	Ethnic differences in childhood right and left cardiac structure and function assessed by cardiac magnetic resonance imaging. 2021 , 180, 1257-1266	
756	The regulatory roles of p53 in cardiovascular health and disease. 2021 , 78, 2001-2018	14

755	Automatic quantification of myocardium and pericardial fat from coronary computed tomography angiography: a multicenter study. 2021 , 31, 3826-3836	2
754	Prospective assessment of subclinical cardiovascular damage and associated factors in liver transplant recipients. 2021 , 34, 127-138	2
753	Impact of hypertension on left ventricular function in patients after anthracycline chemotherapy for malignant lymphoma. 2021 , 323, 126-132	3
752	Influence of early-life body mass index and systolic blood pressure on left ventricle in adulthood - the Cardiovascular Risk in Young Finns Study. 2021 , 53, 160-168	3
751	Grape polyphenols and exercise training have distinct molecular effects on cardiac hypertrophy in a model of obese insulin-resistant rats. 2021 , 87, 108522	2
750	Interaction of Skeletal and Left Ventricular Mass in Older Adults with Low Muscle Performance. 2020 ,	2
749	Prognostic values of left ventricular mass index in chronic kidney disease patients. 2021 , 36, 665-672	4
748	The emerging applications of cardiovascular magnetic resonance imaging in transcatheter aortic valve implantation. 2021 , 76, 73.e21-73.e37	1
747	Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. 2021 , 20, 25	7
746	Lactoferrin ameliorates pathological cardiac hypertrophy related to mitochondrial quality control in aged mice. 2021 , 12, 7514-7526	5
745	Prevalence of and risk factors for abnormal left ventricular geometrical patterns in hypertensive subjects administered irbesartan. 2021 , 35, e23688	0
744	Prognostic effect of increased left ventricular wall thickness in severe aortic stenosis. 2021 , 19, 5	1
743	Alcohol consumption is associated with structural changes in various organ systems: A population-based study in UK Biobank.	1
742	Prognostic power of conventional echocardiography in individuals without history of cardiovascular diseases: A systematic review and meta-analysis. 2021 , 76, e2754	4
741	Associations of the Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay diet with cardiac remodelling in the community: the Framingham Heart Study. 2021 , 126, 1888-1896	3
740	Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1. 2021 , 10, e014311	4
739	The corrected left ventricular ejection fraction: a potential new measure of ventricular function. 2021 , 37, 1987-1997	0
738	Tp-Te interval prolongs in hypertension independent of the left ventricular geometry. 2021 , 5, 183-187	

- 737 [Cardiovascular disorders in autosomal dominant polycystic kidney disease]. **2021**, 17, 18-29
- 736 Left ventricular mass on positron emission tomography: Validation against cardiovascular magnetic resonance. **2021**, 1 1
- 735 Direct Actions of AT (Type 1 Angiotensin) Receptors in Cardiomyocytes Do Not Contribute to Cardiac Hypertrophy. **2021**, 77, 393-404 7
- 734 Long-term outcomes of aortic root operations in the United States among Medicare beneficiaries. **2021**, 5
- 733 Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: Results of the IBERICAN study. **2021**, 156, 157-165
- 732 Concentric vs. Eccentric Left Ventricular Hypertrophy: Does It Matter? It Is All "Blood Pressure Centered". **2021**, 34, 581-582 1
- 731 Cardio-ankle vascular index represents the best surrogate for 10-year ASCVD risk estimation in patients with primary hypertension. **2021**, 43, 349-355 1
- 730 Whole-Exome Sequencing and hiPSC Cardiomyocyte Models Identify , , and of Potential Importance to Left Ventricular Hypertrophy in an African Ancestry Population. **2021**, 12, 588452
- 729 Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. **2021**, 39, 961-969 0
- 728 Association Between M235T and Left Ventricular Mass in Vietnamese Patients Diagnosed With Essential Hypertension. **2021**, 8, 608948 4
- 727 Precision medicine for heart failure based on molecular mechanisms: The 2019 ISHR Research Achievement Award Lecture. **2021**, 152, 29-39 0
- 726 High-content live-cell imaging reveals co-regulation of cardiomyocyte decisions of hypertrophy and apoptosis.
- 725 Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis. **2021**, 24, 510-518
- 724 Metabolic Interventions to Prevent Hypertrophy-Induced Alterations in Contractile Properties In Vitro. **2021**, 22, 0
- 723 A STUDY OF EFFICACY OF THE CLASSIC ECG CRITERIA TO DIAGNOSE LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE SUBJECTS AND EVALUATION OF A NEW SCORE. **2021**, 60-63
- 722 Augmentation index predicts mortality in patients with aortic stenosis: an echo-tracking study. **2021**, 37, 1659-1668 1
- 721 Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy. **2021**, 3
- 720 Age-specific association between invasively measured central blood pressure and left ventricular mass index. **2021**, 43, 419-427

7 ¹⁹	Characterization of laser speckle flowgraphy pulse waveform parameters for the evaluation of the optic nerve head and retinal circulation. 2021 , 11, 6847	3
7 ¹⁸	Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. 2021 ,	4
7 ¹⁷	Habitual cannabis use is associated with altered cardiac mechanics and arterial stiffness, but not endothelial function in young healthy smokers. 2021 , 130, 660-670	1
7 ¹⁶	Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. 2021 , 1	1
7 ¹⁵	Cardiac computed tomography for left ventricular remodeling assessment: does it mean echocardiography moves for the past?. 2021 , 39, 602-603	
7 ¹⁴	Prognostic implications of left ventricular mass-geometry in patients with no or nonobstructive coronary artery disease. 2021 , 21, 187	2
7 ¹³	Pulse arrival time, a novel sleep cardiovascular marker: the multi-ethnic study of atherosclerosis. 2021 , 76, 1124-1130	3
7 ¹²	FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K. 2021 , 320, H1470-H1485	4
7 ¹¹	Metabolic syndrome and coronary artery disease in adults with congenital heart disease. 2021 , 11, 563-576	2
7 ¹⁰	Interactions of hypertension, obesity, left ventricular hypertrophy, and heart failure. 2021 , 36, 453-460	6
7 ⁰⁹	Current Therapeutic Options in Aortic Stenosis. 2021 , 128, 1398-1417	3
7 ⁰⁸	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years. 2021 , 77, 1273-1284	5
7 ⁰⁷	Ethnic differences in coronary anatomy, left ventricular mass and CT-derived fractional flow reserve. 2021 , 15, 249-257	0
7 ⁰⁶	Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence. 2021 , 39, 864-866	0
7 ⁰⁵	Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease. 2021 , 16, e0251333	2
7 ⁰⁴	The TRIB3 R84 variant is associated with increased left ventricular mass in a sample of 2426 White individuals. 2021 , 20, 115	0
7 ⁰³	Myocardial Strain Imaging in Resistant Hypertension. 2021 , 23, 24	1
7 ⁰²	Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis. 2021 , 8, 676076	1

701	Cardiac mechanical efficiency is preserved in primary cardiac hypertrophy despite impaired mechanical function. 2021 , 153,	0
700	Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling in the Community. 2021 , 23, 86	3
699	The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms. 2021 , 8, 695792	16
698	The Ca-activated cation channel TRPM4 is a positive regulator of pressure overload-induced cardiac hypertrophy. 2021 , 10,	4
697	Blood pressure variability and night-time dipping assessed by 24-hour ambulatory monitoring: Cross-sectional association with cardiac structure in adolescents. 2021 , 16, e0253196	0
696	Alcohol consumption in the general population is associated with structural changes in multiple organ systems. 2021 , 10,	3
695	Exposure to secondhand smoke is associated with increased left ventricular mass. 2021 , 19, 43	0
694	Framingham Heart Study: JACC Focus Seminar, 1/8. 2021 , 77, 2680-2692	9
693	Visceral fat level correction of the left ventricular hypertrophy electrocardiographic criteria. 2021 , 26, e12863	1
692	Prognostic value of cardiovascular magnetic resonance left ventricular volumetry and geometry in patients receiving an implantable cardioverter defibrillator. 2021 , 23, 72	1
691	Cardiac hypertrophy caused by hyperthyroidism in rats: the role of ATF-6 and TRPC1 channels. 2021 , 99, 1226-1233	0
690	Determinants of cardiac structure in frail and sarcopenic elderly adults. 2021 , 150, 111351	2
689	Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy. 2021 , 12, 679655	3
688	Curcumin, an Inhibitor of p300-HAT Activity, Suppresses the Development of Hypertension-Induced Left Ventricular Hypertrophy with Preserved Ejection Fraction in Dahl Rats. 2021 , 13,	3
687	Cardiac structural and functional abnormalities in primary hyperparathyroidism. 2021 , 1	1
686	Incremental changes in QRS duration as predictor for cardiovascular disease: a 21-year follow-up of a randomly selected general population. 2021 , 11, 13652	1
685	Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus. 2021 , 13, 847-856	0
684	Diagnosis of left ventricular hypertrophy using non-ECG-gated ¹⁸ O-water PET. 2021 , 1	

- 683 Effect of Preterm Birth on Cardiac and Cardiomyocyte Growth and the Consequences of Antenatal and Postnatal Glucocorticoid Treatment. **2021**, 10, 3
- 682 Association of central arterial blood pressure and left ventricular hypertrophy in patients with chronic kidney disease. **2021**,
- 681 The Pathophysiology of Afterload Mismatch and Ventricular Hypertrophy. 1-11 0
- 680 Blood Pressure and Left Ventricular Geometric Changes: A Directionality Analysis. **2021**, 78, 1259-1266 0
- 679 A nomogram integrating non-ECG factors with ECG to screen left ventricular hypertrophy among hypertensive patients from northern China.. **2022**, 40, 264-273 1
- 678 Association between elevated left ventricular mass index and increased cardiovascular events in patients with acute coronary syndrome: A sub-analysis of the HIJ-PROPER study. **2021**, 38, 1567-1573 0
- 677 Association between race and maladaptive concentric left ventricular hypertrophy in American-style football athletes. **2021**, 0
- 676 Left Ventricular Measurements and Strain in Pediatric Patients Evaluated for Systemic Hypertension and the Effect of Adequate Anti-hypertensive Treatment. **2021**, 1 0
- 675 Subclinic arterial and left ventricular systolic impairment in autosomal dominant polycystic kidney disease with preserved renal functions. **2021**, 1 1
- 674 Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial. **2021**, 16, 1491-1501 2
- 673 Association between exposure to heavy occupational lifting and cardiac structure and function: a cross-sectional analysis from the Copenhagen City Heart Study. **2021**, 1
- 672 Cardiac Hypertrophy Is Associated With Advanced Brain Aging in the General Population. **2021**, 10, e020994 1
- 671 Clinical Assessment of Ventricular Wall Stress in Understanding Compensatory Hypertrophic Response and Maladaptive Ventricular Remodeling. **2021**, 8, 0
- 670 The relationship between systemic inflammation and increased left ventricular mass is partly mediated by noncalcified coronary artery disease burden in psoriasis. **2021**, 7, 100211 2
- 669 Piezo1-Mediated Mechanotransduction Promotes Cardiac Hypertrophy by Impairing Calcium Homeostasis to Activate Calpain/Calcineurin Signaling. **2021**, 78, 647-660 2
- 668 Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments. **2021**, 78, 564-577 8
- 667 Sodium Intake as a Cardiovascular Risk Factor: A Narrative Review. **2021**, 13, 1
- 666 Association between coronary dominance pattern and left ventricular mass index: Is there a gender disparity?. **2021**, 75, e14835 1

665	Nandrolone combined with strenuous resistance training impairs myocardial proteome profile of rats. 2021 , 175, 108916	0
664	Specific amino acid supplementation rescues the heart from lipid overload-induced insulin resistance and contractile dysfunction by targeting the endosomal mTOR-v-ATPase axis. 2021 , 53, 101293	3
663	Oxidized LDL but not angiotensin II induces cardiomyocyte hypertrophic responses through the interaction between LOX-1 and AT receptors. 2021 , 162, 110-118	1
662	Organ and Metabolic Complications: Cardiac. 1996 , 990-1002	1
661	Diagnosis, Prevention, and Treatment of Hypertensive Heart Disease. 2014 , 51-58	1
660	L-Arginine at the Crossroads of Biochemical Pathways Involved in Myocardial Hypertrophy. 2003 , 49-56	1
659	Ca ²⁺ -Dependent Signaling Pathways Through Calcineurin and Ca ²⁺ Calmodulin-Dependent Protein Kinase in Development of Cardiac Hypertrophy. 2003 , 85-94	5
658	Relations of left ventricular geometry and function to prognosis in hypertension. 1997 , 432, 1-12	3
657	Physiological Versus Pathological Hypertrophy. 1997 , 145-158	4
656	Comparison of therapeutic studies on regression of left ventricular hypertrophy. 1997 , 432, 191-8	9
655	Prognostic significance of left ventricular hypertrophy regression. 1997 , 432, 199-205	9
654	Left ventricular hypertrophy and arterial blood pressure in experimental models of hypertension. 1997 , 432, 23-33	9
653	Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension. 1997 , 432, 63-9	7
652	Prognostic Value of Ambulatory Blood Pressure Monitoring. 2001 , 191-218	2
651	Cardiovascular Reactivity in Youth. 2004 , 251-263	1
650	Polyamine Metabolism and the Hypertrophic Heart. 2006 , 123-137	3
649	Cardiac Magnetic Resonance Spectroscopy. 2008 , 673-694	1
648	Minority Women and Cardiovascular Disease. 2009 , 297-320	1

647	The Clinical Use of Noninvasive Modalities in the Assessment of Atherosclerosis. 2007 , 389-408	1
646	Hypertension and the Heart and Vasculature. 2020 , 187-215	2
645	Epidemiology of Atherosclerotic Vascular Disease. 2002 , 3-16	1
644	Myocardial fibrosis: role of angiotensin II and aldosterone. 1993 , 88 Suppl 1, 107-24	30
643	Origins, Evolution, and Prognosis of Acute Myocardial Ischemic Syndromes: Focus on Non-Q-Wave Myocardial Infarction. 1991 , 44-61	0
642	Gene Expression in Cardiac Hypertrophy. 1995 , 165-236	1
641	NHG-Standaard Cardiovasculair risicomanagement. 2011 , 361-408	1
640	Mechano-transduction in Cardiac and Stem-Cell Derived Cardiac Cells. 2010 , 99-139	1
639	The Lipid Hypothesis: Is it the Only Cause of Atherosclerosis?. 1992 , 13-18	1
638	Left Ventricular Hypertrophy, Congestive Heart Failure, and Coronary Flow Reserve Abnormalities in Hypertension. 2005 , 250-280	1
637	Gender and the Heart: Sex-Specific Differences in Normal Myocardial Anatomy and Physiology and in the Experiences of Some Diseases of the Cardiovascular System. 2004 , 185-192	3
636	Quantitative Evaluation of Left Ventricular Structure, Wall Stress, and Systolic Function. 2007 , 187-211	2
635	Hemodialysis. 2012 , 2294-2346	4
634	Discovery and development of ASK1 inhibitors. 2020 , 59, 101-179	9
633	Left ventricular remodelling and cardiac chamber sizes in long-term, normoalbuminuric type 1 diabetes patients with and without cardiovascular autonomic neuropathy. 2019 , 33, 171-177	2
632	Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy.. 1994 , 269, 1110-1119	273
631	Human Growth: Assessment and Interpretation. 2003 ,	44
630	Relationship between left ventricular mass and blood pressure in treated hypertension.	1

629	California Cardiovascular Screening Tool: Findings from Initial Implementation. 2020 , 10, e362-e368	2
628	A perspective on obesity. 1995 , 310 Suppl 1, S68-71	23
627	Prediction of left ventricular mass in youth with family histories of essential hypertension. 1998 , 315, 118-23	44
626	Why is left ventricular hypertrophy so predictive of morbidity and mortality?. 1999 , 317, 168-75	122
625	Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. 1999 , 317, 176-82	38
624	The association of left ventricular mass with cardiovascular risk factors in African American women. 2000 , 320, 13-7	6
623	New drugs for the treatment of hypertension. 1999 , 14, 375-80	6
622	The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. 1997 , 30, 643-8	7
621	Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands. 1998 , 31 Suppl 2, S27-33	3
620	Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension. 1998 , 31, 187-94	13
619	Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. 1998 , 32, 760-8	7
618	Angiotensin II Antagonism and the Heart: Valsartan in Left Ventricular Hypertrophy. 1999 , 33, S33-S36	5
617	Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. 1999 , 33, 433-9	26
616	The effects of mibefradil and enalapril on 24-hour blood pressure control and left ventricular mass in patients with mild to moderate hypertension: double-blind, randomized trial. 1999 , 33, 647-51	3
615	Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. 1999 , 34, 237-47	23
614	Effects of long-term treatment with nonselective endothelin receptor antagonist, TAK-044, on remodeling of cardiovascular system with sustained volume overload. 2000 , 35, 777-85	8
613	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). 2003 , 10, S1-S78	145
612	The Impact of Preeclampsia on Women's Health: Cardiovascular Long-term Implications. 2020 , 75, 703-709	3

611	Assessing the causal role of body mass index on cardiovascular health in young adults: Mendelian randomization and recall-by-genotype analyses.	3
610	Nitric oxide and oxidative stress in cardiovascular aging. 2005 , 2005, re4	15
609	Racial differences in cardiac structure and function in essential hypertension. 1994 , 308, 1011-4	59
608	Left ventricular hypertrophy. 1995 , 311, 273-4	24
607	The Impact of Left Ventricular Hypertrophy and Diastolic Dysfunction on Outcome in Intracerebral Hemorrhage Patients. 2013 , 2013,	2
606	Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. 1995 , 91, 2573-81	313
605	Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. 1995 , 91, 426-30	49
604	Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). 1995 , 91, 698-706	200
603	Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study. 1995 , 91, 1739-48	169
602	Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. 1995 , 91, 2400-6	177
601	Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents. Statistical, biological, and clinical significance. 1995 , 92, 3249-54	180
600	Clinical misconceptions dispelled by epidemiological research. 1995 , 92, 3350-60	49
599	Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Coronary Artery Risk Development in Young Adults. 1995 , 92, 380-7	209
598	Left ventricular hypertrophy has a greater impact on survival in women than in men. 1995 , 92, 805-10	108
597	Left atrial size and the risk of stroke and death. The Framingham Heart Study. 1995 , 92, 835-41	740
596	Hemodynamic mechanisms responsible for reduced subendocardial coronary reserve in dogs with severe left ventricular hypertrophy. 1995 , 92, 978-86	52
595	Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. 1995 , 92, 1808-12	141
594	Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance. 1995 , 92, 2151-6	28

593	Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. 1996 , 93, 259-65	245
592	Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. 1996 , 93, 1148-54	68
591	Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. 1996 , 94, 2923-9	45
590	Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. 1996 , 94, 1304-9	92
589	Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. 1997 , 95, 1260-8	98
588	Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. 1997 , 95, 1464-70	409
587	Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. 1997 , 95, 1471-8	171
586	Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy?. 1997 , 95, 1983-5	26
585	Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. 1997 , 95, 2007-14	184
584	Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. 1997 , 96, 4254-60	333
583	Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. 1997 , 96, 741-7	239
582	Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. 1997 , 96, 864-73	51
581	Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. 1997 , 96, 1416-23	138
580	Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation. 1997 , 96, 1863-73	152
579	Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. 1997 , 96, 2239-46	53
578	Heart rate adjustment of exercise-induced ST-segment depression identifies men who benefit from a risk factor reduction program. 1997 , 96, 2899-904	17
577	Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. 1995 , 25, 92-7	48
576	Gender differences and the electrocardiogram in left ventricular hypertrophy. 1995 , 25, 242-9	58

575	Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. 1995 , 25, 250-9	95
574	Common carotid artery stiffness and patterns of left ventricular hypertrophy in hypertensive patients. 1995 , 25, 651-9	110
573	Role of anthropometric indexes and blood pressure as determinants of left ventricular mass and geometry in adolescents. The Rio de Janeiro Study. 1995 , 26, 1190-4	8
572	Time-voltage area of the QRS for the identification of left ventricular hypertrophy. 1996 , 27, 251-8	24
571	Exercise blood pressure predicts mortality from myocardial infarction. 1996 , 27, 324-9	114
570	Weights at birth and in early infancy, systolic pressure, and left ventricular structure in subjects aged 8 to 24 years. 1996 , 27, 339-45	50
569	Hyperinsulinemia and left ventricular geometry in a work-site population in Japan. 1996 , 27, 729-34	29
568	Contributions of vascular tone and structure to elastic properties of a medium-sized artery. 1996 , 27, 816-22	28
567	Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. 1996 , 27, 1039-45	211
566	Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. 1996 , 28, 16-21	60
565	Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. 1996 , 28, 22-30	174
564	Association of carotid atherosclerosis with electrocardiographic myocardial ischemia and left ventricular hypertrophy. 1996 , 28, 3-7	17
563	Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. 1996 , 28, 31-6	58
562	Utility of new electrocardiographic models for left ventricular mass in older adults. The Cardiovascular Health Study Collaborative Research Group. 1996 , 28, 8-15	48
561	Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. 1996 , 28, 450-6	11
560	Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. 1996 , 28, 457-63	26
559	Stress-induced laboratory blood pressure in relation to ambulatory blood pressure and left ventricular mass among borderline hypertensive and normotensive individuals. 1996 , 28, 641-6	25
558	Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. 1997 , 29, 22-9	87

557	High prevalence of concentric remodeling in elderly individuals with isolated systolic hypertension from a population survey. 1997 , 29, 539-43	31
556	Limited echocardiography for hypertensive left ventricular hypertrophy. 1997 , 29, 560-3	40
555	Left ventricular mass in the elderly. The Cardiovascular Health Study. 1997 , 29, 1095-103	81
554	Relations of left ventricular geometry and function to body composition in children with high casual blood pressure. 1997 , 30, 377-82	28
553	Left ventricular filling profiles in young white-coat hypertensive patients without hypertrophy. 1997 , 30, 746-52	9
552	Systolic function in hypertensive men with concentric remodeling. 1997 , 30, 777-81	29
551	Cardiovascular reactivity to stress and left ventricular mass in youth. 1997 , 30, 782-7	61
550	Heritability of left ventricular mass: the Framingham Heart Study. 1997 , 30, 1025-8	128
549	Relation of exercise-induced myocardial ischemia to cardiac and carotid structure. 1997 , 30, 1382-8	9
548	Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. 1995 , 76, 892-9	41
547	Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. 1995 , 77, 258-65	204
546	Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. 1996 , 79, 887-97	67
545	Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. 1997 , 80, 139-46	108
544	Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. 1997 , 81, 611-7	101
543	Prospectively Randomized Evaluation of Stentless Versus Conventional Biological Aortic Valves. 1999 , 100,	4
542	Regression of Left Ventricular Hypertrophy After Surgical Therapy for Aortic Stenosis Is Associated With Changes in Extracellular Matrix Gene Expression. 2001 , 104,	4
541	Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension. 2017 , 6,	10
540	The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy. 2005 , 46, 1347-1354	4

539	Bioenergetic abnormalities associated with severe left ventricular hypertrophy. 1993 , 92, 993-1003	112
538	Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. 1995 , 96, 438-46	168
537	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. 2001 , 108, 1429-37	337
536	The black sheep of class IIa: HDAC7 SIKens the heart. 2020 , 130, 2811-2813	2
535	Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. 2003 , 111, 1475-86	143
534	Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. 2003 , 111, 869-76	322
533	A friend within the heart: natriuretic peptide receptor signaling. 2003 , 111, 1275-7	61
532	Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. 2003 , 111, 1475-1486	245
531	Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. 2004 , 114, 1058-1071	308
530	Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. 2004 , 114, 1058-71	183
529	Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. 2005 , 115, 2108-18	709
528	Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. 2006 , 116, 1547-60	179
527	A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. 1998 , 102, 929-37	116
526	Cdc42 is an antihypertrophic molecular switch in the mouse heart. 2009 , 119, 3079-88	51
525	Pivotal role of cardiomyocyte TGF- β signaling in the murine pathological response to sustained pressure overload. 2011 , 121, 2301-12	246
524	The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. 2011 , 121, 2447-56	145
523	Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. 2012 , 122, 291-302	108
522	RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. 1999 , 104, 567-76	150

521	Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. 1999 , 104, 1603-12	166
520	IV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload. 2018 , 128, 5561-5572	25
519	Stentless versus Stented Bioprosthetic Aortic Valves. 2009 , 4, 49-60	2
518	Pulmonary Artery Wedge Pressure Relative to Exercise Work Rate in Older Men and Women. 2017 , 49, 1297-1304	20
517	JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease. 2020 , 84, 2037-2119	46
516	Adrenoceptor regulates miRNA expression in rat heart. 2012 , 18, BR309-314	31
515	Echocardiographic markers of left ventricular dysfunction among men with uncontrolled hypertension and stage 3 chronic kidney disease. 2013 , 19, 838-45	5
514	Assessment of the relation between mean platelet volume, non-dipping blood pressure pattern, and left ventricular mass index in sustained hypertension. 2014 , 20, 2020-6	13
513	Arterial stiffness and carotid intima-media thickness in diabetic peripheral neuropathy. 2014 , 20, 2074-81	5
512	Role of MicroRNA-93 I in Pathogenesis of Left Ventricular Remodeling via Targeting Cyclin-D1. 2017 , 23, 3981-3988	4
511	Deletion Polymorphism of Angiotensin Converting Enzyme Gene is Associated with Left Ventricular Hypertrophy in Uighur Hypertension-Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Patients. 2019 , 25, 3390-3396	3
510	Prognosis associated with geometric patterns of left ventricular remodeling: systematic review and network meta-analysis. 8, 1130	2
509	Acute effect of human cardiotrophin-1 on hemodynamic parameters in spontaneously hypertensive rats and Wistar Kyoto rats. 2001 , 24, 717-21	5
508	Betaxolol inhibits extracellular signal-regulated kinase and P70S6 kinase activities and gene expressions of platelet-derived growth factor A-chain and transforming growth factor-beta1 in Dahl salt-sensitive hypertensive rats. 2002 , 25, 211-9	3
507	Fasting plasma glucose is an independent determinant of left ventricular diastolic dysfunction in nondiabetic patients with treated essential hypertension. 2002 , 25, 403-9	20
506	Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. 2002 , 25, 669-76	42
505	Accelerated cardiac hypertrophy and renal damage induced by angiotensin II in adrenomedullin knockout mice. 2003 , 26, 731-6	22
504	Predictors of controlled ambulatory blood pressure in treated hypertensive patients with uncontrolled office blood pressure. 2004 , 27, 805-11	4

503	Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). 2006 , 29 Suppl, S1-105	190
502	Cardiovascular Risk Factors from Early Life Predict Future Adult Cardiac Structural and Functional Abnormalities: A Systematic Review of the Published Literature. 2014 , 2, 78-87	5
501	Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation. 2012 , 7, e34892	37
500	Electrocardiographic left ventricular hypertrophy and outcome in hemodialysis patients. 2012 , 7, e35534	16
499	Mitochondrial function in permeabilized cardiomyocytes is largely preserved in the senescent rat myocardium. 2012 , 7, e43003	20
498	The association of growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients. 2012 , 7, e46534	20
497	DYRK2 negatively regulates cardiomyocyte growth by mediating repressor function of GSK-3 β on eIF2B γ . 2013 , 8, e70848	11
496	EPC-derived microvesicles protect cardiomyocytes from Ang II-induced hypertrophy and apoptosis. 2014 , 9, e85396	50
495	Angiogenesis, cardiomyocyte proliferation and anti-fibrotic effects underlie structural preservation post-infarction by intramyocardially-injected cardiospheres. 2014 , 9, e88590	47
494	Determinants and improvement of electrocardiographic diagnosis of left ventricular hypertrophy in a black African population. 2014 , 9, e96783	16
493	PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3 β and several PKC isoforms. 2014 , 9, e102148	21
492	Associations between childhood body size, composition, blood pressure and adult cardiac structure: the Fels Longitudinal Study. 2014 , 9, e106333	13
491	On cross-sectional associations of leukocyte telomere length with cardiac systolic, diastolic and vascular function: the Asklepios study. 2014 , 9, e115071	15
490	Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD. 2015 , 10, e0118909	66
489	High intensity interval and endurance training have opposing effects on markers of heart failure and cardiac remodeling in hypertensive rats. 2015 , 10, e0121138	33
488	CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. 2015 , 10, e0133616	34
487	Racial Differences in Left Atrial Size: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. 2016 , 11, e0151559	8
486	Life Course Socioeconomic Position: Associations with Cardiac Structure and Function at Age 60-64 Years in the 1946 British Birth Cohort. 2016 , 11, e0152691	7

485	Age, Gender and Load-Related Influences on Left Ventricular Geometric Remodeling, Systolic Mid-Wall Function, and NT-ProBNP in Asymptomatic Asian Population. 2016 , 11, e0156467	15
484	Independent Prognostic Value of Single and Multiple Non-Specific 12-Lead Electrocardiographic Findings for Long-Term Cardiovascular Outcomes: A Prospective Cohort Study. 2016 , 11, e0157563	3
483	Left ventricular functional, structural and energetic effects of normal aging: Comparison with hypertension. 2017 , 12, e0177404	9
482	The impact of cardiovascular risk factors on cardiac structure and function: Insights from the UK Biobank imaging enhancement study. 2017 , 12, e0185114	39
481	Cystatin B, cathepsin L and D related to surrogate markers for cardiovascular disease in children. 2017 , 12, e0187494	5
480	Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: A placebo controlled randomized trial. 2017 , 12, e0188424	36
479	Myocardial adaption to HI(R)T in previously untrained men with a randomized, longitudinal cardiac MR imaging study (Physical adaptations in Untrained on Strength and Heart trial, PUSH-trial). 2017 , 12, e0189204	3
478	The impact of menopausal hormone therapy (MHT) on cardiac structure and function: Insights from the UK Biobank imaging enhancement study. 2018 , 13, e0194015	12
477	Salubrial Alleviates Pressure Overload-Induced Cardiac Hypertrophy by Inhibiting Endoplasmic Reticulum Stress Pathway. 2017 , 40, 66-72	16
476	Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. 2020 , 11, 376-385	1
475	Regression of the Left Ventricular Hypertrophy in Patients with Essential Hypertension on Standard Drug Therapy. 2020 , 8, e115	3
474	Relating Cocaine Blood Concentrations to ToxicityâAn Autopsy Study of 99 Cases. 1998 , 43, 16087J	67
473	The importance of contractile reserve in predicting exercise tolerance in asymptomatic patients with severe aortic stenosis. 2019 , 6, 43-52	3
472	Early regional assessment of LV mass regression and function after stentless valve replacement: comparative randomized study. 2004 , 7, E462-5; discussion E462-5	7
471	Intramyocardial injection of fibroblast growth factor-2 plus heparin suppresses cardiac failure progression in rats with hypertensive heart disease. 2005 , 46, 289-301	10
470	Induction of c-fos mRNA expression by pure pressure overload in cultured cardiac myocytes. 2007 , 48, 359-67	7
469	The Characteristics of Electrocardiography Findings in Left Ventricular Remodeling Patterns of Hypertensive Patients. 2015 , 21, 208-217	4
468	High sympathetic tone in development of the left ventricle hypertrophy and beta-blockers for regression. 2018 , 77-88	2

467	Arterial hypertension in adults. Clinical guidelines 2020. 2020 , 25, 3786	155
466	Early left ventricular remodelling criteria and antihypertensive therapy effectiveness. 2011 , 10, 9-14	6
465	Regression of Left Ventricular Hypertrophy Following Stenting of Renal Artery Stenosis. 2007 , 14, 189-197	11
464	Cardiopulmonary fitness factors, hemodynamic responses, and cardiac events of the middle aged marathon runners according to the completion distance.. 2012 , 21, 121-130	1
463	Effects of 8 Weeks Calorie Reduction and Resistance Exercise on Traf2-NFkB-mTOR and SIRT1-FoxO1 Signal Expression of Cardiac Muscle in High-fat Induced Obese Middle-Aged Rats. 2018 , 27, 126-133	1
462	Endothelial and non-endothelial coronary blood flow reserve and left ventricular dysfunction in systemic hypertension. 2009 , 64, 327-35	8
461	Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. 2000 , 11, 912-916	164
460	Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. 2001 , 12, 2768-2774	206
459	[Gender features of cardiovascular events in patients with chronic glomerulonephritis at the pre-dialysis stage of the disease]. 2017 , 89, 56-61	3
458	Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. 2008 , 8, 214-9	5
457	Tissue specific peculiarities of vibration-induced hypoxia of the rabbit heart, liver and kidney. 2016 , 14, 46-62	4
456	Mouse Sirt3 promotes autophagy in AngII-induced myocardial hypertrophy through the deacetylation of FoxO1. 2016 , 7, 86648-86659	42
455	The relationship among cardiac structure, dietary salt and aldosterone in patients with primary aldosteronism. 2017 , 8, 73187-73197	6
454	Targeting myocyte-specific enhancer factor 2D contributes to the suppression of cardiac hypertrophic growth by miR-92b-3p in mice. 2017 , 8, 92079-92089	17
453	Left ventricular hypertrophy and outcomes: A five-year retrospective analysis of patients with essential hypertension. 2012 , 18, 385-397	2
452	Left ventricular hypertrophy and proteinuria in patients with essential hypertension in Andkhoy, Afghanistan. 2018 , 80, 249-255	2
451	Noninvasive assessment of preclinical atherosclerosis. 2006 , 2, 19-30	77
450	Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. 2008 , 4, 67-73	18

449	Protection myocardique, rigidité artérielle et ondes de réflexion. 2003 , 63, 9-17	3
448	Nouveaux objectifs dans la prise en charge de l'hypertension. 2003 , 63, 45-47	4
447	Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension. 2019 , 17, 180-190	7
446	Considerations in Understanding the Coronary Blood Flow- Left Ventricular Mass Relationship in Patients with Hypertension. 2017 , 13, 75-83	8
445	The spatial QRS-T angle: implications in clinical practice. 2013 , 9, 197-210	36
444	Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. 2009 , 14, 237-62	22
443	Physiological versus pathological cardiac hypertrophy. 2005 , 117-136	5
442	Evaluation of left ventricular diastolic function according to the generation in patients with hypertension using left atrial volume index. 2011 , 38, 447-454	1
441	Cardiac Gq Receptors and Calcineurin Activation Are Not Required for the Hypertrophic Response to Mechanical Left Ventricular Pressure Overload. 2021 , 9, 639509	2
440	Canonical WNT signaling and myocardial remodeling in arterial hypertension and chronic kidney dysfunction. 2020 , 24, 85-92	0
439	Aged garlic extract reduces left ventricular myocardial mass in patients with diabetes: A prospective randomized controlled double-blind study. 2020 , 19, 1468-1471	3
438	Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients. 2006 , 21, 103-8	2
437	Predictive value of CHADS2 score for cardiovascular events in patients with acute coronary syndrome and documented coronary artery disease. 2016 , 31, 73-81	7
436	Left Ventricular Mass and Geometry in Obese Children. 2008 , 1, 58-64	7
435	Assessment of some cardiovascular risk factors in predialysis chronic kidney disease patients in Southern Nigeria. 2015 , 56, 394-9	3
434	Chronic kidney disease in Nigeria: Late presentation is still the norm. 2016 , 57, 185-9	9
433	Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis. 2009 , 19, 153-7	8
432	The association of metabolic syndrome with left ventricular mass and geometry in community-based hypertensive patients among Han Chinese. 2015 , 20, 963-8	4

431	Early Recovery of Left Ventricular Systolic Function after Transcatheter Aortic Valve Implantation. 2018 , 28, 166-170	5
430	Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study. 2015 , 8, 213-225	3
429	Impact of renal sympathetic denervation on cardiac sympathetic nerve activity evaluated by cardiac MIBG imaging. 2016 , 11, 1070-6	7
428	Improved scoring system for the electrocardiographic diagnosis of left ventricular hypertrophy. 2019 , 11, 94-102	4
427	Hypertension and obstructive sleep apnea in Caucasian children. 2010 , 2, 251-6	23
426	Validity of electrocardiographic criteria for increased left ventricular mass in young patients in the general population. 2017 , 9, 248-254	1
425	Assessment of Cardiovascular System Abnormalities in Patients with Advanced Primary Hyperparathyroidism by Detailed Echocardiographic Analysis: A Prospective Study. 2017 , 9, 46-50	2
424	Mitral annular plane systolic excursion in the assessment of left ventricular diastolic dysfunction in obese adults. 2015 , 15, 558-64	6
423	Two-dimensional and M-mode echocardiographic predictors of disease severity in dogs with congenital subaortic stenosis. 2002 , 38, 209-15	11
422	Association of SLC6A9 gene variants with human essential hypertension. 2009 , 16, 201-6	4
421	Comparison of Echocardiographic Variables Between Systemic Lupus Erythematosus Patients and a Control Group. 2015 , 3,	3
420	The Relationship Between Increased Epicardial Fat Thickness and Left Ventricular Hypertrophy and Carotid Intima-Media Thickness in Patients With Nonfunctional Adrenal Incidentaloma. 2016 , 14, e37635	5
419	The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects. 2014 , 25, 233-8	5
418	Left Ventricular Hypertrophy and Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis. 2020 , 22, 206-224	4
417	Longitudinal Shortening of the Left Ventricle by Cine-CMR for Assessment of Diastolic Function in Patients with Aortic Valve Disease. 2020 , 114, 284-292	2
416	Possible correlation among echocardiographic measures, serum brain natriuretic peptide, and angiotensin II levels in hypertensive kidney transplanted children. 2013 , 11, 128-33	6
415	ECG is an inefficient screening-tool for left ventricular hypertrophy in normotensive African children population. 2016 , 4, e2439	1
414	Added value to stress myocardial perfusion imaging studies with measurement of left ventricular mass. 2021 , 1	0

- 413 Plasma mid-regional pro-atrial natriuretic peptide predicts cardiovascular events in patients with type 2 diabetes independently of subclinical organ damage. **2021**, 182, 109095 o
- 412 Association Between the Angiotensin II/Angiotensin (1-7) Imbalance and Left Ventricular Hypertrophy in Patients with Heart Failure. **2021**, 48, 12-18
- 411 Morphological and functional cardiac consequences of rapid hypertension treatment: a cohort study. **2021**, 23, 122 o
- 410 Arterielle Hypertonie. **2000**, 259-268
- 409 Molecular Mechanism of Mechanical Stress-Induced Cardiac Hypertrophy. **2000**, 109-121
- 408 Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. **2000**, 177-182
- 407 Literaturverzeichnis. **2000**, 63-75
- 406 Effects of antihypertensive therapy on blood pressure and left ventricular hypertrophy in patients with severe hypertension. **2000**, 41, 339-48
- 405 Weitere kardiovaskuläre Risikofaktoren. **2000**, 269-291
- 404 Fettstoffwechsel, Übergewicht und Ernährung, Diabetes. **2000**, 239-257
- 403 Stentless Aortic Valve Replacement. **2001**, 21-23
- 402 Adaptation des linksventrikulären Myokards an die genetische, rheologische und hämodynamische Variabilität – Bevölkerungsbezogene Beobachtung. **2001**, 49-56
- 401 Risk Factors for and Prevention of Atherosclerotic Cardiovascular Disease. **2001**, 97-106
- 400 Left Ventricular Hypertrophy: A Neglected Risk Factor for Sudden Cardiac Death?. **2002**, 219-227
- 399 Immunomodulation in Heart Failure: Experimental Models. **2003**, 203-219
- 398 The vegetative regulation and central hemodynamics at ischemic heart disease patients with arterial hypertension and various types of the left ventricle hypertrophy. **2003**, 9, 92-94
- 397 Remodelling and left ventricular diastolic function in relation to blood pressure variability in patients with arterial hypertension and coronary heart disease. **2003**, 9, 124-127 1
- 396 Dietary Prevention of CHD. **2003**,

- 394 Genetic Predisposition to Cardiac Hypertrophy. **2004**, 177-202

- 377 Angiotensin II antagonists and protection against subclinical cardiac and vascular damage. **2006**, 111-126 1
- 376 Positron emission tomography application for myocardial blood flow and coronary flow reserve measurement in patients with cardiovascular pathology. **2006**, 12, 200-211 4
- 375 ??????II??????? : ??????II,????????,????????????(5.????????????,?70????????). **2006**, 14, 271-276
- 374 Aging Changes Seen on Echocardiography. **2007**, 952-968
- 373 Diagnostiek bij hartfalen. **2007**, 71-93
- 372 Hypertension: Impact of Echocardiographic Data on the Mechanism of Hypertension, Treatment, Options, Prognosis, and Assessment of Therapy. **2007**, 816-847
- 371 Lipid Abnormalities in Polycystic Ovary Syndrome. **2007**, 79-97
- 370 Cardiovascular Disease and Inflammation. **2007**, 181-190
- 369 Waist Circumference May be More Important than Body Mass Index (BMI) in Determinants of Left Ventricular Mass in Korean Hypertensive Patients. **2007**, 31, 130
- 368 ACE Inhibition in Heart Failure and Ischaemic Heart Disease. **2007**, 21-54
- 367 Evaluation of left ventricular functions after aortic valve replacement in a specific young male patient population with pure aortic insufficiency or aortic stenosis: 5-years follow-up. **2007**, 10, E57-63
- 366 Determinants of evolution of ECG signs of left ventricular hypertrophy during long-term antihypertensive treatment in patients with high risk arterial hypertension. **2007**, 13, 39-43
- 365 Integrative Renal Regulation of Sodium Excretion. **2007**, 193-218
- 364 The Kidney: A Target Organ of Excessive Dietary Salt Intake. **2007**, 365-378
- 363 Acute Coronary Syndrome in African Americans and Hispanic Americans. **2008**, 229-245
- 362 Diuretics and BBlockers. **2008**, 591-600
- 361 Echocardiographic Measurements inElderly Patients Without Clinical Heart Disease. **2008**, 45-74
- 360 Echocardiography. **2008**, 1-9 1

359 Vozmozhnosti traditsionnoy rentgenografii organov grudnoy kletki pri vyavlenii gipertrofii levogo zheludochka u muzhchin i zhenshchin, stradayushchikh arterial'noy gipertoniey. **2008**, 5, 75-84

358 Structural Cardiovascular Changes in Hypertension. **2008**, 115-119

357 Ventricular Adaptation to Valvular Heart Disease. **2009**, 59-72

356 Insulin Resistance, Diabetes, and Cardiovascular Risk in Women and the Paradigm of the Polycystic Ovary Syndrome. **2009**, 57-81

355 Unique Aspects of Vascular and Cardiac Ultrasound in Racial/Ethnic Groups. **2009**, 247-268

354 Left Ventricular Hypertrophy and Treatment with Renin Angiotensin System Inhibition. **2009**, 103-119

2

353 Left Ventricular Adaptation to Pressure and/or Volume Overload. **2009**, 55-61

352 NHG-Standaard Cardiovasculair risicomanagement. **2009**, 106-152

2

351 The Effects of aerobic exercise on cardiovascular disease risk factor and cardiac function according ACE genotype in middle-aged woman. **2009**, 18, 11-20

1

350 Stentless versus Stented Bioprosthetic Aortic Valves. **2009**, 4, 61-73

1

349 ???????(??????). **2009**, 17, 11-17

348 Hypertension. **2009**, 437-464

347 Coronary Artery Disease and Cardiomyopathy. **2010**, 499-513

346 Definition, Diagnosis, Epidemiology, Etiology and Pathophysiology of Heart Failure. **2010**, 1-19

345 Diabetes Mellitus: Is the Presence of Nephropathy Important as a Cardiovascular Risk Factor for Cardioneral Syndrome?. **2010**, 145-157

344 Papel da ecocardiografia na hipertrofia ventricular esquerda. **2010**, 2, 1-6

343 Interventional Treatment of Renal Artery Stenosis. 664-673

342 Sequelae of Hypertension in Children and Adolescents. **2011**, 443-455

- 341 The Clinical Application of Ambulatory Blood Pressure Monitoring in Pediatrics. **2011**, 02, 650-660
- 340 Update cardiovascular screening methods. **2011**, 38, 737-743
- 339 Assessment and Treatment of Cardiovascular Disease in Obese Children. **2011**, 101-140
- 338 Assessment of cardiovascular events prediction in patients with hypertension therapy. **2011**, 38, 557-563
- 337 Myocardial Contrast Echocardiography in the Evaluation of Hypertensive Heart Disease. **2011**, 2, 259-268 1
- 336 The effects of prolonged exercise on cTnT and inflammatory markers in young-aged adults.. **2011**, 20, 1-10 1
- 335 Sostoyanie serdtsa po dannym ekhokardiografiiu lits s ozhireniem, manifestirovavshimv pubertatnyy period. **2011**, 8, 38-45 2
- 334 Exerc io de for a ativa a via AKT/mTor pelo receptor de angiotensina II tipo I no m sculo card aco de ratos. **2011**, 25, 377-385 2
- 333 The Right Heart Diaries in Sleep Disordered Breathing. **2011**, 8,
- 332 PET in Cardiovascular Diseases. **2013**, 255-331
- 331 Innovations in Twenty-First Century Cardiovascular Medicine. **2012**, 509-523
- 330 Assessment of Total Cardiovascular Risk in Hypertension: The Role of Subclinical Organ Damage. **2012**, 199-211
- 329 Clinical Implications and Management of Sub Clinical Hyperthyroidism: A Review. **2012**, 02, 27-35 1
- 328 Left Ventricle Hypertrophy, Dilatation and Ejection Fraction Changes Before and After Kidney Transplantation. **2013**, 4, 31-34 2
- 327 Sequelae of Hypertension in Children and Adolescents. **2013**, 453-464
- 326 Transcatheter Aortic Valve Replacement (TAVR): A Clinician s Perspective Aortic Stenosis: Natural and Unnatural (Treated) History. **2014**, 65-70
- 325 LEFT VENTRICULAR MASS INDEX: A PREDICTOR OF MORBIDITY AND MORTALITY IN ESSENTIAL HYPERTENSION. **2013**, 2, 7714-7721 0
- 324 Aldosterone and Cardiovascular Diseases. **2014**, 155-196

- 323 Factors influencing left ventricular hypertrophy in children and adolescents with or without family history of premature myocardial infarction. **2014**, 3, 60 1
- 322 Cardiovascular System. **2014**, 157-189
- 321 Aortic Stenosis and Stressed Heart Morphology. **2014**, 04, 151-157 1
- 320 Epidemiology of Atherosclerotic Vascular Disease. **2014**, 1-21
- 319 Reproducibility of left ventricular mass by echocardiogram in the ELSA-Brasil. **2015**, 104, 104-11 2
- 318 Plötzlicher Herztod und hypertensive Herzkrankheit. **1991**, 130-141
- 317 ACE-Hemmung als therapeutisches Prinzip. **1991**, 539-566
- 316 Die Bedeutung früher hypertoniebedingter Endorganschädigungen für die Diagnostik und Therapie der arteriellen Hypertonie. **1991**, 1-5
- 315 Pathophysiologie, Klinik und Prognose des Hochdruckherzens. **1991**, 40-129
- 314 Cardiological Findings in Patients with End-Stage Renal Failure Under Treatment with Erythropoietin. **1992**, 177-180 1
- 313 Left Ventricular Mass as a Measure of Preclinical Disease in Patients with Hypertension. **1992**, 209-214
- 312 Das kardiovaskuläre Risiko bei Hypertonie; Interaktionen mit anderen Risikofaktoren. **1992**, 53-63
- 311 Patienten mit Hypertonie und linksventrikulärer Hypertrophie. **1992**, 192-208
- 310 Literatur. **1992**, 103-112
- 309 Modulation of myocardial sarcoplasmic reticulum Ca(++)-ATPase in cardiac hypertrophy by angiotensin converting enzyme?. **1992**, 87 Suppl 2, 191-204 9
- 308 ACE-inhibitors and coronary microcirculation. **1993**, 88 Suppl 1, 97-106 1
- 307 The Microcirculation in Cardiac Hypertrophy. **1993**, 176-184
- 306 Function and Energy Metabolism of Isolated Hearts Obtained from Hyperthyroid Spontaneously Hypertensive Rats (SHR) A 31P-Nuclear Magnetic Resonance Study. **1993**, 43-50

305 Myokardfibrose: Die Rolle von Angiotensin II und Aldosteron. **1993**, 115-134

304 ACE-Hemmer und koronare Mikrozirkulation. **1993**, 103-113

303 Regression of Cardiac Hypertrophy with Pharmacotherapeutic Regimen. **1993**, 195-206

302 Pathophysiology of hypertension in the elderly. **1993**, 147-152

301 Arterial system, left ventricular structure and function. **1993**, 155-179

300 Myocardial Fibrosis: Structural Basis for Diastolic Dysfunction. **1994**, 213-220

299 Ventricular tachyarrhythmias, myocardial ischemia and sudden cardiac death in patients with hypertensive heart disease. **1994**, 191-204

298 Molecular Basis of Genetic Disorders of the Heart. **1995**, 237-264

297 E. **1995**, 1015-1196

296 Nonemergent Hypertension. **1995**, 13, 1009-1035

7

295 Large hearts in children. Biology or disease?. **1995**, 92, 3156-7

1

294 Role of the Renin-Angiotensin System in the Development of Hypertensive Left Ventricular Hypertrophy. **1996**, 409-415

293 Molecular Aspects of Mechanical Stress-Induced Cardiac Hypertrophy and Failure. **1996**, 3-26

292 Molecular aspects of mechanical stress-induced cardiac hypertrophy. **1996**, 197-201

291 Comparison of meta-analyses of therapeutic studies on regression of left ventricular hypertrophy. **1997**, 432, 189-90

290 Changes in Heat Shock Proteins in Cardiac Hypertrophy. **1997**, 83-97

289 Myocardial Hypertrophy and Coronary Circulation Before and After Relief of Pressure Overload. **1997**, 33-46

288 Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy. **1997**, 265-271

- | | | |
|-----|--|---|
| 286 | Hypertension, left ventricular hypertrophy, and heart rate variability. 1997 , 432, 181-7 | |
| 285 | Prognostic Evaluation of Ventricular Arrhythmias in Athletes. 1997 , 45-53 | |
| 284 | Blockers in the Treatment of Hypertension: Focus on Carvedilol. 1998 , 15-26 | |
| 283 | Pulmonale Metastasierung von primär-extrapulmonalen Tumoren. 1998 , 599-614 | 1 |
| 282 | Essential Hypertension. 1998 , 1183-1194 | |
| 281 | Angiotensin-Converting Enzyme Inhibitors in Acute Coronary Syndromes. 1999 , 357-382 | |
| 280 | Left Ventricular Hypertrophy: Reversal by Antihypertensive Therapy. 1999 , 131-138 | |
| 279 | Negative U-wave as a predictor of antihypertensive treatment effect on regression of echocardiographic hypertrophy in hypertensive patients. 1999 , 40, 31-44 | |
| 278 | Hypertension –Diagnosis And Treatment. 1999 , 127-147 | |
| 277 | The Athlete’s Heart: A Physiological or a Pathological Phenomenon?. 1999 , 85-106 | |
| 276 | Left Ventricular Hypertrophic Heart Disease Studied by MR Imaging and 31P-MR Spectroscopy. 1999 , 107-119 | |
| 275 | Microvascular Angina and Hypertensive Left Ventricular Hypertrophy. 1999 , 269-279 | |
| 274 | Assessment of Left Ventricular Hypertrophy: A Comparison of Electrocardiography, Echocardiography and Magnetic Resonance Imaging. 1999 , 43-53 | |
| 273 | Left Ventricular Hypertrophy: Pathology Versus Physiology. 1999 , 65-84 | 1 |
| 272 | Salt sensitivity and cardiovascular risk. 1999 , 8, 199-203 | |
| 271 | ?? : II????????????????????(63????????). 1999 , 7, 241-251 | |
| 270 | EARLY HEART DISORDERS IN HYPERTENSIVE PERSONS AS THE RESULTS OF PREVENTIVE EXAMINATION ON INDUSTRIAL ENTERPRISE. 2014 , 13, 65-70 | |

269 Nuclear Cardiology 1: Myocardial Contractility and Assessment of Cardiac Function. **2015**, 433-461

268 The Endpoint on Measuring the Clinical Effects of Renal Denervation: What Are the Best Surrogates. **2015**, 25-43

267 The application of torasemide in patients with arterial hypertension: evidence-based and practical approaches. **2014**, 11, 79-83

266 Epidemiology of Atherosclerotic Vascular Diseases. **2015**, 1499-1516

265 Mechanisms of Cardiac Fibrosis and Heart Failure. **2015**, 279-297

264 Hypertension in the Kidney Transplant Recipient. **2016**, 167-202

263 Risk Factors for Stroke in Sulaimaniyah Iraqi Kurdistan Region-Iraq. **2016**, 07, 639-651

262 Coronary Artery Disease and Cardiomyopathy. **2016**, 1-21

261 HSF and Heart Diseases. **2016**, 243-259

260 Value of Routine Screening for Hypertension in Childhood. **2016**, 1-11

259 Evaluation of the improvement of myocardial ischemia after CABG using coronary flow velocity reserve in patients with severe left ventricular hypertrophy. **2016**, 22, 145-150

258 STUDY OF CARDIOVASCULAR INVOLVEMENT IN ESRD PATIENTS IN A TERTIARY CARE CENTER. **2016**, 5, 680-682

257 [Sigmoid septum: A variant of the ventricular hypertrophy or of the hypertrophic cardiomyopathy?]. **2016**, 86, 110-22

3

256 Is hepatic steatosis associated with left ventricular mass index increase in the general population?. **2017**, 9, 857-866

255 Left Ventricular Measurements in Black Sub-Saharan Africans and White Maghreb. **2017**, 07, 195-206

254 Coronary Artery Disease and Cardiomyopathy. **2017**, 1-21

253 The Coronary Circulation in Cardiomyopathies and Cardiac Allografts. **2017**, 119-135

252 Coronary Artery Disease and Cardiomyopathy. **2017**, 637-657

- 251 Study of Left Ventricular Mass and Its Determinants on Echocardiography. **2017**, 11, OC13-OC16 6
- 250 Sequelae of Hypertension in Children and Adolescents. **2017**, 1-14
- 249 MORPHO-FUNCTIONAL CHANGES OF CARDIOVASCULAR SYSTEM IN METABOLIC SYNDROME BY ULTRASOUND. **2017**, 13, 049
- 248 Wave Intensity Patterns in Coronary Flow in Health and Disease. **2017**, 263-275
- 247 Structural Remodeling in the Development of Chronic Systolic Heart Failure: Implication for Treatment. **2017**, 247-265
- 246 Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). **2017**, 14, 6-28 1
- 245 Newer echocardiographic techniques for aortic-valve imaging: Clinical aids today, clinical practice tomorrow. **2018**, 10, 62-73 1
- 244 THE STUDY OF CARDIAC ABNORMALITY IN GERIATRIC POPULATION OF RURAL CENTRAL INDIA. **2017**, 4, 4427-4434
- 243 The Impact of Cardiorespiratory Fitness on Cardiometabolic Risk Factors and Mortality. **2017**, 6, 71-77
- 242 Biomarkers: Population Screening and Risk-Stratification. **2018**, 323-333
- 241 Sequelae of Hypertension in Children and Adolescents. **2018**, 695-708
- 240 Hypertensive Heart Disease. **2018**, 189-212
- 239 ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC EVALUATION OF LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS- A HOSPITAL-BASED STUDY. **2018**, 7, 1189-1193
- 238 CORRELATION BETWEEN ELECTROCARDIOGRAM AND ECHOCARDIOGRAPHY IN THE ASSESSMENT OF LEFT VENTRICULAR HYPERTROPHY AMONG HYPERTENSION PATIENTS. **2018**, 5, 1385-1389
- 237 Intravital and postmortem diagnostics of myocardial hypertrophy of the left ventricle: identity or convention?. **2018**, 90, 73-80 1
- 236 Towards cardiovascular risks in children with chronic kidney disease: a prospective cohort study. 7, 1794
- 235 RESULTS OF PROSTHETIC AORTIC STENOSIS IN PATIENTS AFTER IMPLANTATION OF AORTIC ALLOGRAFT. **2019**, 17, 668-676
- 234 Left Ventricular Remodeling Patterns in Primary Healthcare. **2020**, 114, 59-65 0

- 233 Interaction Between the Haemodynamics of Coronary Flow and Aortic Valve Pathologies. **2019**, 115-126
- 232 Metabolic Profiling of Aortic Stenosis and Hypertrophic Cardiomyopathy Identifies Mechanistic Contrasts in Substrate Utilisation. **2019**, 25, 237-246
- 231 PDGFC, MARK3 and BCL2 Polymorphisms are Associated with Left Ventricular Hypertrophy in Korean Population. **2019**, 25, 237-246
- 230 Impact of Arteriovenous Fistula on Cardiac Size and Function in Kidney Transplant Recipients: A Retrospective Evaluation of 5-Year Echocardiographic Outcome. **2019**, 17, 619-626
- 229 Cardiac pathology in patients with resistant hypertension. **2019**, 34, 53-59
- 228 Novel target identification using single cell sequencing and electrophysiology of cardiac sympathetic neurons in disease.
- 227 Identifying and treating high blood pressure in men under 55 years with grade 1 hypertension: the TREAT CASP study and RCT. **2019**, 6, 1-90
- 226 Left ventricular hypertrophy in Japanese pregnant women with chronic hypertension predicts blood pressure elevation during pregnancy. **2020**, 8, 15-21
- 225 Ventricular Remodeling in Aortic Sclerosis. **2020**, 17, 21-33
- 224 The Patient with Preoperative Evaluation. **2020**, 239-248
- 223 History of Lipidology. **2021**, 1-9
- 222 Difference of Clinical Outcomes According to Left Ventricular Hypertrophy and Its Subtype in Korean Patients with Acute Myocardial Infarction. **2020**, 95, 387-397
- 221 The Ca²⁺-activated cation channel TRPM4 is a positive regulator of pressure overload-induced cardiac hypertrophy.
- 220 Evaluation of heart chambers and left ventricular geometry in civil aviation pilots of senior age groups according to echocardiography data. **2020**, 96, 515-521
- 219 Associations among Coronary Artery Calcium Score, Left Ventricular Mass Index and Septal E/E_a Ratio in Subjects with Normal Left Ventricular Ejection Fraction. **2020**, 21, 94-102
- 218 Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias. **2020**, 27, 715-725
- 217 Oxidized LDL but not angiotensin II induces the interaction between LOX-1 and AT1 receptors.
- 216 Targeting persistent normal left ventricular geometry in the general population: a 25-year follow-up study. **2021**, 39, 952-960

- 215 Cardiac Gq receptors and calcineurin activation are not required for the hypertrophic response to mechanical left ventricular pressure overload. 0
- 214 Perioperative management of patients with hypertension. Guidelines. **2020**, 7-33 1
- 213 Echocardiographic Evaluation of Left Atrial Volume Index in Patients with Chronic Kidney Disease. **2020**, 31, 750-758 1
- 212 Revisiting the transplantation of donor heart with left ventricular myocardial hypertrophy. **2020**, 12, 42-48 0
- 211 Heart function in juvenile idiopathic arthritis patients: A biventricular two-dimensional speckle-tracking echocardiography study. **2021**,
- 210 Traditional Risk Factors and Newly Recognized Emerging Risk Factors for Cardiovascular Disease. **2003**, 63-89
- 209 Physiologie und Pathophysiologie des Alterns. **2005**, 5-15
- 208 Arterielle Hypertonie bei Diabetes mellitus. **2005**, 26-39
- 207 Serial Changes in Left Ventricular Mass in Hypertension: Prognostic Impact. **2005**, 75-81
- 206 Second Messenger Systems Involved in Heart Mechanotransduction. **2007**, 93-105
- 205 Mechanisms of Sudden Cardiac Death. **2005**, 323-351
- 204 Left Ventricular Hypertrophy. **2007**, 116-149
- 203 Ventricular Electrical Remodeling in Compensated Cardiac Hypertrophy. **2008**, 305-315 1
- 202 Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. **2006**, 3, 733-749
- 201 Basis of Cardiac Imaging 1: Myocardial Contractility and Assessment of Cardiac Function. **2006**, 330-351
- 200 Kronik b rek hastalar nda anormal kalp geometrisi ve sol ventrik l hipertrofisi. **2020**, 45, 1089-1098
- 199 Impact of obstructive sleep apnea on left ventricular mass index in men with coronary artery disease. **2020**, 16, 1675-1682 3
- 198 Blood pressure variability and night-time dipping assessed by 24-hour ambulatory monitoring: cross-sectional association with cardiac structure in adolescents.

197	Left ventricular diastolic function and circadian variation of blood pressure in essential hypertension. 2005 , 32, 28-34	10
196	Screening persons aged 65 and older for coronary heart disease risk factors. 1992 , 156, 45-9	1
195	1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. 1999 , 161 Suppl 12, S1-17	38
194	Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension. 1999 , 161 Suppl 12, S18-22	2
193	Role of echocardiography in primary care medicine. Controversies in hypertension, atrial fibrillation, stroke, and endocarditis. 1996 , 164, 269-75	1
192	Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients?. 2000 , 50, 735-42	16
191	Report of the Canadian Hypertension Society Consensus Conference: 2. Diagnosis of hypertension in adults. 1993 , 149, 409-18	16
190	Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension. 1993 , 149, 575-84	17
189	"Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. 1998 , 53 Suppl 3, S25-8	51
188	Echocardiography for primary care evaluation of hypertension. 1998 , 44, 2702-6	3
187	1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. 1993 , 71, 503-17	22
186	Hypertension in perspective. 2005 , 13, 186-189	
185	Einthoven Dissertation Prizes 2002. 2003 , 11, 188-192	
184	The 894T allele of endothelial nitric oxide synthase gene is related to left ventricular mass in African Americans with high-normal blood pressure. 2005 , 97, 197-205	11
183	Cardiovascular disease mortality. 2003 , 95, 1146-51	8
182	Report of the NHLBI Working Group on research in coronary heart disease in blacks: issues and challenges. 1995 , 87, 597-603	1
181	Adducin 1 (alpha) Gly460Trp variant is associated with left ventricular geometry in Caucasians and African Americans: The HyperGEN Study. 2010 , 1, 367-76	1
180	Impact of left ventricular geometry on prognosis-a review of ochsner studies. 2008 , 8, 11-7	14

179	New paradigms in preventive cardiology: unconventional coronary risk factors. 2000 , 2, 209-17	0
178	Natural occurrence of aflatoxin residues in fresh and sun-dried meat in Nigeria. 2010 , 7, 14	2
177	Point-of-care screening for left ventricular hypertrophy and concentric geometry using hand-held cardiac ultrasound in hypertensive patients. 2011 , 1, 119-25	6
176	Relation of components of the metabolic syndrome to left ventricular geometry in hispanic and non-hispanic black adults. 2011 , 1, 84-91	3
175	Normotensive offspring of hypertensive Nigerians have increased left ventricular mass and abnormal geometric patterns. 2012 , 11, 6	3
174	Electrocardiogram abnormalities and coronary calcification in postmenopausal women. 2010 , 5, 19-24	1
173	Genetic epidemiology of left ventricular hypertrophy. 2012 , 2, 267-78	18
172	Simvastatin activates the PPAR α -dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signaling. 2013 , 40, 140-7	17
171	Correlates of left ventricular mass in hypertensive Nigerians: an echocardiographic study. 2010 , 21, 79-85	4
170	Relationship between left ventricular geometric pattern and systolic and diastolic function in treated Nigerian hypertensives. 2010 , 21, 21-5	7
169	Bioimpedance and echocardiography used interchangeably in volume comparison of dialysis patients. 2012 , 16, 329-34	4
168	Risk factors for acute non-ST-segment elevation myocardial infarction in a population sample of predominantly African American patients with chest pain and normal coronary arteries. 2011 , 21, 421-8	4
167	Prevalence and determinants of left ventricular hypertrophy in hypertensive patients at a primary care clinic. 2012 , 7, 2-9	3
166	Expressions of CD11a, CD11b, and CD11c integrin proteins in rats with myocardial hypertrophy. 2014 , 17, 874-8	2
165	Exercise preconditioning attenuates pressure overload-induced pathological cardiac hypertrophy. 2015 , 8, 530-40	8
164	The impact of sub-clinical over-hydration on left ventricular mass in peritoneal dialysis patients. 2015 , 8, 5890-6	10
163	The cardiac ventricular myocyte as a substrate for sudden death. The regional lecture in Bath 1993. 1993 , 27, 428-34	2
162	CD47 antibody suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy. 2020 , 12, 5908-5923	1

161	Performance of a novel ECG criterion for improving detection of left ventricular hypertrophy: a cross-sectional study in a general Chinese population. 2021 , 11, e051172	
160	Using deep learning method to identify left ventricular hypertrophy on echocardiography. 2021 , 1	1
159	Lower B-type natriuretic peptide levels predict left ventricular concentric remodelling and insulin resistance. 2021 ,	2
158	Cardiovascular Morbidity and Mortality in Adult Patients With Repaired Aortic Coarctation. 2021 , 10, e023199	2
157	Association between Coronary Artery Disease and Left Ventricle Remodeling Parameters in Hypertensive Patients: A Cross-Sectional Study in a Limited Resource Setting. 2020 , 9, 1364-1369	
156	The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity. 2021 , 10,	3
155	GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway.. 2021 , 24, 103517	0
154	Resident Macrophages in the Heart: Cardioprotective Under Pressure. 2021 , 129, 1102-1104	0
153	Relations Between Cardiac Magnetic Resonance Imaging-Derived Left Ventricular Mass, Early Repolarization, and Cardiovascular Events (from the Dallas Heart Study). 2021 , 161, 108-114	
152	Scutellarein protects against cardiac hypertrophy via suppressing TRAF2/NF- κ B signaling pathway.. 2022 , 49, 2085	1
151	Cardiovascular Burden Is High in Pediatric Lung Transplant Recipients.. 2022 ,	0
150	Sodium Glucose Cotransporter 1 (SGLT1) Inhibitors in Cardiovascular Protection: Mechanism Progresses and Challenges.. 2021 , 176, 106049	0
149	Circular RNAs in the regulation of cardiac hypertrophy.. 2022 , 27, 484-490	1
148	The Status of Frontal QRS-T Angle in Hypertensive Patients with Different Left Ventricular Geometry.	
147	Blood pressure trajectories in early adulthood and myocardial structure and function in later life.. 2022 ,	1
146	Emerging therapeutic targets for cardiac hypertrophy.. 2022 ,	0
145	Left Ventricular Structure is Associated with Postoperative Death After Coronary Artery Bypass Grafting in Patients with Heart Failure with Reduced Ejection Fraction.. 2022 , 15, 53-62	0
144	Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis.. 2022 , 23, 34	0

- 143 Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study - Protocol for a Multicenter, Open-Label, Exploratory Interventional Study.. **2022**, 4, 99-104 0
- 142 Transient receptor potential vanilloid 1-expressing cardiac afferent nerves may contribute to cardiac hypertrophy in accompany with an increased expression of brain-derived neurotrophic factor within nucleus tractus solitarius in a pressure overload model.. **2022**, 1-9 0
- 141 Magnetic Resonance for Differential Diagnosis of Left Ventricular Hypertrophy: Diagnostic and Prognostic Implications.. **2022**, 11, 0
- 140 Implication of Different ECG Left Ventricular Hypertrophy in Patients Undergoing Transcatheter Aortic Valve Replacement.. **2022**, e023647 1
- 139 The Path to Better Understanding Heart Failure Epidemiology.. **2022**, 79, 369-371
- 138 Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression.. **2021**, 135, 163-163 1
- 137 Does diabetes increase the risk of cardiovascular events in patients with negative treadmill stress echocardiography?. **2022**,
- 136 Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes.. **2022**, 11, 3
- 135 Associations of maternal angiogenic factors during pregnancy with alterations in cardiac development in childhood at 10 years of age.. **2022**,
- 134 Interrelations Between High Blood Pressure, Organ Damage, and Cardiovascular Disease: No More Room for Doubt.. **2022**, 79, 516-517 1
- 133 Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy. **1997**, 176, 265-71 6
- 132 Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. **2000**, 212, 177-82 7
- 131 Insulin resistance-related differences in the relationship between left ventricular hypertrophy and cardiorespiratory fitness in hypertensive Black sub-Saharan Africans. **2021**, 11, 587-600
- 130 Value of Routine Screening for Hypertension in Childhood. **2022**, 1-12
- 129 Prevalence and long-term prognostic implications of prolonged QRS duration in left ventricular hypertrophy: a population-based observational cohort study.. **2022**, 12, e053477
- 128 Role of strain echocardiography in patients with hypertension.. **2022**, 28, 6 0
- 127 Isolated systolic hypertension is associated with increased left ventricular mass index and aortic stiffness in adolescents: a cardiac magnetic resonance study.. **2022**,
- 126 A new CHA2DS2VASC score integrated with eGFR, left ventricular hypertrophy, and pulse pressure is highly effective in predicting adverse cardiovascular outcome in chronic kidney disease.. **2022**,

- 125 Different activation of MAPKs and Akt/GSK3 β after preload vs. afterload elevation.. **2022,**
- 124 Effect of hypertension on the optimal anthracycline cumulative dose for developing left ventricular dysfunction in patients with malignant lymphoma. 1 O
- 123 Preconception lifestyle intervention in women with obesity and echocardiographic indices of cardiovascular health in their children.. **2022,** O
- 122 Obesity, hypertension and tobacco use associated with left ventricular remodelling and hypertrophy in South African Women: Birth to Twenty Plus Cohort.
- 121 Left ventricular hypertrophy and incident cognitive decline in older adults with hypertension.. **2022** ,
- 120 Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.. **2022,** 23,
- 119 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. **2022,** 101161CIR00000000000001063 35
- 118 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. **2022,** 49
- 117 Performance of a novel ECG criterion for improving detection of left ventricular hypertrophy: a cross-sectional study in a general Chinese population. **2021,** 11, e051172 O
- 116 Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?. **2022,** 15, 644-656 1
- 115 Basal Septal Hypertrophy as the Early Imaging Biomarker for Adaptive Phase of Remodeling Prior to Heart Failure.. **2021,** 11, 1
- 114 Efficacy of Renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy -from the KUNIMI Registry Acute Cohort.. **2021,** O
- 113 Thymoquinone ameliorates pressure overload-induced cardiac hypertrophy by activating the AMPK signalling pathway.. **2021,** 2
- 112 Prognostic association supports indexing size measures in echocardiography by body surface area.
- 111 T1 Mapping and Extracellular Volume in Cardiomyopathy Showing Left Ventricular Hypertrophy: Differentiation Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease.. **2022,** 15, 4163-4173 O
- 110 Cardiovascular risk in children: a burden for future generations.. **2022,** 48, 57 O
- 109 Presentation_1.PDF. **2018,**
- 108 Data_Sheet_1.docx. **2019,**

- ¹⁰⁷ Impact of weight loss with diet or diet plus physical activity on cardiac magnetic resonance imaging and cardiovascular disease risk factors: Heart Health Study randomized trial.. **2022**, 30, 1039-1056 0
- ¹⁰⁶ Glycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study.. **2022**, 22, 186 0
- ¹⁰⁵ Glycated hemoglobin, diabetes mellitus, and cardiovascular risk in a cross-sectional study among She Chinese population. **2012**, 35, 35-41 2
- ¹⁰⁴ Systemic hypertension counteracts potential benefits of growth hormone replacement therapy on left ventricular remodeling in adults with growth hormone deficiency. **2013**, 36, 243-8 1
- ¹⁰³ Left ventricular hypertrophy is independently associated with all-cause mortality.. **2022**, 12, 38-41
- ¹⁰² Change of Left Ventricular Geometric Pattern in Patients with Preserved Ejection Fraction Undergoing Coronary Artery Bypass Grafting.. **2022**,
- ¹⁰¹ Necropsy Validation of a Novel Method for Left Ventricular Mass Quantification in Porcine Transthoracic and Transdiaphragmal Echocardiography.. **2022**, 9, 868603
- ¹⁰⁰ The Aryl Hydrocarbon Receptor Ligand FICZ Improves Left Ventricular Remodeling and Cardiac Function at the Onset of Pressure Overload-Induced Heart Failure in Mice. **2022**, 23, 5403 1
- ⁹⁹ Left ventricular mass as a predictor of cardiovascular events in the era of hypertension management using home blood pressure measurement: the J-HOP study.. **2022**, 1
- ⁹⁸ Aortic arch calcification and risk of all-cause mortality and cardiovascular disease: The Guangzhou Biobank Cohort Study.. **2022**, 23, 100460 1
- ⁹⁷ Left Ventricular Reverse Remodeling After Surgical Therapy for Aortic Stenosis: Correlation to Renin-Angiotensin System Gene Expression. **2002**, 106, 9
- ⁹⁶ Autonomic nervous system state, calcium channel activity and gene polymorphisms of angiotensin-converting enzyme inhibitor and α -adrenergic receptor in patients with complicated essential arterial hypertension. **2011**, 38-45
- ⁹⁵ Quantitative Evaluation of Left Ventricular Structure, Wall Stress, and Systolic Function. **2017**, 107-127 1
- ⁹⁴ Parâmetros Ecocardiográficos Simples podem Substituir o Círculo do Modelo Probabilístico ASCVD?. **2022**, 118, 925-926
- ⁹³ Parâmetros Ecocardiográficos Simples são Fortes Preditores de Risco Cardiovascular em Indivíduos Assintomáticos: Coorte Elsa-Brasil. **2022**, 118, 916-924 1
- ⁹² Differences in Regulation of Cortisol Secretion Contribute to Left Ventricular Abnormalities in Patients With Essential Hypertension.. **2022**, 101161HYPERTENSIONAHA12219472 1
- ⁹¹ Meditation in Prevention and Treatment of Cardiovascular Disease: An Evidence-Based Review. **2022**, 303-325
- ⁹⁰ The Transcription Factor EB (TFEB) Sensitizes the Heart to Chronic Pressure Overload. **2022**, 23, 5943 0

- 89 Determination of sources of error and improvement in accuracy of left ventricular mass measurement by echocardiography. ○
- 88 Improving the diagnostic search for the assessment of left ventricular hypertrophy in men during screening studies. **2022**, 25, 67
- 87 Subclinical Left Ventricular Dysfunction in Children and Adolescence With Thalassemia Intermedia. 10, ○
- 86 Isolated diastolic hypertension in childhood and risk of adult subclinical target organ damage: a 30-year prospective cohort study. Publish Ahead of Print, ○
- 85 Angiotensin II Mediates Cardiomyocyte Hypertrophy in Atrial Cardiomyopathy via Epigenetic Transcriptional Regulation. **2022**, 2022, 1-20
- 84 A new method to quantify left ventricular mass by 2D echocardiography. **2022**, 12,
- 83 Exercise Testing in Hypertension and Hypertension in Athletes. **2022**, 1-17
- 82 Pathophysiology of heart failure and an overview of therapies. **2022**, 149-221
- 81 Remodeling of Retinal Arterioles and Carotid Arteries in Heart Failure DevelopmentâA Preliminary Study. **2022**, 11, 3721 ○
- 80 Identification of Major Risk Factors and Non-linear Effects to the Development of Left Ventricular Hypertrophy in Chronic Kidney Disease by Constructing and Validation of Nomograms. 9, ○
- 79 The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction. 9, ○
- 78 Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study. **2022**, 11, 3885 ○
- 77 Cardiac structure and function of elite volleyball players across different playing positions.
- 76 Cyclothymic affective temperament is independently associated with left ventricular hypertrophy in chronic hypertensive patients. **2022**, 160, 110988
- 75 Hypertensive Heart Disease or Acute Coronary Syndrome?. **2000**, 30, 302-304
- 74 Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction. ○
- 73 FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status. ○
- 72 Risk of future cardiovascular diseases in different years postpartum after hypertensive disorders of pregnancy: A systematic review and meta-analysis. **2022**, 101, e29646 ○

71	A comparison of echocardiographic and circulating cardiac biomarkers for predicting incident cardiovascular disease. 2022 , 17, e0271835	0
70	Association of obstructive sleep apnea with endothelial function and heart remodeling in hypertension: A cross-sectional study. 2022 ,	0
69	Exercise Hypertension in Athletes. 2022 , 11, 4870	
68	Growth Hormone Secretory Capacity Is Associated with Cardiac Morphology and Function in Overweight and Obese Patients: A Controlled, Cross-Sectional Study. 2022 , 11, 2420	1
67	Artificial Intelligenceâ€Enabled Model for Early Detection of Left Ventricular Hypertrophy and Mortality Prediction in Young to Middle-Aged Adults. 2022 , 15,	
66	COMPREHENSIVE HYPERTENSION CARE IN YOUNG URBAN BLACK MEN. 2000 , 35, 773-793	2
65	Changes of left ventricular remodeling due to increased afterload in patients with essential hypertension. 2022 , 367, 74-80	0
64	Biomarkers of inflammation and left ventricular remodelling in psoriasis patients treated with infliximab. 2022 , 36, 039463202211111	0
63	Maternal Cardiac Changes in Women With Obesity and Gestational Diabetes Mellitus.	0
62	Obesity, hypertension, and tobacco use associated with left ventricular remodeling and hypertrophy in South African women: Birth to Twenty Plus Cohort. 2022 , 22,	0
61	Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials. 2022 , 22,	1
60	Differentially Methylated DNA Regions and Left Ventricular Hypertrophy in African Americans: A HyperGEN Study. 2022 , 13, 1700	0
59	Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.	1
58	Aortic pressure-only wave separation analysis in adolescents: accuracy and associations with left ventricular mass index.	0
57	Cardiovascular effects of immunosuppression agents. 9,	0
56	Peripartum Screening for Postpartum Hypertension in Women With Hypertensive Disorders of Pregnancy. 2022 , 80, 1465-1476	0
55	Value of estimated glucose disposal rate to detect prevalent left ventricular hypertrophy: implications from a general population. 1-9	1
54	Association of total lymphocyte count and echocardiographic parameters in human immunodeficiency virus-positive patients. 2021 , 18, 14	0

53	Prediction of cardiovascular events by central blood pressure using radial tonometry in type 2 diabetes mellitus patients. 2022 , 28,	0
52	Inhibition of TRIF-Dependent Inflammation Decelerates Afterload-Induced Myocardial Remodeling. 2022 , 10, 2636	0
51	Left ventricular remodeling following aortic root and ascending aneurysm repair. 9,	0
50	Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy. 2022 , 80, 1516-1525	0
49	Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR). 1-10	2
48	Left ventricular mass and global wall thickness â€”prognostic utility and characterization of left ventricular hypertrophy.	0
47	Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy.	0
46	Cardio-sarcopenia: A syndrome of concern in aging. 9,	1
45	Impact of Nijinjâ€”oeito on frailty and short life in klotho-hypomorphic (kl/kl) mice. 13,	1
44	The Vascular System. 2022 , 40, 557-574	0
43	Hypertension in Children and Young Adults. 2022 , 69, 1165-1180	0
42	Aging Increases Susceptibility to Develop Cardiac Hypertrophy following High Sugar Consumption. 2022 , 14, 4645	0
41	Juvenile idiopathic arthritis polygenic risk scores are associated with cardiovascular phenotypes in early adulthood: a phenome-wide association study. 2022 , 20,	0
40	High-Quality Artery Monitoring and Pathology Imaging Achieved by High-Performance Synchronous Electrical and Optical Output of Near-Infrared Organic Photodetector. 2203870	0
39	Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice. 2023 , 158, 114069	0
38	Left Ventricular Hypertrophy Geometry and Vascular Calcification Co-Modify the Risk of Cardiovascular Mortality in Patients with End-Stage Kidney Disease: A Retrospective Cohort Study. 2022 ,	0
37	Prognostic significance of geometric patterns of left ventricular hypertrophy in a 12-year cohort study. 2022 , 28, 532-545	0
36	Obeziteye Yatkâ€” Genâ€”erâ€”ilerde Aort Elastisite Parametrelerinin Ekokardiyografik Deâ€”erlendirilmesi.	0

- 35 Echocardiographic Evidence of Cardiac Atrophy in the Critically Ill. **2022**, 4, e0804 ○
- 34 The Impact of Bariatric Surgery on Cardiac Structure, and Systolic and Diastolic Function in Patients with Obesity: A Systematic Review and Meta-analysis. ○
- 33 Extent of Left Ventricular Mass Regression and Impact of Global Left Ventricular Afterload on Cardiac Events and Mortality after Aortic Valve Replacement. **2022**, 11, 7482 ○
- 32 Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. ○
- 31 Value of Routine Screening for Hypertension in Childhood. **2023**, 285-295 ○
- 30 Renin Angiotensin System in the Pathophysiology of Diabetic Cardiomyopathy in Type 2 Diabetes. **2023**, 237-258 ○
- 29 Biomarker for detecting myocardial ischemia using multi class particle swarm optimization. 1-12 ○
- 28 Exercise Testing in Hypertension and Hypertension in Athletes. **2023**, 827-842 ○
- 27 Effect of Parathyroidectomy on Left Ventricular Mass Index in Patients With Primary Hyperparathyroidism. **2023**, ○
- 26 The significance of central blood pressure for cardiovascular target organ damage in children and adolescents after kidney transplantation. ○
- 25 Large-Scale Metabolomics and the Incidence of Cardiovascular Disease. **2023**, 12, ○
- 24 NT-proBNP Levels in Relation to Various Grades of Hypertension âAn Observational Study. 1-6 ○
- 23 Cardiorespiratory Optimisation By Arteriovenous fistula Ligation after renal Transplantation (COBALT): study protocol for a multicentre randomised interventional feasibility trial. **2023**, 13, e067668 ○
- 22 Sex disparity in left ventricular hypertrophy in South Asians with hypertension: influence of central obesity and high blood pressure. **2023**, 37, 327-329 ○
- 21 Single cell and lineage tracing studies reveal the impact of CD34+ cells on myocardial fibrosis during heart failure. **2023**, 14, ○
- 20 Longitudinal left ventricular mass indexing for DEXA-measured lean mass and fat mass: novel normative reference centiles in postpubertal adolescents and young adults. **2023**, 324, H571-H577 ○
- 19 Structural changes in training aerobic soccer players. **2018**, 5, 215-223 ○
- 18 Heart Diseases in Geriatric Patients. **2023**, 109-135 ○

- 17 Effect of the geometry and severity of left ventricular hypertrophy on cardiovascular mortality in patients on chronic hemodialysis. ○
- 16 Elevated Blood Pressure and Worsening Cardiac Damage During Adolescence. **2023**, 113374 ○
- 15 Prevalence of Elevated Blood Pressure and Left Ventricular Hypertrophy in Adolescents with Congenital Heart Disease. ○
- 14 Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model. 13, ○
- 13 O-GlcNAcylation-induced GSK-3 β activation deteriorates pressure overload-induced heart failure via lack of compensatory cardiac hypertrophy in mice. 14, ○
- 12 Conduction velocity is reduced in the posterior wall of hypertrophic cardiomyopathy patients with normal bipolar voltage undergoing ablation for paroxysmal atrial fibrillation. ○
- 11 Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions. Publish Ahead of Print, ○
- 10 Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study. **2023**, 24, ○
- 9 Treatment Decision in Aortic StenosisâLook at the Valve but Do Not Forget the Ventricle. **2023**, 5, ○
- 8 Associations of accelerometer-based sedentary time, light physical activity and moderate-to-vigorous physical activity with resting cardiac structure and function in adolescents according to sex, fat mass, lean mass, BMI, and hypertensive status. ○
- 7 Cardioprotective effect of ultrasound-targeted destruction of Sirt3-loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy. **2023**, ○
- 6 Prevalence of different echocardiographic abnormalities in a large Turkish workers population. ○
- 5 Estrogen: Impact on cardiomyocytes and the heart. **2023**, 681-697 ○
- 4 HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBP β Axis. ○
- 3 Relation of the left ventricular geometric patten to coronary artery disease in hypertensive patients using a 320-detector-row CT scanner. **2023**, 75, ○
- 2 Impact of Diabetes and Hypertension on Left Ventricular Structure and Function: The Jackson Heart Study. **2023**, 12, ○
- 1 Hypertensive heart: from left ventricular hypertrophy to chronic heart failure. **2023**, 29, 138-149 ○